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"If you prick us, do we not bleed?"
WILLIAM SHAKESPEARE
The Merchant of Venice, Act III, Scene 1.
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Coagulation factor VIII is needed for the
treatment of patients with haemophilia. Requirements
for factor VIII are important in determining the numbers
of blood donations to be collected in Scotland. The
final yield of factor VIII:C in products prepared from
blood plasma, when prepared either in the Transfusion
Centres or the National Fractionation Centre, is relatively
low (30-40%). Improvements in these processes would have
major implications for the Transfusion Service.
Present technology requires the freezing of
plasma from blood donations prior to the preparation of
cryoprecipitate; this may then be processed further to
produce factor VIII concentrate. In this study, the
effects of using different anticoagulants (citrate,
heparin), of varying the rate of freezing and the
duration of storage on the factor VIII content of plasma
and subsequent products have been investigated. The
influence of ABO blood group and of drug induced enhance¬
ment on levels of factor VIII in starting plasma were
also studied.
Improvements in the mode of preparing cryo¬
precipitate from plasma have been made on the basis of
the observed effects on processing plasma of different
quality (collection procedure, age, etc.) and by various
methods. Investigation of the mechanism of cryoprecipi-
tation has led to the development of a high-yield method
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for the preparation of factor VIII from unfrozen plasma
by precipitation with hydrophilic polymers.
In the course of this work, methods were
developed for the isolation of factor VIII and fibronectin
and immunological assays for these and other proteins
(fibrinogen), based on immunoprecipitation and immuno-
radiometric methods, were set up. The immunoradiometric
methods were used to follow the recovery and survival of
factor VIII components following infusion into patients
deficient in this protein.
Based on the work described in this thesis,
recommendations will be made on the possibilities for





(A) DEVELOPMENTS IN THE UNDERSTANDING OF HAEMOPHILIA
Writings from the 2nd century A.D. in the
Jewish Talmud (Rosner 1969) mention rulings exempting a
woman's third son from being circumcised if his two
elder brothers had died of bleeding after circumcision.
Similar rulings forbid a boy to be circumcised if the
sons of his mother's sisters had died after circumcision
(Rothschild 1882 qu. Bulloch and Fildes 1911). These
features of fatal bleeding after minor surgery in
brothers or in maternally related boy cousins are
characteristic of the disorder called haemophilia. Down
the years there are other scattered records of bleeding
disorders more or less closely agreeing with the
clinical picture of the disease (Ingram 1976). By the
19th century an extensive literature had developed,
which noted the mode of inheritance of the disease as
well as the nature of the bleeding disorder. The name
'haemophilia' - literally 'love of blood' - occurred
first in the title of Hopff's treatise in 1828 (Ingram
1976). The characteristic bleeding and subsequent
arthropathy in the joints was first described by Kftnig in
1890. The famous 'Royal haemophilia' (McKusick 1965)
originated from Queen Victoria, who was a carrier of the
disease. Two of her daughters proved to be carriers,
and one of her sons, Leopold Duke of Albany, was a
haemophiliac, dying of a cerebral haemorrhage at 31 after
falling and hitting his head. History's most famous
haemophiliac, Alex Tsarevich of Russia, was the son of
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a grand-daughter of Queen Victoria, Alix of Hesse. The
boy's tragic history of illness and near brushes with
death led to the rise of Rasputin, whose influence rose
after apparently resolving some of the boy's bleeding
episodes. Thus, haemophilia might be said to have had
a crucial role in the subsequent events which led to the
overthrow of the Tsar in 1917 and brought about the
modern Soviet Union.
The work of Addis (Addis 1911) showed that a
component of the globulin fraction of normal plasma
corrected the prolonged clotting time of haemophilic
blood. Addis thought that this was prothrombin but
because this factor was found to be normal in haemophilia
(Govaerts and Gratia 1931), his important observation
was not pursued. Although the classical blood
coagulation theory of Morawitz only acknowledged four
coagulation factors - prothrombin, thromboplastin,
calcium ions and fibrinogen (Morawitz 1905) - the concept
of an 'antihaemophilic globulin' essential for normal
coagulation slowly evolved. The work of Patek and
Taylor confirmed Addis' observation of a plasma fraction
capable of correcting the coagulation defect (Patek and
Taylor 1937) and Brinkhous (Brinkhous 1939) showed that
it accelerated the conversion of prothrombin to thrombin
in haemophilic blood. Development of better test
systems such as the Prothrombin time and the Thrombo¬
plastin Generation Test led to the identification of
numerous other components necessary for normal blood
6
coagulation (reviewed by Macfarlane 1976) which were
organised in a series of clotting factors designated by
Roman numerals - antihaemophilic globulin was named
■factor VIII*. In the classic 'cascade' scheme for
blood coagulation reactions (Macfarlane 1964, Davie
and Ratnoff 1964) factor VIII was assigned an enzymatic
role, but subsequent work (Suomela et al 1977, Neal and
Chavin 1979, van Dieijen et al 1981) has demonstrated
a cofactor role of factor VIII in the enzymatic
conversion of factor X to Xa by factor IXa (Figure 1-2).
Investigation of the defect in haemophilia
was complicated in the 1950's by the demonstration that
von Willebrand's disease, a haemostatic disorder
characterised by autosomal inheritance and a prolonged
bleeding time (seldom found in haemophilia) was also
associated with a low level of factor VIII (Alexander
and Goldstein 1953, Nilsson et al 1957). Developments
in the immunological investigation of haemophilia
revealed the presence of an antigen associated with
purified factor VIII fractions that could be used to
raise heterologous antisera after injection of such
preparations in animals (Zimmerman et al 1971). Sub¬
sequent testing using the electroimmunoassay technique
of Laurell (Laurell 1966) revealed normal levels of this
antigen in the plasma of haemophiliacs but low levels in
the plasma of patients with von Willebrand's disease.
Thus it seemed that factor VIII was composed of two
TABLE1-1NOMENC ATUREDBIOLOGICALCHARACT RISTICSFTHHUM NF TORV I/vonWI L BRANDFACTORC MPL XES NameofC mpon nt (Abbreviation)Characteristicsnd PhysiologicalFunctionDiseaseAs ociat d WithDeficiency
Methodsof Detection/Assay
FactorVIII ProcoagulantA tivity (VIII:C)
Proteinwhichcorrectsth coagulationabnormalityi haemophiliaA.Mrs 200,000(Weinsteintal 1981).Synthesisedi liver(St leta1983). Concentrationi plasma 50-100ng/ml.Cofactori theactivationofFXby FIXa(vanDieijentl 1981)
HaemophiliaA:sexlink d recessivetrait.Incid¬ enceabout5-10per 100,000population (Bloom1982)
Coagulationassaysu g one-stagertwo-st e methods(Rizzaanhyme 1982)
FactorVIII CoagulantAntigen (VIII:CAg)
Antigenicexpr ss onof VIII:C
HaemophiliaA.Mostly foundashaemophiliaA" withtotallackf VIII:CAg,about10-20%of patientshavedetectable VIII:CAg-haemophiliaA+
a)Immunoradiometricassays usinghumaantibodiesto VIII:C;liquid(Lazarchick andHoyer1978)solid phaseassays(Peak1982) canbeused. b)Inhibitionneutralisa¬ tionassays(Denson1967)
vonWillebrand FactorProtein (vWF)
Proteinwhichcorrectsth bleedingtimeabnormality
invonWillebrand's disease.Multimeric proteinMr=8xl05-12xl06, subunitize220,000 (Hoyer1981).Synthesised
vonWillebrand'sdis se- varioustypeduo deficiencyand/orbnormal¬ ityofvWF(Zimmermanand Ruggeri(1982).Usually autosomaldominanttrait. Incidenceaboutthesams
Prolongationfthebleed¬ ingtime.Semi-quantit¬ ativemethods-platelet retentioninglassb d columns(Salzman1963); plateletadhesionto perfusedsubendoth lium
TABLE1-1(Cont)NOMENCLATUREDBIOLOGICALCHARA TERISTICSFTHEUMANFA ORVlll/vonWIL B ANDF CT COMPLEXES NameofCompon nt (Abbreviation)Characteristicsnd PhysiologicalFunctionDiseaseAs ociat d WithDeficiency
Methodsof Detection/Assay
vonWillebrand FactorProtein (vWF)
invascularendothelium (Bloometal1973). Concentrationiplasma 5-10ug/ml.Mediationof plateletadhesiontosub- endothelium(Weissta 1978)
haemophiliaA
(Sakariassenetl1979)
FactorVIII RelatedAntig n (VIIIR:Ag)
Antigenicexpr ss onof vonWillebrandFactor
vonWillebrand'sdise se (V.W.D.)
a)Electroimmunoassay (Zimmermanetal1975) b)Immunoradiometricassay liquid(Hoyer1972)r solidphase(Peak1982) usingheterologousantisera c)Radioimmunoassayusi g radiolabelledVIIIR:Ag (Paulssenetl1975)
Ristocetin Cofactor (VIIIR:RCF)
Apropertyofv n WillebrandFactorwhich promotesagglutinationf plateletsinthresence oftheantibioticristo¬ cetin.Theequivalent propertyinbovinand porcinevWFagglutinat s humanplateletswithout ristocetin
vonWillebrand'sdis se
VIIIR:RCFassayu ingfixed plateletsandristoc tin (Macfarlaneetl1975); doesnotalwayscorrela e withassaysforvWF activity(Ogatael1983)
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entities - 'Factor VIII antigen" - measured by reaction
with heterologous antisera raised against purified
factor VIII fractions and needed for a normal bleeding
time; and 'Factor VIII coagulant', measured by coagu¬
lation assay and needed for normal plasma clotting.
The different mode of inheritance of the two disorders
argued for the separate identity of the two components,
but for many years the question as to whether they were
one or separate molecules was vigorously debated
(reviewed by Bloom 1977).
(B) THE FACTOR VIII/von WILLEBRAND FACTOR COMPLEX.
STRUCTURE AND FUNCTION
Present knowledge about the various components
of the factor VIII complex, together with the clinical
conditions associated with their deficiency, is
summarised in Table 1-1.
Factor VIII:C and von Willebrand factor
usually circulate together in plasma and a number of
techniques such as gel filtration point to their close
association. This has prompted suggestions that they
are properties of the same macromolecule (Ratnoff et al
1976, Switzer and McKee 1976). However, the existence
of independent genetic control for the two proteins has
long provided compelling evidence that they are distinct.
In addition, the two proteins can be separated from one
another by procedures that do not disrupt covalent bonds
(Weiss and Hoyer 1973, Tuddenham et al 1979). von
Willebrand Factor has been purified by various groups
FIGURE 1-1
DIAGRAMATIC REPRESENTATION OF THE ROLE OF FACTOR
VIII-RELATED ANTIGEN/von WILLEBRAND FACTOR IN
PLATELET AND VESSEL WALL INTERACTION.
AA = arachidonic acid
PGI2 = prostacyclin
GP = glycoprotein




SIMPLIFIED SCHEME OF THE COAGULATION SEQUENCE.
For the sake of this simplicity important control
systems such as feed-back mechanisms and humoral
inactivators and inhibitors, for example,
protein C and antithrombin III, are omitted. The
'extrinsic' and 'intrinsic' systems are separated
for descriptive purposes and their many possible
points of interaction are omitted.
The dashed lines indicate the activation
activities of thrombin considered to be the most





(Legaz et al 1973, Olson et al 1977, Beck et al 1979) and
has been well characterised as an oligoraeric protein
consisting of a series of multimers (Hoyer and Shainoff
1980). Factor VIII:C, which contributes about 1% to the
mass of the VIII/VWF complex (Hoyer 1981) is less well
characterised but present evidence points to it being a
single chain polypeptide with Mr = 8 x lO1*-^ x 105
(Weinstein et al 1981, Fulcher and Zimmerman 1982, Fay
et al 1982).
While Figure 1-1 shows the role of von
Willebrand Factor in mediating platelet adhesion to
exposed subendothelium, Figure 1-2 shows the role of
factor VIII:C in the coagulation sequence, (both
figures are taken from Bloom (1982)).
(C) EARLY DEVELOPMENTS IN THERAPY FOR THE FACTOR VIII
DEFICIENCY DISORDERS
Current therapy has resulted in haemophiliacs
having an almost normal life expectancy (Ikkala et al
1982), a situation in sharp contrast to the efforts at
therapy outlined in the early literature (Birch 1937).
The present position has developed over the past forty
years but the modern treatment of replacing the missing
component in blood dates from 1840 when the first blood
transfusion for a case of haemophilic bleeding was given
(Lane 1840). Rather fortuitously, no incompatibility
problems were recorded, but further use of this form of
treatment had to await Landsteiner's discovery of blood
groups in 1901. Subsequent claims of benefit from the
use of a variety of measures, ranging from the admini¬
stration of lime to the use of egg white (Ingram 1976)
must today be viewed very sceptically.
Macfarlane's use of Russell's Viper venom
(Macfarlane and Barnett 1934) as a topical application on
wounds was one of the first efforts based on a scientific
appreciation of the defect. By 1938 however,
Macfarlane (Macfarlane 1938) had realised that only blood
transfusion offered effective treatment for a bleeding
episode, by replacing the missing essential component.
Patek's group showed this to be present in the cell free
plasma (Patek and Taylor 1937) and in Cohn's classic
fractionation scheme it was shown to be in Fractions I
and II of normal, but not haemophilic plasma (Minot and
Taylor 1947). These fractions and similar fibrinogen-
rich components from ether-fractionated plasma (Kekwick
and Wolf 1957) were recognised as potentially therapeutic
materials. These early products were relatively crude
and insoluble due to their high fibrinogen content and
tended to be unstable. The Blomb&ck modification of
Cohn Fraction I (Blombdck 1958) led to a product that was
much improved in stability and purity.
The introduction of cryoprecipitate as a thera¬
peutic blood product by Pool and co-workers (Pool and
Shannon 1965) was a big step forward. Although the
gelatinous residue that remains undissolved when frozen
plasma is allowed to thaw at a low temperature was known
to be rich in fibrinogen and factor VIII (Ware et al 1947,
TABLE1-2SOMEARLYTYP SFTHE APEUTICMATERIALSFORTHEREATM NTFFACTORVIIID FIC Y Nameof PreparationMethodofPr ductionPurification OverPlasma(X)
GeneralComments
CohnFractionI(F-I) (Cohnetal1946)
Precipitationofplasmaro¬ teinswith8%ethanolat -3°C,pH7mostofthe fibrinogenandfactorVIII areprecipitated
7-20
Carefultechniq eallowsf ctorVIIIt beharv stedatighyields;however, F-Iispoorlyoluble,ratherunstab andca notbesterile-filtered,d hastobepr paredyelabo ate steriletechniqu s
FI-0 (Blomback1958)
ExtractionofF-It0°Cw h aglycine-citratebufferd resolutionoftheprecipi¬ tateinsotonicsaline
10-30








Experienceiswithmallbatches;at¬ temptsoreplicateinit lfindings producedwid lyvaryingresults,prob¬ ablyduetowidevariabilityin batchesoft nnicacid
Bentonite-F-I (Soulier1959)




Additionofglycinet plasmatoconcentration of2.3Mat0°Ctprecipi¬ tatefac orVIIIwithsome fibrinogen
20-30
Useofglycineathighconcentrations expensivea dwastefulipreclu s theuseofsupernatantplasma- techniquesstillusedoprepare'high purityconcent ates(Tabl1-6A)
Brinkhous 1954) Pool developed this as a clinical
product which could be produced by small centres. This
made the widespread adequate treatment of haemophilia
feasible.
Despite the benefits of cryoprecipitate, it
has several limitations: it must be stored frozen, it
has only about five times the potency of plasma, it is
not standardised and it may induce reactions following
administration. Cryoprecipitation was used by Johnson's
group (Johnson et al 1969) in the bulk preparation of an
intermediate purity factor VIII concentrate (classification
of Smith and Bidwell 1979 - Table 1-5). This method,
allowing production of a standardised bulk product, still
forms the basis of most available factor VIII concentrates.
Other methods, involving treatment of plasma or plasma
fractions with chemicals, were used to prepare
concentrates of varying quality. These are summarised
in Table 1-2. Nowadays most of these products, with the
exception of Fraction 1-0, have been superseded by
concentrates prepared by other techniques.
The production of animal factor VIII concentrate
(Bidwell 1955) played a role in providing therapy when
human products were scarce. Such products were
associated with problems due to antigenicity and side
reactions were common, as was thrombocytopenia from the
Platelet Aggregating Factor associated with bovine and
porcine factor VIII. Nowadays such products have been
mostly superseded, although they still play a role in the
TABLE1-3V RIABLESINVOLV DNCRYOPRECIPITATEP DUCTIONTH REFFECTNPRODUCQUAL Y (A)AnticoagulantCPDgiveshi h ryieldthanAC(Regio alTransfusionDir ctor 'Committee1978); somegroupsfindodiffe ence(Slicht rtal1976)rvenb ttyieldswi hACD (Vermeertal1976) (B)PlasmapHAcidificationreducesy eld,optimalH=6.9(Poo1967) (C)PlasmaFreezingMoststudiesclaimfasfreezingimprov syieldanpurity(V m erl1976) (D)PlasmaThawingMoststudiesclaimrapidth wingimprovesyiel(Bre l1967)ndpurity (Vermeertal1976) (E)Blood-GroupHigherVIII:CingroupAplasmasreflectedh ram untsicryo(R gio al TransfusionDirectors'Committee1978);ngroupclaimshi h ryieldcryo fromgroupAplasma(Pr wseetl1982) (F)IonicC mposition ofPlasmaMaintenanceofphysiologicalC 2+levelsiclaimedtimpr vel(Rockt 1979) (G)AdditivesinPlasmaSomeworkersclaimincre s dyieldbyad ingthanol(Newmatl1971)poly¬ ethylenegl col(Johnsontal1979)buoth rsdisputt is(F teret1982). Onegroupclaimsincreas dyieldbyad inghepari(Rocktl1980) (H)ConditionsfStorage ofFrozenPlasmaMoststudiesadvoca eoragbel w-30°C(R kandTittl y1979),thperiodf storagedoesnotappeartbcrucial(K sperel1975) (I)StoragefBlood Priort ProcessingGeneralagreementthatupo6h sr omt mp raturesoeff ctyi ld (Avoyetal1978);longerperi dsr sultilow ryie sacco dingtsomer ups (Vermeertal1976),oth rsclaimnodifferencebetw nlo dproces edt6 18hrsafterdona ion(RegionalTr nsfusionDi ectors'Committee1978)
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management of patients with inhibitors to human factor
VIII (Rizza 1976b). Fractionation using 'polyelectro-
lyte' chromatography (see Table 1-6B) removes most of the
Platelet Aggregating Factor from porcine factor VIII and
lessens the risk of thrombocytopenia.
(D) SURVEY OF AVAILABLE PRODUCTS USED IN TREATMENT OF
HAEMOPHILIA A AND von WILLEBRAND'S DISEASE
1. Cryoprecipitate ('cryo'):
Although being gradually superseded by
freeze-dried concentrates, blood bank cryoprecipitate
is still important due to its ease of preparation
and the relatively high yield of factor VIII which is
obtained. The original technique (Pool and Shannon
1965) was designed to allow the harvesting of cryo¬
precipitate while allowing the recovery of other
blood components. Blood was collected into the
primary bag of a double bag system, and after centri-
fugation platelet poor plasma was expressed into the
secondary bag and frozen. Overnight thawing of the
plasma was achieved in a normal blood bank cold room
or refrigerator and the cryoprecipitate was then
harvested by centrifugation. This allowed the
supernatant plasma to be transferred back to the
cells or used for further fractionation.
A large number of variables have been
studied with respect to the yield and quality of
cryoprecipitate and the results are summarised in
Table 1-3. Table 1-4 lists some of the types of
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TABLE 1-5 CLASSIFICATION OF FACTOR VIII CONCENTRATES
(Smith and Bidwell 1979)
Group 1 Concentrates of low purity - < 0.2 i.u./mg protein
soluble at = 5 i.u./ml, contain 50-80% fibrinogen,
obtained at a yield > 300 i.u./litre fresh frozen
plasma
Group 2 Concentrates of intermediate purity - 0.2-0.5 i.u./
mg protein soluble at 5-20 i.u./ml, contain 40-60%
fibrinogen, obtained at a yield of 200-300 i.u./
litre fresh frozen plasma
Group 3 Concentrates of high purity - > 0.5 i.u./mg protein
soluble at > 20 i.u./ml, contain < 50% fibrinogen,
obtained at a yield of less than 200 i.u./litre
fresh frozen plasma
FIGURE 1-3
PRODUCTION OF INTERMEDIATE PURITY FACTOR VIII CONCENTRATE FROM FRESH
FROZEN PLASMA (NEWMAN et al 1971). ALSO INCLUDED ARE MODIFICATIONS
AT CERTAIN STEPS INTRODUCED BY SUBSEQUENT WORKERS.
NEWMAN PROCEDURE SUBSEQUENT MODIFICATIONS
Crushed Frozen Plasma
bulk thawed to slurry





washed in 20 mM Tris/






20 mM Tris/HCl pH 7
for 30 min at 25°C
V
Factor VIII Rich Extract
adsorbed with 5% v/v
Al (OH) 3 gel for 5 min
at 25°C; gel spun off
and solution clari¬
fied by filtration
1. Ethanol addition omitted as
this compromised purity without
improving yield (James and
Wickerhauser 1972).
2. Plasma blocks mechanically
crushed to 'snow' to increase
surface area and rate of thawing
(Foster et al 1982).
3. Continuous instead of bulk
thawing to improve yield and
purity (Foster et al 1982).
Washing with 20 mM Tris/HCl pH 7
without ethanol improved purity
and solubility (Wickerhauser et
al 1978).
1. Extraction into lower volume
of buffer to increase potency
(James and Wickerhauser 1972).
2. Cold precipitation at acid
pH of contaminants to improve
solubility and filterability
(Smith et al 1979).
3. Extraction time optimised to
improve purity (Smith et al
1979).
Proper pH control during
adsorbtion improves filtrability
and solubility of final solution
(Liu et al 1980).
FIGURE 1-3 (Cont)
I







1. Addition of Ca2+ to prevent
VIII:C lability due to citrate
(Foster et al 1983b).
2. Adjustment of pH of final
solution to 6.6 to improve
stability (Liu et al 1980).
3. Addition of dextrose and
celite to improve solubility and
remove activation products
(Margolis and Rhoades 1979).
cryoprecipitate produced.
Factor VIII Concentrates;
Following the classification of Smith and
Bidwell (Smith and Bidwell 1979) these can be defined
as in Table 1-5.
Group 1 concentrates include FI and cryoprecipitate,
which have been discussed.
Group 2 concentrates are mostly derived from further
processing of bulk cryoprecipitate. The process
described by Newman et al (Newman et al 1971) is out¬
lined in Figure 1-3 in some detail, as it is the most
widely used procedure for manufacture of clinical
concentrates at present.
The 'Newman' method and its modifications
superseded nearly all previous techniques for
producing factor VIII concentrates. Cryoprecipitation
for large scale processing had the advantage that the
fraction harvested was a by product and its production
did not interfere with subsequent Cohn fractionation
of the plasma to immunoglobulin and albumin. Also,
the processing of frozen plasma to cryoprecipitate
had an inherent advantage over the previous precipi¬
tation methods (alcohol, ether,etc.) which involved
the use of plasma which had to be fairly fresh if a
good product was to be obtained. This was because
these precipitation techniques were only suitable for
liquid plasma; processing of frozen-thawed plasma was
not satisfactory. The use of freeze-thawing as a
TABLE1-6APRODUCTIONOFHIGH-PURITYFAC RVI ICON ENTRATES-PREC P TA IONM TH D StartingMater alFractionationProcedure
ProductCharacteristicsndYi l
'Newman' Intermediate Type Concentrate
Fractionalprecipitationwi hPolyethylene Glycol(P.E.G.)Newmanta1971-first precipitationabout4%P.E.G.000pre¬ cipitatesfibrinog nwhichsremoved, factorVIIIisprecipitatedandoncentrated byincreasingP.E.G.concentrat ont11%
Dependingonaturefstartim te ial (plasmage,durationofstoragee c.) productis125-300foldpurifiedoverlasma Yieldisusually<20%.
Solubilised Cryoprecipitate
Fractionalprecipitationwi hP.E.G.t removefibrinog n,ollowedyglycinepre-' cipitationinthecold(Shanbr mnFek te 1971)toprecipitatefactorVIII.Heparin addedinprocessingbuffertinc ea e yieldanpurity(Feketel1974)
Productis110-380f ldpurifiedver plasma,yield=17%.
'Newman' Intermediate Type Concentrate
AdditionofZn2+tfinal[ImM]atpH6.6 and1u/mlheparinrecipitatesabout90% ofthefibrinogenandonectile v s factorVIIIinthesupernatant(Foster al1983a)
Producthasughlytwicethespecific activityofnormalconcentr tendisb¬ tainedtyi lof>90%fr mcryoprecipi¬ tate.Productcanbsubj ctedhe treatmentoinac ivatentaminating viruses(Macleodetl1983)
Solubilised Cryoprecipitate
Precipitationw thglycinea30°Cpre¬ cipitatesfibr nogenbutleavesac orVIII insolution,fr mwhichtcanbesubse¬ quentlyconcentratedbyprecipit ionwi h P.E.G.orNaCl'(BlombMckandThorell1982)
Finalproductisobtainedatyiel=60% fromcryoprecipitate(T a&Myllyla1983) specificactivityibetween3nd7u/mg dependingothefinalr cipitating conditions(Thorelletal1983).Pr duct correctsthbleedingimed f ctinV.W.D. (Thorelleta1983)
tsj
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TABLE1-6BPRODUCTIONFHIGH-PURITYFACTORVI IC N EN A ES-CHROMATOGRAPHICMETH D StartingMaterialFractionationProcedure
ProductCharacteristicsndYiel
Plasmaor Cryoprecipitate
Ionexchangechromatography'Poly lectro- lyte'resin-VIII:Cisadsorbedbatchw se andelutedwithhigio icstrengthbuff rs containinglysine(Joh sonetal1978). VIII:CisthenconcentratedbyP.E.G.
' Polyelectrolyte'VIII:Cis=50f ldpurified overplasmaandislmostfre fvonWi le- brandFactor.Theproc ssyieldov rcryo¬ precipitateis=40%.Theconcentrate producedfromrcinelasmah sbeeuse successfullytoreatpati n sw thVIII:C inhibitors(Kern fftal1981).Thehuman productgaveodclinicalres ltsihaemo¬ philiaAbutoorresultsinV.W.D. (Tuddenhamtal1982)
Intermediate Purity Concentrate
FiltrationonControlledPorGl ss( .P.G.) column(MargolisndRh ade1981).Fibri ¬ ogenisretainedandubs quentlyadsorbed bytheg l,whilefactorVIIIiscollect d inthevoidolume
Concentrateis=90f ldpurifiedoverlasma andisobtainedt=90%yielverth intermediatepurityate ial.Clinica resultsaregood
Intermediate Purity Concentrate
Columnchromatographyveraminohexyl Sepharose(Austenandmith1982)icl im d toremovemuchfhefibrinogenwit possiblereductionfhepat tisBviruand bloodgroupisohaemagglutinins
Finalco centrateis=90foldpurifiedver plasmaatyieldof=43%thestarting material.Noclinic luserep ted-s il insmallcalerese rcht ge
Solubilised Cryoprecipitate
Adsorbtiontandelutifr mTris-Acryl matrix.Fac orVIIIiselutedthigh ionicstrengthafterl waltw sto removefib inogen(L vital1982)
FinalfactorVIIIfrac i nhasspecific activityof>5u/mgndtheyielv r initialcryos=70%.Noclinicaluse reported-stillinma lca erese rchst g
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fractionation step without any reagent addition was
thus much more suitable. A recent report describing
the production (Casillas and Simonetti 1982) and
clinical use (Simonetti et al 1981) of a concentrate
produced by precipitation with the synthetic polymer
polyvinylpyrrolidone indicates that this approach
might be feasible on a small scale, provided that the
plasma can be obtained fairly fresh.
Group 3 concentrates are usually produced by further
fractionation of Group 2 materials. A variety of
procedures are utilised, which are summarised in
Table 1-6A.
A number of recent developments have
utilised chromatographic techniques for the production
of high purity concentrates. These are summarised
in Table 1-6B.
It is worth noting that the term 'high-
purity concentrates' is a misnomer, the specific
activity of pure factor VIII:C being about 2000 u/mg
(Tuddenham 1983). The only major advantage of high
purity concentrates is that of high potency which may
be required in clinical situations needing high doses
and less fibrinogen to avoid associated 'dysfibrino-
genaemia' with high dose therapy. Otherwise, the
loss of factor VIII that is associated with the manu¬
facture of high purity concentrates makes their
production difficult to justify.
(E) BIOCHEMICAL ASPECTS OF FACTOR VIII FRACTIONATION
The development of more sophisticated assays to
measure the different factor VIII related activities have
led to several studies on the levels of these activities
in therapeutic materials (Nilsson and Hedner 1977, Allain
et al 1980, Nilsson et al 1980, Barrowcliffe et al 1981).
Studies showed that all concentrates examined had higher
levels of factor VIIIR:Ag than factor VIII:C (Yang and
Duffy 1978, Nilsson et al 1980) suggesting a selective
loss of clotting activity during fractionation.
Furthermore, the VIIIR:Ag/VIII:C ratio was highest for
the more purified products (Yang and Duffy 1978). Other
studies confirmed these results, although an increase in
VIIIR:Ag/VIII:C ratios for more purified material was not
always found (Allain et al 1980).
Use of the VIII:CAg assay increased the scope
of such investigations. The ratio VIII:CAg/VIII:C was
found to be much closer to unity than VIIIR:Ag/VIII:C
suggesting that rather than inactivation of clotting
activity, mechanical loss of VIII:C molecules is occurring
during fractionation (Barrowcliffe et al 1981). Other
studies indicate that both inactivation and mechanical
loss are occurring, as evinced by increasing VIII:CAg/
VIII:C and VIIIR:Ag/VIII:CAg ratios (Prowse et al 1981).
The development of more sophisticated assays
for VIIIR:Ag led to greater understanding. Using immuno-
radiometric assays (I.R.M.A's) the levels of VIIIR:Ag in
concentrates were shown to be much lower than when measured
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by electroimmunoassay (Laurell) (Nilsson et al 1980).
The increased levels detected by Laurell assays were shown
to be due to a higher electrophoretic mobility of the
VIIIRrAg in concentrates compared to that found in plasma,
due to the loss of higher molecular weight VIIIR:Ag
multimers. VIIIR:Ag in concentrates also had an abnormal
antibody binding capacity in some I.R.M.A's (Nilsson et
al 1980). A lack of large VIIIR:Ag multimers in concen¬
trates was shown by the two-dimensional Laurell technique
(Barrowcliffe et al 1981) and by sodium dodecyl sulphate
polyacrylamide gel electrophoresis (S.D.S.P.A.G.E.)
(Jakab et al 1978). It seems that molecular changes
during fractionation are generating a population of
VIIIR:Ag molecules of lower molecular weight, by selective
removal or/and degradation of higher molecular weight
multimers.
The failure of certain high-purity concentrates
to correct the bleeding time defect in V.W.D. had been
previously noted (Blatt et al 1976). Since these concen¬
trates also lacked higher VIIIRrAg multimers, which had
been shown to be associated with VIIIRrRCF activity,
(Over et al 1978), such a lack was seen to be the reason
for failing to correct the bleeding time in V.W.D. This
explanation however assumes a direct relationship between
the 'bleeding time factor' of V.W.F. and VIIIRrRCF.
Other studies indicated that the question is more complex.
It was shown that high VIIIRrRCF in some concentrates did
not result in these materials correcting the defect in
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V.W.D. (Nilsson et al 1980). One study indicated that
the technique used for measuring VIIIRrRCF was of
importance, a platelet counting technique giving lower
values for most concentrates than the usual aggregometric
method (Barrowcliffe et al 1981). Moreover, recent
findings show that the VIIIR:RCF assay does not always
correspond to von Willebrand activity (Ogata et al 1983).
It is possible that V.W.F. activity and even VIIIR:RCF
(Martin et al 1983) could be a function of some specific
polypeptide chain rather than being solely dependent on
molecular size. One study showed that concentrates
cannot correct the abnormal retention to subendothelium
of platelets in V.W.D. plasma, but no relationship to
multimer size was shown (Sixma et al 1981). It thus
seems that for concentrates, unlike cryoprecipitate,
higher molecular weight VIIIRrAg multimers are lost during
production, and this loss leads to decreased VIIIRrRCF
activity. However, the loss of V.W.F. activity and the
inability to correct the bleeding time defect in V.W.D.
is likely to be the result of an accompanying, less well
characterised, molecular change.
Some reports have claimed that highly purified
concentrates give in vivo recoveries and half-lives for
VIII:C that are lower than for less purified fractions,
suggesting a detrimental effect on the integrity of VIII:C
upon further processing (Smith et al 1972, Nilsson and
Hedner 1977). Other reports find no difference, however
(Weiss et al 1976). One study claims a normal recovery
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and half-life for VIII:C, but greatly reduced values for
VIII:CAg (Holmberg et al 1981) but another study shows
identical in vivo behaviour for VIII:C and VIII:CAg
(McLellan et al 1982). Differences in assay techniques
may account for these discrepancies.
(F) HAZARDS OF REPLACEMENT THERAPY
A life-long dependence on blood products almost
inevitably results in some complications. These will be
briefly reviewed below.
I. Viral Infections:
Liver disease in haemophiliacs.
Using sensitive radioimmunoassays the
incidence for Hepatitis B virus (HBV) exposure in
haemophiliacs approaches 100 percent as assessed by
presence of antibodies to surface antigen (anti-HBsAg)
(Enck et al 1979). The prevalence of the antigen
(HBsAg) ranges from 4 to 9 percent (Self and Hoofnagle
1976). Lack of suitable markers renders difficult a
detailed study on the exposure to non-A, non-B
viruses (NANB), but strong evidence suggests that they
are found in clotting factor concentrates and can be
transmitted to haemophiliacs (Mannucci et al 1982,
Tabor et al 1983).
In the light of these facts, the relatively
low incidence (6-26 percent) of clinical hepatitis in
haemophiliacs is surprising (Self and Hoofnagle 1976).
However, a number of studies have shown a history of
abnormal liver function tests and liver biopsy
histology in the majority of haemophiliacs (Hruby
and Schauf 1978). A recent report (Mannucci et al
1982) indicates that in patients with chronic liver
disease the disease was non-progressive in individuals
having no evidence of hepatitis B or 6 virus markers.
This indicates that NANB might not pose as big a
threat as these other agents.
Acquired immunodeficiency syndrome (AIDS) and
haemophilia.
AIDS is a recently recognised and relatively
poorly understood syndrome associated with abnormali¬
ties of immunoregulation and a profound susceptibility
to opportunistic infections. It is eventually fatal
in many patients (Marx 1982). One report has
included three haemophiliacs among cases of the
disease (Centers for Disease Control 1982) and the
number has subsequently grown. More disturbingly,
other reports (Lederman et al 1983, Menitove et al
1983) have reported abnormalities in the immune
status of haemophiliacs as revealed by laboratory
tests that are similar to but not of the same degree
as found in AIDS patients.
These reports have shown abnormalities in
lymphocyte function in patients receiving freeze-dried
concentrate with normal values in patients receiving
cryoprecipitate (Lederman et al 1983). The most
commonly measured parameter is the ratio of helper to
suppressor cells and as far as abnormalities in this
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ratio are concerned, the plasma source - voluntary or
commercial - does not seem to matter (Cable et al 1983,
Froebel et al 1983). However, data from this rather
non-specific test cannot be extrapolated to the actual
clinical manifestation of AIDS and there seems little
doubt that American concentrates now constitute a
high-risk product. Although more patients need to
be studied before definite conclusions can be drawn,
it seems that AIDS poses a potentially major threat
for haemophiliacs.
Measures to decrease the possibility of viral
contamination of therapeutic products.
The dangers of hepatitis transmission and
the new threat posed by AIDS, necessitate measures to
decrease the possibility of viral contamination of
factor VIII concentrates. Some recent studies cast
doubts on certain long-held beliefs in this area.
Although early reports suggested that plasma from
paid donors exhibits a higher incidence of hepatitis
transmission than plasma from voluntary donors
(Sgouris and Wickerhauser 1973) a recent survey on
Australian haemophiliacs cast some doubt on this
assumption (Rickard et al 1982). All blood products
in Australia are furnished from a voluntary donor
system, yet liver abnormalities were found in 67% of
severe and 45% of mild haemophiliacs. A study on
Edinburgh haemophiliacs showed that the introduction
of sensitive assays for HBsAg for screening donor
plasma also had no effect on the prevalence of
infection as determined by liver function tests
(Ludlam et al 1982).
Heat treatment at 60°C is the traditional
way of sterilising the main plasma protein fraction -
albumin - but is not such a straightforward option
with a protein as labile as factor VIII. Both
VIII:C and VIII:CAg have been shown to be extremely
labile at high temperatures (Furlong and Peake 1983)
and for pasteurisation to work, ways of protecting
the molecule must be found. The first heat-treated
factor VIII concentrate had sucrose added to the
solution to stabilise the factor VIII:C (Heimberger
et al 1981). Yields achieved, however, are of the
order of 5%. Some success has been claimed in
heating lyophilised concentrate (Rubenstein 1981) with
retention of activity. Infectivity studies with
chimpanzees (the only suitable model for hepatitis as
it is the only mammal in which the infection has been
described) tend to support claims that these procedures
result in reduction in infectivity. A new method
involving sorbitol and glycine stabilisation of a
fibrinogen-depleted cryoprecipitate extract has been
described (Macleod et al 1983). This has allowed
the standard pasteurisation of 60°C for 10 hours to
be carried out with retention of 75% of the starting
VIII:C, while inactivating several model viruses
added to the system (Foster et al 1983c).
Alternatives to heat treatment include the
addition of HBsAg immunoglobulin to concentrates
(Brummelhuis et al 1983) and combined treatment with
ultraviolet irradiation and chemical agents and
detergents (Prince et al 1983). The AIDS problem
has highlighted the necessity for developing general
ways of inactivating viruses rather than specific
removal of one type of virus. The well-tried
method of heat-treatment seems to be the best approach
in this regard, but other less well validated methods
may be acceptable provided they lead to a product
with the same characteristics.
Other Hazards;
Development of VIII:C inhibitors.
It is still not known why about 10% of
haemophiliacs develop inhibitors to factor VIII:C
following replacement therapy (Deykin 1974). Develop¬
ment of such inhibitors constitutes an obvious
therapeutic problem. The use of massive doses of
conventional high-purity concentrate in an attempt to
overcome inhibitors puts a strain on the supply of a
limited resource, and such therapy often induces an
anamnestic response (Rizza and Matthews 1982). The
recent development of 'polyelectrolyte' porcine
factor VIII:C (Hyate, Speywood Laboratories) has had
some success while avoiding the problems previously
associated with animal concentrates. Complications
using the product have been reported however (Exner
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and Rickard 1983).
The use of activated prothrombin complex
concentrates first reported in 1972 (Fekete et al
1972) has led to intensive investigation of such
materials for this purpose (Abildgaard et al 1980).
Normal prothrombin complex concentrates have been
shown to be equally effective (Lusher et al 1983) and
this finding is difficult to reconcile with hypotheses
linking the effectiveness of these products with their
content of activated clotting enzymes. Recently it
has been shown that the significant amounts of
VIII:CAg found in these concentrates (Onder and Hoyer
1979) is bound to phospholipid at a site close or
identical to the antibody binding site (Barrowcliffe
et al 1983). This finding suggests a mechanism for
the action of these products, and has implications in
devising better concentrates for tackling this
problem.
Blood group antibodies.
Haemolysis due to the presence of anti-A
and anti-B in factor VIII preparations has been
reported (Orringer et al 1976) but does not necessarily
depend on the concentrations of these antibodies
(Seeler 1976). Some companies supply 'isoagglutinin-
free' or group-specific concentrates but such a policy
adopted generally would be too restrictive.
It has been shown that prior mixing of
multiple ungrouped donations of plasma resulted in
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Sufficient Products Available 25 19
Insufficient Products Available 16 18
Not Used 2 6
Total Number of Countries
Reporting
43 43







Domestic and Imported 10
Total 19
Both tables taken from Britten (1983)
high concentrations of anti-A in the final concentrate,
whereas processing of single donations to cryopreci-
tate resulted in much lower concentrations (Smith et
al 1980). This suggests that formation of a macro-
molecular A substance - anti-A complex results in such
a complex being concentrated in the final product,
possibly by cryoprecipitation during fractionation.
Resolution of the dried concentrate then dissociates
the complex releasing the antibody. Processing of
single donations or group specific pools avoids this
problem.
(G) THE PRESENT STUDY
Despite the advances which have been described,
there is a world-wide shortage of factor VIII products
for haemophilia treatment. Tables 1-7 and 1-8 show the
results of an investigation carried out by the World
Federation of Haemophilia (Britten 1983). It can be
seen that less than half the countries reported having
sufficient factor VIII concentrate, and only 14% of
countries reported producing enough concentrate themselves
to meet their needs.
Moreover, 80% of the world's factor VIII
concentrate is produced from plasma collected in the
United States by plasmapheresis of paid donors. Countries
which lack the technology to produce their own materials
have to rely on importation of these expensive products.
In the writer's own country of Malta a population of 25
haemophilia A patients and 3 von Willebrand's disease
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patients is supplied with one million units of factor VIII
yearly in the form of imported concentrate, at a cost of
about 150,000 U.S. dollars. Such an outlay of scarce
foreign currency on a small number of patients provides
a heavy burden on the limited resources of underdeveloped
nations. These financial considerations ignore the
ethical problems associated with providing patients with
materials derived from commercial plasma sources, problems
which are once again highlighted by the AIDS problem.
The range of concentrates now available are
usually manufactured by bulk processing of frozen plasma
on the 1000 kg scale. After the preliminary extraction
of factor VIII, such plasma is then further fractionated
to immunoglobulin and albumin by industrial Cohn
fractionation. These procedures are carried out by
large industrial plants, both for commercial and state-
funded concerns. Small scale processing is still largely
made up of single donation or small pool cryoprecipitate
made by blood banks. The disadvantages of cryoprecipi¬
tate have already been outlined. Some attempts have
been made to overcome some of these by e.g. lyophilisation
to enable more convenient storage and reprecipitation in
the cold to improve purity (Milligan et al 1981, Smit-
Sibinga et al 1981). However, freeze-dried concentrates
in use by technologically unadvanced countries are still
mainly supplied through large scale industrial
fractionation in the developed countries, in the form of
materials derived from commercially acquired plasma.
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There thus exists a need to develop approaches
for producing factor VIII concentrates that do not rely
on present methods based on industrial fractionation of
bulk plasma. These methods need to have the following
characteristics:
(1) They have to be adapted to small scale processing
(5-50 kg scale) such that they can be carried out in
local blood banks.
(2) They must be able to produce factor VIII at a high
yield, in order to make the most out of the limited
plasma available.
(3) They must be based on technology that is simple and
cheap to set up and maintain.
(4) They must fulfil all the pharmaceutical criteria for
a good product, such that they are an acceptable
substitute for commercially produced materials.
(5) They must allow use of the residual plasma after
factor VIII extraction as a volume expander or
possibly to be used to derive other products.
It is the object of this study to examine the
possibilities for improved procurement of factor VIII with
the above considerations in mind, ie. to make possible a
level of self-sufficiency in factor VIII concentrates for
countries without access to high technology. In the
course of this work, optimal conditions for processing
plasma to cryoprecipitate have been derived after investi¬
gation of such variables as storage temperatures, storage
periods, anticoagulants, freezing rates etc. The use of
alternatives to cryoprecipitation as a means of concen¬
trating factor VIII have been examined and a new method
involving the use of hydrophilic polymers to precipitate
factor VIII from unfrozen plasma has been developed.
Methods of further purification have also been investi¬
gated. The influence of ABO blood group and of drug
induced enhancement on levels of factor VIII in starting
plasma have also been studied.
Based on these findings, recommendations will
be made for improved procurement of factor VIII from
blood donations.
CHAPTER II
GENERAL MATERIALS AND METHODS
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(A) PREPARATION OF NORMAL POOLED PLASMA STANDARD
The plasma was prepared for use as a routine
coagulation control in the South-East Scotland Blood
Transfusion Service. Each of 12 dry Fenwal double
blood bags were injected with 50 ml of trisodium
citrate/Hepes anticoagulant (106 mM citrate, 210 mM Hepes)
on the morning of collection. 450 ml of blood were
collected into each bag. Selection of donors was on the
basis of blood group only; 6 group A and 6 group 0 were
chosen. Plasma was separated at 4°C by centrifugation
in a Damon (IEC) GPR 6000 centrifuge at 4,200 r.p.m. for
10 minutes. Plasma was expressed into the secondary
packs which were then centrifuged at the same speed for
10 minutes to obtain platelet poor plasma. This was
pooled into a 5 litre pack and mixed thoroughly. A
platelet count was performed at this stage and was
typically less than 5 x 109/litre. The plasma was
aliquoted (0.8 ml ) into prelabelled polypropylene
test tubes using a Watson Marlow 10 channel peristaltic
pump, silicone rubber tubing being used throughout.
Screw caps were fitted and all tubes placed in
the vapour phase of a liquid nitrogen refrigerator.
Several coagulation parameters including assays for
factor VIII related activities were tested at least
5 times and a mean value was calculated. A supply of
the material was placed in -40°C storage every week for
routine use. A fresh preparation was made every 4
months.
(B) ASSAY OF FACTOR VIII COAGULANT ACTIVITY (VIII:C)
The assay used in this study was the one-stage
assay based on the partial thromboplastin time (Hardisty
and Macpherson 1962). In this assay system, dilutions
of test material are used to clot samples of plasma
totally deficient in VIII:C. The substrate plasma
supplies all the factors required for the formation of
fibrin except VIII:C which is supplied by the sample.
The first stages of the coagulation sequence (see
Figure 1-2) are initiated by addition of a negatively
charged surface and phospholipid acts as a substitute for
the platelet surface. Both these reagents were added
in the form of the General Diagnostics APTT reagent,
which provides these components as a mixture of micro-
nised silica and cephalin. Calcium chloride was added
to initiate the later stages of coagulation. Reagent
addition and optical detection of the end point (fibrin
formation) were done using a automated clot-detector,
the Coag-a-pet (General Diagnostics). The assay can be
summarised as follows:
*0.1 ml test dilution (in 50 mM Tris, 60 mM NaCl pH 7.4)
*0.1 ml substrate plasma
+ 0.1 ml activator (Silica / Cephalin)
Incubated 5 minutes
+0.1 ml 33 mM CaCl?




ESTIMATION OF VIII:C CONTENT IN COAGULATION ASSAY
Standard and test lines are shown, with intrapolation
from test to standard to obtain test VIII:C content
as a % of standard.
4 6
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Calculation of sample potencies; A standard of known
VIII:C content was assayed at 3 dilutions (1/10, 1/20
and 1/40) along with 3 dilutions of each sample. Clotting
times obtained for each dilution were plotted on semi¬
log graph paper with log concentration being plotted
against clotting time. Straight lines were drawn
through the points for each sample. Lines for standard
and test samples should be parallel - Figure 2-1.
By interpolation from test to standard lines,
the potency of the test samples relative to the standard
was estimated. As shown in Figure 2-1, this results in
112% for test 1 and 72% for test 2 samples. Using
these and the assigned standard potency, the test
potency was estimated e.g. if in Figure 2-1,
standard = 0.7 u/ml
then test 1 = 112% of standard = 0.78 u/ml
test 2 = 72% of standard = 0.5 u/ml
Dilutions of test samples were chosen so as to
result in clotting times which overlap with those of the
standard. Thus in samples containing low VIII:C
levels, e.g. cryosupernatants, lower dilutions were used
e.g. 1/5, 1/10, 1/20. The opposite was done with samples
of high VIII:C content. When assaying concentrates, a
concentrate standard supplied by the National Institute
of Biological Standards and Control, London, was used.
This was first diluted to 1 u/ml and then diluted as for
plasma. Samples of concentrate for assay were also
pre-diluted to about 1 u/ml.
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Repeated assay of the same sample gave a between
run geometric coefficient of variation for the assay of
5%.
Preparation of artificial factor VIII deficient substrate
for use in the one-stage assay.
As congenitally deficient substrate plasma was
not always available, assays were sometimes performed with
artificial factor VIII deficient substrate. This
material was generously provided by Mrs. Brenda Griffin
of the Headquarters Unit Laboratory of the Scottish
National Blood Transfusion Service and was prepared as
follows:
Components
1. Serum: Serum was obtained from human blood donations
and supplied by the Reagents Laboratory of the South-
East Scotland Blood Transfusion Service. To each
100 ml of serum, 1 ml sodium azide (20% solution)
was added to prevent bacterial growth. The serum
was incubated at 37°C for 72 hours, citrated with
1 part 0.55 M trisodium citrate to 24 parts serum, and
kept for a further 72 hours at 4°C. It was then
centrifuged at 15,000 r.p.m. for 2 hours at 4°C to
allow removal of lipid and the infranatant was
collected. Tests found no detectable VIII:C in the
material. Batches were also tested for prothrombin
content, as a final level of > 20% average normal was
necessary for satisfactory results in the VIII:C assay.
2. Factor V preparation: (Nyman 1970) Oxalated bovine
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plasma was obtained from the West of Scotland Blood
Transfusion Service or from the local abattoir. It
was kept frozen at -40°C until used. The plasma was
thawed at 37°C and recalcified with 1/4 of its volume
of 0.1 M CaC^. It was incubated at 37°C for 4
hours. The clot was loosened from the sides of the
bottle and removed by centrifugation at 13,000 r.p.m.
for 10 minutes at 20°C. The serum was then adsorbed
with barium sulphate (50 mg/ml) for 45 minutes at room
temperature with constant stirring. The barium
sulphate was removed by centrifugation at 13,000
r.p.m. for 10 minutes at 0°C. In later preparations,
the barium sulphate step was omitted. The serum was
immediately brought to 35% saturation with ammonium
sulphate (i.e., 19.4 g (NH4) SO4 per 100 ml super¬
natant) . Mixing was carried out for 30 minutes at
0°C (in ice-water mixture in a 4°C cold room) and the
precipitate was then removed by centrifugation at
13,000 r.p.m. for 15 minutes at 0°C. The supernatant
was brought to 55% saturation with ammonium sulphate
(i.e., 11.8 g (NH4) SO4 per 100 ml 35% supernatant),
mixed for 45 minutes at 0°C and centrifuged at 13,000
r.p.m. for 15 minutes at 0°C. The precipitate was
dissolved in a minimum amount of 1 part physiological
saline to 4 parts distilled water and dialysed for
24 hours at 4°C against 50 mM Tris, 150 mM NaCl
pH 7.4. The factor V preparation was citrated with
1/24 of its volume of 0.55 M trisodium citrate and
FIGURE 2-2
COMPARISON OF ARTIFICIAL AND CONGENITAL SUBSTRATE
PLASMA IN VIII:C ONE-STAGE ASSAY
Plasma samples were assayed against a known standard
using both types of substrate.




ns57 Congenital Mean s o-767 ± o>165 U/ml
Artificial Mean = o772 ± o«142 U/ml
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concentrated on an Amicon cell (YM 10 membrane) to
10 mis. Factor V estimation revealed that the
preparation had about 34 times the potency of normal
pooled plasma. Factor VIII:C content was about 7%
of normal pooled plasma but as the preparation was
diluted 1/50 in the final substrate, VIII:C content
was only 0.14%. Assay for thrombin revealed levels
of less than 0.01 u/ml.
3. Fibrinogen: Lyophilised human fibrinogen (Kabi
Grade L) was dissolved in the serum preparation to
give a concentration of 2 g/litre. The VIII:C level
was 0.3%.
Preparation of substrate.
Fibrinogen was dissolved in serum and the
mixture was centrifuged to deposit any undissolved
material. 7 ml of the factor V preparation was added
and the mixture was aliquoted, frozen at -40°C overnight
and then cooled further in liquid nitrogen. The
aliquots were then freeze-dried for 2 days. One sample
of freeze-dried material was reconstituted with distilled
water and had a VIII:C level of 0.75% of normal pooled
plasma (assayed using congenitally deficient substrate)
and a factor V level of 82%.
Validation of the VIII:C assay using artificial substrate.
Figure 2-2 shows the results of an exercise
designed to assess the behaviour of the VIII:C assay using
artificial substrate plasma. A good agreement with the
assay using congenital substrate was obtained, showing the
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suitability of the artificial substrate.
Assay of VIII;C in samples containing additives.
1. Heparin: In studies utilising heparin as a plasma
anticoagulant or additive (Chapters III, V and VI) it
was necessary to remove heparin from the samples prior
to VIII:C assay. This was done using either of two
methods.
(a) ECTEOLA - cellulose chromatography (Thompson and
Counts 1976): ECTELOA-cellulose (100 g, SIGMA) was
suspended to form a slurry and then poured into a
sintered glass funnel. It was washed alternately
with 200 ml* of 0.5 M NaOH, 0.5 M HC1 and 0.5 M NaOH.
Between these washes, one litre washes with distilled
water were applied. Following the last water wash,
the cellulose was equilibrated with 50 mM Tris,
150 mM NaCl pH 7.4 and stored at 4°C. For use in
removing heparin from samples, the cellulose was
packed into 3 ml plastic columns placed vertically
into glass tubes and the buffer wash was allowed to
flow into the bed. 1 ml samples containing heparin
were then applied to the top of the cellulose and
allowed to flow into the bed. When pigmented plasma
was visible in the effluent, another 1 ml of the
sample was applied. The first 1 ml of pigmented
effluent was discarded, as it was found to be diluted
with column buffer. The second 1 ml was collected
and assayed for total protein and VIII:C. Table 2-1
shows that this method effectively removed heparin
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FIGURE 2-3
TITRATION OF HEPARIN-CONTAINING PLASMA WITH
PROTAMINE SULPHATE
Plasma contained 10 u/ml of sodium heparin and was
titrated with a 1 mg/ml protamine solution as
described in the text.
CLOTTINGTIME(S)
from samples of varying VIII:C content. However, it
was rather laborious and needed at least 2 mis of
sample per assay. The method was furthermore
unsuitable for samples containing high amounts of
fibrinogen, which tended to adsorb to the cellulose
and clog up the column. For assay of large numbers of
samples, the method involving protamine neutralisation
was found preferable.
(b) Protamine-titration: This was performed as
described by Rock (1983a) with some modifications.
Plasma samples containing heparin at concentrations
%
of 2 to 12 u/ml were processed as follows: 0.1 ml
aliquots of the plasma samples were placed in 2 ml
plastic tubes. Amounts of 2 to 24 |il of a stock
solution of 1 mg/ml protamine sulphate were added to
12 such tubes, so that tubes with 2, 4, 6.... 24 p,l
of protamine sulphate were thus made up. The
contents were then mixed and made to 1 ml with
50 mM Tris, 60 mM NaCl pH 7.4. 0.1 ml of each of
these mixtures was then assayed for VIII:C in
duplicate as described above. For each sample, the
12 individual mixtures containing heparin and different
amounts of protamine were assayed together, with a
series of dilutions of standard plasma being included
in the assay run. The clotting times shortened and
reached a plateau with increasing amounts of protamine
sulphate, excessive amounts tending to increase the
clotting time (Figure 2-3). In general, the shortest
TABLE2-2ASSAYOFVIII:CINPLASMACONTAININGHEP RINDEPARIN/CALCIUM SampleVIII:C(u/ml) NoHeparinVIII:C(u/ml) +5u/mlHeparin +ProtamineTitr tion






























clotting time was found at a heparin:protamine ratio
of 1 u of heparin: 15 iig of protamine. The shortest
clotting time was used to derive the VIII:C value from
the standard curve. Although this method utilised
single point determinations instead of parallel line
interpolation, assay of known plasma standards, to
which heparin had been added, using this technique
gave results corresponding closely with the assigned
values (Table 2-2). The presence of added calcium,
as well as heparin, did not affect the VIII:C
determination.
%
2. Zinc salts: In fractionation experiments using zinc
ion precipitation (Chapter VI) it was important to
determine whether the added zinc salts had any effect
on the VIII:C assay. Addition of 1 mM zinc acetate
to samples of concentrate of known potency had no
effect on the VIII:C content as determined by the one-
stage assay. Linearity and parellelism with respect
to the standard curve were also y.naffected. It should
be noted that 1 mM zinc acetate in the sample was
diluted about 600 fold as a result of the assay
procedure.
(C) ASSAY OF FACTOR VIII COAGULANT ANTIGEN (VIII:CAg)
To measure VIII:CAg, a one-site fluid phase
immunoradiometric assay (IRMA) was used, based on the
method of Rotblat and Tuddenham (1981). The principle
of the assay is shown in Figure 2-4.
Preparation of stock anti-VIII:CAg reagent: 2 ml of
60
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plasma from a patient with an inhibitor to VIII:C (2400
Bethesda units/ml) was clotted by incubation at 37°C for
18 hours with 1 u/ml of thrombin. The clot was removed
and the serum was dialysed for one hour against 2 litres
of 10 mM phosphate buffer, pH 6.5. 20 g of DEAE A25
Sephadex (Pharmacia) were swollen overnight in 0.5 M
phosphate, packed into a column and washed with 10 mM
phosphate pH 6.5 until the conductivity equalled that of
the wash buffer. The serum was pumped through the
column which was eluted with wash buffer. 2 ml fractions
were collected and the absorbence at 280 nm was measured.
Fractions containing unbound protein were pooled, and the
protein content was estimated from absorbence at 280 nm,
assuming an extinction coefficient of 14 for IgG. The
pool was concentrated in an Amicon cell (YM 10 membrane).
4 ml of concentrate were dialysed against 0.1 M acetate
buffer pH 4.2 for 3 hours. The IgG was then digested
with pepsin at a concentration of 2 mg/100 mg IgG. This
was added as a solution of 1 mg/ml in 0.1 M acetate
buffer pH 4.2. Cysteine was then added to a final
concentration of 10 mM. The mixture was incubated at
37°C for 22 hours after which it was neutralised with
solid Tris and the protein content was estimated. The
digest was mixed with Protein A Sepharose (Pharmacia)
(1 ml packed gel in 50 mM phosphate pH 7.4) for 15
minutes at room temperature. The mixture was centrifuged
to deposit the gel with the bound Fc fragments of the IgG.
The supernatant protein represented 64% of the total
TABLE 2-3 PREPARATION OF STOCK ANTI-VIII:CAg Fab FROM
INHIBITOR PLASMA




1. Inhibitor Serum 2.9 112
2. DEAE Unbound Fraction 27.5 24.8
3. Concentrate of (2) 6.7 21.8
4. Pepsin Digest 4 13.8
5. Protein A Unbound Fraction 3.4 8.8
6. (5) Post Dialysis
%
12.6 8.8
digest, which is the proportion expected if the Fc was
removed by protein A and the Fab was left in the super¬
natant. The supernatant was then dialysed against 50 mM
phosphate pH 7.4. The stock Fab reagent thus prepared
was stored frozen at -40°C in 20 ul aliquots. Table 2-3
summarises the various stages of the procedure.
Radiolabelling of stock Fab reagent: Labelling of Fab
with 125Iodine was done using the chloramine-T method
(Greenwood et al 1963) as follows:
Reagents:
Chloramine-T - 50 mg in 10 ml> of 50 mM phosphate pH 7.4
KI - 0.1 g in 10 ml of 50 mM phosphate pH 7.4
Na2S2C>5 - 160 mg in 10 ml of 50 mM phosphate pH 7.4
then 0.1 ml of this in 10 ml of 50 mM
phosphate for use.
Method:
20 ul Fab reagent
20 nl 125I (2 mCi)
10 nl Chloramine-T
mixed for 10 seconds
add 0.85 ml Na2S2C>5
0.1 ml KI
Separate iodinated Fab by gel filtration (Figure 2-5a)
Purification of labelled Fab by immunoaffinity chroma¬
tography: 10 ml of intermediate purity factor VIII
concentrate (15 u/ml VIII:C, Protein Fractionation Centre
Edinburgh) were coupled to 7.5 g of cyanogen bromide
activated Sepharose 4B (Pharmacia). The beads were
FIGURE 2-5
PREPARATION OF STOCK 1251 ANTI-VIII:CAg Fab
(A) shows the gel filtration of the mixture obtained
%
after iodination. Fractions 6 and 7 were pooled
and immunopurified as described in the text.
(B) shows the elution of specific 125i anti-VIII:CAg
Fab off the immobilised factor VIII column,




swollen in 500 ml of 1 mM HC1, stirred at room temperature
for 30 minutes and sedimented by centrifugation. The
hydrated beads were resuspended in 1 M NaCl and the pH
was adjusted to 7 with 0.1 M NaHCC>3. • The factor VIII
concentrate was added, and the pH was brought to 7.8.
The gel was mixed end over end at room temperature for
24 hours and was then filtered and washed on a glass
sintered funnel with normal saline. The gel was
equilibrated in 0.5 M NaCl, 50 mM phosphate pH 7.5 prior
to use in immunopurification.
The pool containing the peak fractions of
protein-bound radioactivity was mixed with 10 ml of
Sepharose-coupled factor VIII concentrate for 2 hours at
room temperature. The gel was then packed into a small
column and washed with 0.5 M NaCl, 50 mM phosphate pH 7.5.
Fractions were collected and the eluted radioactivity was
monitored. When the radioactivity had reached a base¬
line, elution was continued with 50 ml of 0.1 M glycine-
HC1 pH 2.5. 1 ml fractions were collected. Fractions
containing peak radioactivity were pooled (Figure 2-5b)
and incubated at 37°C for 30 minutes. The pH of the
pool was adjusted to 7.2 with solid K2 HPO4 and 1 ml of
turkey serum was added. For use in the assay this stock
1251 anti-VIII:CAg Fab was diluted with 50 mM Tris,
150 mM NaCl 1% turkey serum pH 7.4 until a count of about
2000/100 n,l/minute was registered in an NE 1600 gamma-
counter.
Assay of factor VIII:CAg: The assay was performed as
FIGURE 2-6
STANDARD CURVE OF THE VIII:CAg IMMUNORADIOMETRIC
ASSAY
To estimate sample potency, normal pooled plasma was




0.1 ml 1251 anti-VIII:CAg Fab
0.1 ml test sample
0.1 ml turkey serum
incubated 18 hours at 37°C
0.3 ml 76% saturated (NH4)2SC>4 added
mixture incubated 30 min. at 22°C, centrifuged
for 36,000 g min.5*-
precipitates
washed with 1 ml 38% saturated (NH^^SC^
centrifuged for 35,000 g min.
count radioactivity of washed precipitate.
A standard curve was constructed using normal pooled
plasma (Figure 2-6). In general, the assay was sensitive
to levels of about 2% of the VIII:CAg level of normal
plasma. In assaying samples, 2 dilutions were usually
used, suitably estimated to fall on the linear part of
'the standard curve. The amount present in 1 ml of
pooled plasma was taken as 1.U. The assay gave a between
assay coefficient of variation of 21% when assaying
repeatedly the same sample.
(D) ASSAY OF FACTOR VIII RELATED ANTIGEN - VIIIR:Ag
Initial assays in this study used the Laurell
technique with a commercial antiserum to VIIIR:Ag
(Hoechst). During the course of the work, an antiserum
to VIIIR:Ag was raised and used to set up Laurell and
IRMA assays for this protein.
Purification of VIIIR:Ag for use as an immunogen; Several
* Except where i£ is otherwise specified, in this thesis total
centrifugal force is expressed as g min, being the centrifugation
in g per minute multiplied by the time in minutes. Speeds and




GEL-FILTRATION OF 4% FICOLL-70 PRECIPITATE
Gel filtration was performed on Sepharose CL-4B as
described in the text.
Fractions containing VTIIR:Ag without detectable














































SDS-PAGE OF PURIFIED IMMUNOGENS
Factor VIIIRrAg and fibronectin were purified as
described in the text. Samples of each protein were
electrophoresed in the presence of SDS. The
preparations were reduced with 1% mercaptoethanol.
The gels were 6% acrylamide.
The respective tracks from left to right were:
(1) Pharmacia low molecular weight marker proteins





(6) Pharmacia high molecular weight marker proteins.
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preparations of VIIIR:Ag were made utilising cryo-
precipitate or plasma as starting material. A typical
preparation is described below:
Six donations of blood were taken from routine collection
sessions and the plasma separated by centrifugation for
90,000 g min. at 4°C. The plasma was pooled into poly¬
carbonate bottles and precipitated with 4% Ficoll 70 at
0°C for 2 hours (Chapter V). The resulting precipitate
was harvested by centrifugation for 30,000 g min. at 0°C,
dissolved in 35 ml of 15 mM citrate, 150 mM NaCl pH 6.9.
The dissolved precipitate was applied to a column (2.5 x
65 cms) of Sepharose CL-4B (Pharmacia) equilibrated with
(ftftTWOff e.1 «<- 1164)
citrate-saline-3 mM sodium azidejl Figure 2-7 shows the
elution profile for this column. Fractions were screened
for VIII:C by coagulation assay, for VIIIR:Ag, fibrinogen
and fibronectin by Laurell assay and for total protein by
absorbence at 280 nm. Fractions containing VIIIR:Ag
without detectable fibrinogen were pooled. The pool was
concentrated by dialysis against 50% PEG 6000 in citrate-
saline, and the concentrate was stored frozen at -40°C.
Prior to immunisation, samples were dialysed against
150 mM NaCl, 50 mM phosphate pH 7.5 without any azide.
Table 2-4 summarises the purification procedure. SDS-
polyacrylamide gel electrophoresis in the presence of
reducing agent confirmed that the VIIIR:Ag had a subunit
molecular weight of 220,000 (Hoyer 1981) (Figure 2-8).
Production of antiserum: The purified VIIIR:Ag was used
to immunise 6 New Zealand white rabbits. Immunisation
FIGURE 2-9
IMMUNOELECTROPHORESIS USING RABBIT ANTISERA TO
VIIIR:Ag
2DIEP and Laurell electrophoresis are shown for
bleeds from three different rabbits.
In Laurell electrophoresis, samples were four
dilutions each of normal plasma and factor VIII
concentrate respectively.
Normal plasma was electrophoresed in 2DIEP.
T 7
was by subcutaneous 4-site injections consisting of 150 p,g
of antigen in Freund's complete adjuvant. Boosts were
given 2 months and 3 months after the primary injection
and consisted of 65 jig of antigen in Freund's incomplete
adjuvant. The rabbits were bled at intervals to test
the sera for reactivity with VIIIR:Ag. This was done
by incorporating the antisera in agarose and testing them
in the Laurell technique with pooled plasma and factor
VIII concentrate (Figure 2-9). Specificity was tested
using two-dimensional Immunoelectrophoresis (2DIEP) and
immunodiffusion. In 2DIEP, the antisera produced only
one precipitin arc against normal pooled plasma
(Figure 2-9). Using immunodiffusion one or two faint
precipitin lines were sometimes observed in addition to
the main line due to VIIIR:Ag. However, a validation
exercise carried out by the Coagulation Laboratory of the
South-East Scotland Blood Transfusion Service demonstrated
good agreement between Laurell assays using a commercial
anti-VIIIR:Ag antiserum and the pooled antiserum from the
rabbit bleeds (Mackay 1984, personal communication)^" The
antisera were thus considered suitable for use. The
pooled antiserum was heat inactivated at 56°C for 30
minutes, aliquoted and stored frozen at -40°C for use.
£ 1 » M M e A MrtM
Assay for VIIIR:Ag - Laurell assay I: Commercial and later
on locally produced antisera to VIIIR:Ag were used to set
up an electroimmunoassay using the technique of Laurell
(1966). Agarose (Bio-Rad) was dissolved to a final
concentration of 1% in buffer consisting of 0.1 M Tris,
* In this exercise, the anti-serum failed to produce a precipitin
'rocket' with plasma from a patient with severe von Willebrand's
disease, thus demonstrating specificity towards VIIIR:Ag.
FIGURE 2-10




3.2 mM ethylenediaminetetraacetic acid (disodium salt)
15 mM boric acid pH 8.9, by heating to 80°C. The agarose
was then cooled to 56°C and antiserum to VIIIRrAg added
and mixed. The volume of antiserum was 0.4% and 0.09%
v/v of agarose for the commercial and locally produced
antisera respectively. The agarose was poured onto a
piece of Gel-Bond (Miles Laboratories) to a thickness of
2 mm and allowed to set. Wells were punched along one
end of the plate and filled with 10 y. 1 of sample.
Electrophoresis was then carried out at 120 V for 18
hours using a Pharmacia 2000/300 power supply with the
plate on a Pharmacia 3000 flat-bed support. Wicks at
each end of the plate consisted of 3 thicknesses of
Whatman No.1 filter paper and connected the plate to
two 300 ml reservoirs of the buffer used for making up
the agarose.
After electrophoresis, the plate was dried
under a stream of warm air and stained using 0.25%
Coomassie Blue R in 14% methanol, 7% acetic acid. The
plate was then destained using 14% methanol, 7% acetic
acid. The height of the 'rockets' (see Figure 2-9) were
measured and a standard curve was plotted using dilutions
of normal pooled plasma (100%, 50%, 25%, 12.5%). Rocket
height was plotted against the logarithm of the concen¬
tration. The standard curve was linear for VIIIR:Ag
concentrations of between 100% and 25% of normal pooled
plasma (Figure 2-10). Samples for assay were pre-
diluted to levels of about 1 u/ml and then assayed using
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two separate dilutions. The coefficient of variation
of the assay was 8%.
Two-dimensional Immunoelectrophoresis^: An example of
this is shown in Figure 2-9. Agarose was dissolved to a
concentration of 1% in buffer composed of 22 mM Tris,
45 mM glycine, 28 mM barbitone, 15 mM sodium barbitone
pH 8.6 and poured on Gel-Bond as in the Laurell assay.
A 40 |il well was punched at one laterial edge of the plate
and was filled with sample. The plate was then subjected
to electrophoresis at 200 V until a 4% bovine serum
albumin (BSA) - bromophenol blue marker had migrated
5 cms from the well. The flat-bed support was cooled
internally with running tap water throughout the
procedure. Electrophoresis was then discontinued and a
strip of gel was removed from above the strip adjacent to
the sample well. This was replaced by agarose into which
antiserum to VIIIR:Ag had been incorporated. The anti¬
serum concentration was 2.5 fold that used in the Laurell
assay. The plate was then electrophoresed for 18 hours
at 120 V as for the normal technique, with the first
dimension strip running along the cathode edge. The
plate was then stained as described above.
IRMA: Rabbit antiserum to VIIIR:Ag (DAKO antibodies)
was used to develop an IRMA for VIIIRrAg using the same
principle as for the VIII:CAg IRMA. Production of
immuno-purified 125i anti-VIIIR:Ag Fab fragments was
exactly as for the production of the VIII:CAg reagent.
The assay was also similar, except that 125I anti-VIIIR:Ag
FIGURE 2-11






















Fab was used in the incubation mixture. The assay was
sensitive to levels of VIIIR:Ag of 0.5% of normal plasma
(Figure 2-11) and was thus 50 times more sensitive than
the Laurell technique. Another advantage over the
Laurell assay was the ability of the IRMA to measure
VIIIR:Ag in samples which produced faint immunoprecipitates
notably cryosupernatants.
(E) ASSAY OF FACTOR VIII-RELATED RISTOCETIN COFACTOR
(VIIIR:RCF)
The assay used was based on the method of
Macfarlane et al (1975). Platelets fixed with form¬
aldehyde are aggregated with ristocetin in the presence
of factor VIII. The rate and extent of aggregation
depend on the amount of VIIIR:RCF present.
Reagents - Fixed platelets: 72 hour old platelet
concentrates were centrifuged for 6000 g min. at room
temperature to remove residual red cells. The platelet
concentrates were then incubated for one hour in plastic
tubes at 37°C after which an equal volume of 2% formalin
in 10 mM Tris, 1 mM EDTA, 150 mM NaCl pH 7.5 was added
(giving a final formaldehyde concentration of 0.4%). The
fixed platelets were stored at 4°C for 45 hours, after
which they were washed 3 times in 0.15 M phosphate pH 7.3.
After the third wash the platelets were resuspended in
phosphate buffer at a concentration of 100 x 109/litre and
an equal volume of 20% dimethyl sulfoxide (DMSO) in
phosphate buffer was added. The suspension was kept at
room temperature for one hour and was then frozen in 20 ml
FIGURE 2-12
STANDARD CURVE OF THE VIIIR:RCF ASSAY
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aliquots in a -40°C freezer. For use, the platelets were
thawed at 37°C, centrifuged for 27,000 g min. at room
temperature and resuspended for 30 minutes in phosphate
buffer. This procedure was repeated 4 times and the
platelets were resuspended in Tris-EDTA-saline buffer at
a concentration of 300 x 109/litre.
Ristocetin; A 30 mg/ml solution in normal saline was
used.
Buffer for dilutions was Tris-EDTA-saline made 4% w/v
with BSA.
The assay was performed as follows:
0.7 ml platelets
30 p.1 ristocetin
stirred in 37°C heating-block
transferred to aggregometer
^ test sample added (0.1 ml)
aggregation recorded on Mallin aggregometer.
The initial rate of aggregation was calculated by
determining the slope of the steepest portion of the
recorded trace. This was plotted against concentration
using a log-log plot. A standard curve consisting of
doubling dilutions of normal plasma was constructed
during each run of assays, (Figure 2-12) and sample
potencies were estimated from the linear part of the
standard curve. Samples were assayed at 2 or more
dilutions. The assay coefficient of variation was 10%.
(F) ASSAY FOR FIBRINOGEN
In this study, two different fibrinogen assays
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were used. Plasma samples could be assayed by the
.ON
Ellis and Stransky (1961) method, based/the opacity of a
clot generated by addition of thrombin. This technique
was found to be unsuitable for samples containing low
fibrinogen levels e.g. column fractions, which tended to
produce wispy clots that could not be quantitated.
Concentrates containing high fibrinogen levels also could
not be assayed accurately by this method as spuriously
low levels were obtained (see below). Therefore, in
assessing fibrinogen distribution during fractionation, a
Laurell assay using a commercially purchased antiserum
was used throughout.
Ellis and Stransky method: In this technique, 0.5 ml
of the sample being assayed was diluted in 5.5 ml of
28 mM sodium barbitone, 50 mM NaCl pH 7.2 and well mixed.
50 y.1 of calcium-thrombin reagent (0.56 M CaCl2 and 5 u/ml
thrombin) were then added to 3 ml of the mixture in a
plastic cuvette and mixed by inversion, care being taken
not to allow any air bubbles in the mixture. The
residual 3 ml were placed in a plastic cuvette without
any reagent. After 20 minutes at room temperature, the
absorbence of the test mixture at 470 nm was read using
a CECIL spectrophotometer. The control mixture was used
as blank. The absorbence was multiplied by 8.63 to
obtain the fibrinogen concentration in g/litre.
Electroimmunoassay: A commercial antiserum to human
fibrinogen (Hoechst) was used to set up a Laurell assay
as described previously for VIIIR:Ag. Antiserum
TABLE 2-5 COMPARISON OF FIBRINOGEN ESTIMATION METHODS




Plasma 13 2.8 ± 0.35 (100)* 2.6 ± 0.52 (100)
Cryosupernatant 5 2.2 ± 0.2 (70) 2.1 ± 0.4 (70)
Cryoprecipitate 5 3.7 ± 1.4 (16) 5.3 ± 1.8 (25)
Plasma was fractionated using the thaw-siphon technique.
Results show mean ± standard deviation.
* Figures in brackets show fibrinogen yield relative
to starting plasma.
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concentration was 0.53%. Standards were dilutions of
1/50, 1/100, 1/200 and 1/400 of normal pooled plasma.
Samples were assayed at two dilutions.
Table 2-5 shows a comparison between the two
fibrinogen estimation methods for assays on plasma
fractions derived by cryoprecipitation (Chapter IV).
Using the Ellis and Stransky technique tended to give low
fibrinogen estimates in the cryoprecipitates, although
good agreement between the two methods was observed for
plasmas and cryosupernatants. In order to use the same
method for each step of fractionation procedures, the
Laurell assay was used throughout.^
(G) ASSAY FOR FIBRONECTIN
As with VIIIR:Ag, initial assays for fibronectin
used a Laurell technique with a commercially purchased
antiserum. During the course of the study, fibronectin
was purified and used to raise an antiserum.
Preparation of purified fibronectin: The method used was
based upon that of Hayashi and Yamada (1982) employing
sequential affinity chromatography on immobilised gelatin
and heparin. These were coupled to cyanogen-bromide
activated Sepharose (see purification of 125i anti-
VIII:CAg Fab above). Several purifications were done
during the course of the study, using plasma or fibro-
nectin-rich fractions as starting material. A typical
preparation is described as follows:
A litre of thaw-siphon cryoprecipitate prepared in the
Components Division of the South-East Scotland Blood
* Although the antiserum used could have cross-reacted with
fibrinolytic products of fibrinogen/fibrin, this was not
considered a major handicap as (for the purpose of this thesis),
such products had characteristics similar to fibrinogen.
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Transfusion Service was thawed and thoroughly mixed.
PEG 6000 (SIGMA) was added, as solid flakes with constant
stirring, to a final concentration of 5% w/v. Stirring
was continued for 15 minutes at room temperature and the
precipitate was harvested by centrifugation for 22,500 g
min. at 20°C. The precipitate was dissolved at 37°C in
100 ml of 150 mM NaCl, 10 mM Tris, 5 mM EDTA pH 7.5.
Insoluble material was removed by centrifugation and the
supernatant was applied to a column of gelatin-agarose
(bed volume 90 ml ) which had been pre-washed with 200 ml
of 4 M urea, 10 mM Tris pH 7.5 followed by 500 ml of
150 mM NaCl, 10 mM Tris, 5 mM EDTA pH 7.5. After the
sample had passed through, the column was washed with
300 ml of 500 mM NaCl, 10 mM Tris, 5 mM EDTA pH 7.5 and
washing was continued with 150 mM NaCl, 10 mM Tris, 5 mM
EDTA pH 7.5 until the absorbance at 280 nm of the effluent
had reached a constant basal level. The gelatin-agarose
column was then eluted with 4 M urea, 10 mM Tris pH 7.5
and the eluted protein was applied to a heparin-agarose
column (bed volume 170 ml,) which had been pre-washed
with 400 ml of 500 mM NaCl, 10 mM Tris, 5 mM EDTA pH 7.5
followed by 400 ml of 150 mM NaCl, 10 mM Tris, 5 mM EDTA
pH 7.5. Bound fibronectin was eluted off the column
with 500 mM NaCl, 10 mM Tris pH 7.5, concentrated by
addition of solid (NH4)2S04 to 40% saturation and dialysed
against 150 mM NaCl, 10 mM Tris pH 7 for 18 hours at 4°C.
It was stored in polypropylene (Nunc) tubes in liquid
nitrogen. Yields were typically 55% from cryoprecipitate.
FIGURE 2-13
IMMUNOELECTROPHORESIS USING RABBIT ANTISERA TO
FIBRONECTIN
2DIEP and Laurell electrophoresis were performed.
In 2DIEP, plasma (P) and purified fibronectin (C) were
electrophoresed with locally produced (upper strip)
and commercial (lower strip) antisera to fibronectin
incorporated in the second dimension.
In Laurell electrophoresis, samples were four




Lane 5 in Figure 2-8 shows the reduced protein in SDS-
PAGE - a molecular weight of 205,000 was found which is
in agreement with the accepted subunit size for fibro-
nectin (Mosesson and Amrani 1980).
Assay for fibronectin: The purified protein was sent to
the Scottish Antibody Production Unit, Carluke, where it
was used to raise an antiserum in a rabbit. Upon
analysis of the antiserum in immunoelectrophoresis against
human plasma, multiple precipitin lines were obtained,
indicating multiple specificity. This was presumably
due to contaminating proteins in the immunogen. Further
preparations of immunogen were therefore made and the
resulting protein was adsorbed with immobilised antisera
to human albumin, fibrinogen and immunoglobulin, which
were thought to be the main potential impurities in the
initial preparation. These antibodies were prepared by
coupling sodium sulphate fractions of the appropriate
antisera to cyanogen-bromide activated Sepharose 4B. The
immunogen adsorbed with the immobilised antibodies was
used to immunise further rabbits. Antisera produced
proved to be monospecific in immunoelectrophoresis
against human plasma. The antiserum also gave a single
immunoprecipitin arc in 2DIEP against normal plasma and
was found to be suitable for use in a Laurell assay at a
concentration of 0.2% (Figure 2-13). In this assay,
normal pooled plasma at dilutions of 1/10, 1/20, 1/40 and
1/80 was used as standard and was assumed to contain
0.33 mg/ml of fibronectin (Mosesson and Amrani 1980)
* The antiserum did not give a precipitin 'rocket' with gelatin-
absorbed plasma (fibronectin level < 1 p.g/ml) indicating its
specificity.
FIGURE 2-14
STANDARD CURVE OF THE BIURET PROTEIN ASSAY
PROTEIN CONCENTRATION
(mg/ml)
(H) ASSAY FOR TOTAL PROTEIN
The Biuret technique (Gornall et al 1949) was
the main method used to assay protein in this study. In
some measurements of low protein levels (less than
5 mg/ml) and in solutions containing dextran (Chapter V)
which was found to cause precipitation of the Biuret
reagent, absorbance at 280 nm was used to estimate protein
content.
The Biuret assay: The reagent was prepared by dissolving
1.5 g of copper sulphate (CUSO4 5H20), 6 g of potassium
sodium tartrate and 300 ml of 10% w/v sodium hydroxide
in a total volume of 1 litre of distilled water. The
assay was performed as follows:
0.1 ml sample
5 ml reagent
10 minutes at room temperature
read absorbance at 540 nm
Protein content estimated from standard curve.
A standard curve was constructed using BSA of known
protein content (Figure 2-14).
Protein estimation by measurement of optical density at
280 nm: was performed by measuring the absorbance at
280 nm of the protein solution in a 1 cm deep quartz
cell. It was assumed that an absorbence of one was
equivalent to a protein concentration of 1 mg/ml unless
the extinction coefficient of the protein involved was
known.
(I) ANALYSIS OF PROTEIN COMPOSITION BY SODIUM DODECYL-
SULPHATE POLYACRYLAMIDE GEL ELECTROPHORESIS (SDS-
PAGE)
The principle of this technique has been
discussed by Weber and Osborne (1969). Proteins are
separated in polyacrylamide gel of a predetermined porosity
by migration in an electric field. Addition of the
anionic detergent sodium dodecyl sulphate (SDS) imparts a
uniform negative charge density on the proteins, so that
migration rate is dependent on their molecular weight.
The different proteins in a mixture thus separate on the
basis of their molecular weight and by running known
standards, the molecular weight of a component can be
determined and different components can be identified.
Method: The method outlined below was used to make gels
5% with respect to acrylamide. Different concentrations
can be made by adjusting the acrylamide concentration.
Two glass plates each 16 x 8 cms were rinsed in water and
then in ethanol. The plates were then placed on clean
tissue paper with the side which was to be in contact with
the gel uppermost, and swabbed with an acetone-soaked
tissue held in a gloved hand. After a final rinse with
ethanol, the plates were allowed to air dry. The plates
were then brought facing each other but held apart with
plastic spacers of 4 mm thickness. The spacers were
attached firmly to the plates using adhesive tape. The
plate assembly was then placed in a Pharmacia GSG8 gel-
casting apparatus and the spacer comb was placed on top.
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The following reagents were used to make poly-
acrylamide gel:
(a) 0.2 M phosphate buffer pH 7.1 (prepared by making
70 ml* 5 M NaOH and 12 ml H3PO4 up to one litre with
distilled water).
(b) 22.2% acrylamide (22. g + 0.6 g bis in 100 mis H2O).
(c) 10% SDS.
(d) 10% ammonium persulphate (made up fresh every time).
(e) TEMED (N,N,N',N',-Tetramethylethylenediamine).
To make 2 gels, 50 ml of (a), 22.5 ml of (b),
10 ml of (c), 1.5 ml. of (d) and 0.2 ml of (e) were
mixed and made up to 100 ml ■ with distilled water in a
measuring cylinder, with gentle mixing to avoid too much
air getting into the mixture. The mixture was then
poured into the casting apparatus, until the plate
assembly was covered. The gels were left for 2 hours at
room temperature, excess gel was trimmed away and the
gels were subjected to a pre-run for 45 minutes at 30 V,
150 mA in a Pharmacia GE-2/4 apparatus. The tank
buffer was 0.1 M phosphate 0.1% SDS pH 7.1. Samples for
analysis were mixed with an equal volume of 8 M urea,
0.2 M phosphate 1% SDS 1% bromophenol blue pH 7 and
incubated for one hour at room temperature. Mercapto-
ethanol (1%) was added when proteins were to be reduced.
50 \ig of protein in a volume of 8 0 nl was applied to each
sample well on the gel and electrophoresis was carried out
for 18 hours at 30 V, 150 mA. The gels were then
carefully removed from the glass plate assembly and fixed
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FIGURE 2-15
CALIBRATION CURVE FOR MOLECULAR WEIGHT DETERMINATION
USING SDS-PAGE
Marker proteins (Pharmacia) were electrophoreses! and
Rf values were measured
DISTANCE MIGRATED BY PROTEIN BAND
R =
DISTANCE MIGRATED BY DYE FRONT
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for 18 hours in 400 mis of 25% isopropanol, 10% acetic
acid. They were then stained for 4 hours in 0.1%
Coomassie Blue R, 25% isopropanol, 10% acetic acid and
destained with several changes of 14% methanol, 7% acetic
acid. If required, gels were scanned densitometrically
using a Bio-Rad densitometer. Molecular weight markers
(Pharmacia) were incorporated in each run and used to
construct a calibration curve (Figure 2-15), from which
the molecular weight of different components could be
inferred.
(J) STATISTICAL ANALYSIS
Statistical comparisons in this study utilised
mainly the student's t-test for paired and unpaired
comparisons as appropriate. Data presented in Chapter III
regarding the fibrinopeptide A content of blood donations
was analysed non-parametrically using the Wilcoxon rank
sum test, due to the fact that the results approached
zero and were thus not normally distributed.
CHAPTER 111
FACTOR VIII IN BLOOD DONATIONS
COLLECTED INTO DIFFERENT ANTICOAGULANTS
AND USING DIFFERENT TECHNIQUES
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INTRODUCTION
The ever increasing demand for factor VIII
concentrates has led to many studies into the stability
%
of this protein. Early work, although hampered by a
lack of accurate and sensitive assays, quickly established
the lability of VIII:C (Penick and Brinkhous 1956,
Goldstein et al 1964). This had led to blood banks
developing special procedures for processing donations
intended for factor VIII concentrate production. However,
uncertainty exists as to what factors involved in blood
donation and processing influence the stability of
factor VIII. The type of anticoagulant has been shown
to be an important variable, most studies reporting that
Citrate-Phosphate-Dextrose (CPD) improves VIII:C stability
compared to Acid-Citrate-Dextrose (ACD) (Schanberge et al
1972, Lane 1981) although some studies claim no difference
(Goldstein et al 1964, Slichter et al 1976), and one
study claims that ACD is better (Vermeer et al 1976).
There is agreement that citrate based anticoagulants are
better than oxalate or EDTA for preserving VIII:C (Spaet
and Garner 1955, Mustard 1958) and that an optimal
citrate concentration exists (Mustard 1958, Weiss 1965).
Recent studies have demonstrated marked stability of
VIII:C in blood collected in heparin (Rock et al 1979,
Smith 1 983b) and one group claims higher levels of VIII:C
in fresh heparin plasma (Rock et al 1979). Other workers
have failed to confirm this (Smit-Sibinga et al 1981).
The level of cellular contamination in the
plasma has also been the subject of disagreement; some
studies claim an improved stability of VIII:C in cell-
%
free (Nilsson et al 1983) or platelet poor plasma
(Mustard 1957), while others claim that cellular contamin¬
ation has no influence on VIII:C stability (Preston 1967,
Pepper et al 1978). High platelet contamination in
frozen plasma, however, has been shown to result in low
VIII:C levels (Pepper et al 1978) and low yields due to
processing difficulties in producing factor VIII concen¬
trate (Smith et al 1977).
Discrepancies also exist regarding optimal
conditions for storing blood or plasma prior to the
freezing of plasma. The majority of reports indicate
retention of 75 to 85% of initial plasma VIII:C levels at
temperatures between 4° and 22°C 6 to 8 hours after
donation with a subsequent fall to 55 to 75% at 4°C by
18 to 24 hours (Penick and Brinkhous 1956, Rapaport et
al 1959, Stibbe et al 1972, Hondow et al 1982a). Losses
at room temperature have been reported to be similar
(Vermeer et al 1976, Kahn et al 1979) or greater (Pool
and Robinson 1959, Rock et al 1980a). Some reports show
losses of VIII:C in blood stored at low temperatures
(about 2° to 4°C) due to cryoprecipitation of cold
insoluble proteins, including the factor VIII complex,
and subsequent removal with the cells during centrifug-
ation (Vermeer et al 1976, Rock and Tittley 1979).
Other studies have not found this (Hondow et al 1982a,b,
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Carlebjftrk et al 1983). Although one study claims little
loss of VIII:C even at outdate in banked blood (Weaver
et al 1967) the many reports confirming lability have led
%
to stringent conditions being formulated for the
production of plasma destined for production of factor
VIII concentrate. Initial instructions by the American
Association of Blood Banks required that such plasma be
frozen within 4 hours of collection (American Association
of Blood Banks 1970), although this period was subsequently
extended to 6 hours (American Association of Blood Banks
1978).
Although most studies have investigated the
stability of VIII:C, some work has been published
regarding the other activities of the factor VIII complex.
VIII:CAg and VIIIRrAg have been reported to be stable in
plasma at room temperature (Rock et al 1983a). At 4°C,
VIIIRrAg in blood and plasma have been reported to be
stable in one study (Hondow et al 1982b), but another
group reports gradual degradation of VIIIRrAg over one
week at 4°C (Nilsson et al 1983). VIIIRrRCF has been
shown to be lost from banked blood (Hondow et al 1982b)
and plasma (Rock et al 1983a) after 3 weeks storage at
4 °C.
A recent study has emphasised difficulties of
processing blood to factor VIII concentrate from plasma
with high fibrinopeptide A (FpA) levels due to poor
donation procedure (Pflugshaupt and Kurt 1983). Inade¬
quate mixing of blood with anticoagulant has been claimed
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to lead to high FpA plasma levels, indicating thrombin
formation. This was associated with processing
difficulties and poor stability in the factor VIII
concentrate derived from such plasma. One other study
reports low VIII:C yields from plasma with high FpA
levels, induced by deliberate thrombin addition (TOrmS
and Myllyia 1983). An early study claims 15%
differences in VIII:C from mixed and unmixed blood
(Perkins et al 1962). Other studies, however, have
found no such differences (Preston 1967, Slichter et al
1976) .
It is necessary for blood banks to ensure that
plasma destined for factor VIII products has a high
initial content of factor VIII. Processing to cryo-
precipitate indicates that the yield of VIII:C is pro¬
portional to the amount in the starting plasma (Kasper et
al 1975, Pepper et al 1978). This is not always found
when factor VIII concentrate is produced, with equivalent
yields being obtained from 4 and 18 hour old plasma
(although 4 hour old has a higher initial VIII:C content)
(Smith et al 1978,1979). This is probably because the
large losses involved in large-scale production mask any
differences between the initial content of the various
plasma grades. Another manufacturer finds the difference
in VIII:C content between 4 and 18 hour old plasma is
reflected in higher yields in the final product (Foster
et al 1982). In the case of small-scale production by
blood banks, processing losses encountered in industrial
fractionation may be minimised by careful attention to
processing variables. The final yield may then be
expected to reflect more closely the initial VIII:C level
In this study, the storage lability of factor
VIII in CPD and heparin blood donations has been examined
with a view to finding optimal conditions for production
of plasma with a high factor VIII content. Addition of
calcium back to CPD plasma has been examined as an
alternative to heparin collection in maintaining the
levels of ionised calcium necessary for optimal VIII:C
stability. The amount of citrate in plasma compatible
with such stability has also been determined. The
effect of different mixing techniques during donation on
VIII:C and FpA was also investigated.
METHODS
Blood Collection
CPD donations: Three groups of 10 donations each, were
taken into Tuta single blood bags at regular donor
sessions. Each group was collected using one of three
mixing procedures:
(a) Fully mixed - with the bag inverted so that blood
entered through the anticoagulant and with continual
gentle manual mixing throughout the donation.
(b) Partly mixed - with the bag inverted and 3 or 4
manual mixes during donation, this being the standard
technique in this centre.
(c) Unmixed - with the pack upright and mixing only at
the end of the donation.
After donation the bags were mixed and a 10 ml blood
sample was obtained and centrifuged for 75,000 g min. at
4°C to give platelet poor plasma. Samples were frozen
and stored at -40°C for subsequent VIII:C and FpA assay.
Heparin donations: A group of 6 donations were taken
into Fenwal heparin bags (R0601), each containing 2250
units of sodium heparin in 30 ml of phosphate buffered
saline.
All donations involved withdrawal of 420 ml. of
blood from the donor. Donations were not selected for
blood group or venesection time although these were noted.
Factor VIII stability in CPD and heparin: Each donation
in the CPD partly mixed group was aliquoted into 10 ml
tubes; 16 such tubes were collected. The remaining
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blood was centrifuged for 75,000 g min. at 4°C and the
platelet poor plasma obtained was aliquoted into another
16 10 ml tubes. Tubes of blood and plasma were held at
various temperatures and periods of time as outlined in
Results. In a further experiment, 20 ml of blood were
collected from 3 different donors into CPD. The ratio
of blood to anticoagulant was the same as in normal
donations (7:1). Plasma aliquots from each donation
were incubated for 18 hours and then processed as shown
in Results. The heparin collections were treated in the
same manner to produce tubes of blood and plasma and held
under the conditions outlined in Results. At the end of
the stated periods, samples of blood and plasma were
centrifuged at the same temperatures as they were incubated
and the plasma thus prepared was rapidly frozen in 2 ml
aliquots and stored at -40°C for subsequent assay.
Samples of CPD plasma were frozen without any prior
centrifugation, while heparin plasma samples were centri¬
fuged prior to freezing.
Factor VIII:C stability in plasma with different citrate
concentrations: 10 ml aliquots from each of 6 donations
of heparin plasma were made to various concentrations of
citrate by addition of appropriate amounts of 1 M tri-
, i m med iate I y after collection and separation.
sodium citrate^ The various types of plasma were then
held for 18 hours at room temperature and rapidly frozen
for subsequent assay.
Factor VIII:C stability in recalcified CPD plasma: 10 ml
aliquots from a group of 6 donations of CPD plasma were
1 12
made to various concentrations of calcium by addition of
different amounts of 1 M calcium chloride containing
heparin. In all cases, the amounts of heparin added
were such as to result in a concentration of 2 u/ml in
the plasma. The various plasmas were held for 18 hours
at room temperature and then frozen for subsequent assay.
Cooling rate of blood donations: A bag of outdated CPD
whole blood was placed in a 37°C water-bath. The
internal temperature of the bag was monitored by a thermo¬
couple (Comark Instruments), placed in the middle of the
bag. As soon as the temperature had reached 37°C, the
bag was placed in a 4°C cold room and 30 minute recordings
of the temperature were taken.
Assays
Factor VIII:C, factor VIIIR:Ag, fibronectin and fibrino-
peptide A were measured as described in Chapter II.
Ionised calcium was measured at the Protein Fractionation
Centre, Edinburgh, using an ion-specific electrode
calibrated with calcium solutions of known concentration.
The help of Mrs. Ida Dickson in carrying out these
measurements is acknowledged.
Statistical analyses were by the paired t-test or unpaired
t-test as appropriate. Logarithmic transformation of
data relating to VIII:C did not affect the significance
of any of the differences described, despite the reported
logarithmic distribution of VIII:C in the plasma from
normal individuals (Bangham et al 1971).
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FIGURE 3-1
STABILITY OF FACTOR VIII IN CPD DONATIONS
A,B,C,D show data for VIII:C
E,F,G,H show corresponding values for VIIIR:Ag
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TABLE3-1STABILITYOFF CTORV INDFI RONECTINPDP ASMAA0° ParameterFresh Plasma LevelsLevelsafter18hourt0°C Centrifuge Supernatantdat0°C
Precipitate
Centrifugedat20°C after30mint7°C
VIII:Cu/ml VIIIR:Agu/ml Fibronectin antigenu/ml
0.89 0.88 0.83
0.28±.09(52)* 0.51±04(6 ) 0.4(53)
1.28±0.1(37) 2.12±0 37(41) 3.3±1.05(68)
0.54±.12 0.80±13 0.76±14
Aliquotsofplasma(3.2ml,)wereheldnme tingicandproc sseddescrib . Samplesheldandcentrifugedt0°Cshow damallpr cipitatewh chs dissolvedn0.5mlf1 Mcitrate,50mNaCl,pH6.9. *Amountfoundasperce tagefthwarmeds ple.
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RESULTS
(A) FACTOR VIII STABILITY IN CPD DONATIONS
Stability of factor VIII was investigated at
3 temperatures: 0°C (achieved by holding tubes in ice/
water); 10°C (using a controlled temperature water bath,
Grant Instruments) and room temperature (measured at
20°C). Figure 3-1 shows the results. Factor VIII:C
appears equally stable in plasma at all 3 temperatures
studied, and similar results were obtained at 10°C and
20°C in blood. In blood at 0°C VIII:C appeared less
stable. This loss, however, was shown to be due to
cryoprecipitation of VIII:C into the cell layer at this
temperature as warming samples at 37°C for 30 minutes
prior to plasma separation led to VIII:C recoveries very
similar to those observed at higher temperatures
(Figure 3-1A). Although this effect was not observed
in plasma at 0°C (Figure 3-1C,E), these samples were not
centrifuged prior to plasma freezing and storage.
However, a further experiment on a smaller group of donors
confirmed that cryoprecipitation of factor VIII occurs in
plasma held at 0°C (Table 3-1). Measurement of fibro-
nectin antigen showed precipitation of this protein.
Fibrinogen was not precipitated to the same extent.
Corresponding assays for VIIIR:Ag (Figure 3-1
E-H) showed great stability in both blood and plasma over
24 hours at all temperatures studied, with the same cryo¬
precipitation occurring in blood at 0°C as occurred for
FIGURE 3-2
COOLING OF BLOOD BAG AT 37°C PLACED IN 4°C AIR
The temperature probe was secured to a thin wooden
stick and placed in the middle of the bag through
an opening in the transfusion port. After
allowing the temperature to rise to 37°C in a
water-bath, the bag was placed in a 4°C cold-room
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FIGURE 3-3
STABILITY OF FACTOR VIII AND FIBRONECTIN ANTIGEN
IN HEPARIN DONATIONS
A & B show data for VIII:C
C,D & E,F show corresponding data for VIIIR:Ag and
fibronectin antigen (1 u of fibronectin antigen was
taken as being the amount in 1 ml of normal pooled
plasma)




VIII:C. Warming to 37°C led to full recovery ofVIIIR:Ag.
The cooling rate of a blood donation at 37°C
placed in 4°C refrigeration is shown in Figure 3-2. It
took over 2 hours for the internal temperature to fall
to 6 °C.
(B) FACTOR VIII STABILITY IN HEPARIN DONATIONS
Stability of factor VIII was studied at two
temperatures: 4°C (blood bank cold room) and 22°C (room
temperature). Figure 3-3 shows the results.
Factor VIII:C in heparin blood showed no
significant instability over 18 hours at room temperature
(t=1.5, p > 0.1 compared to fresh plasma VIII:C) in
contrast with VIII:C in CPD blood, which showed marked
instability over the same period (t = 6, p < 0.01 compared
to fresh plasma VIII:C). This was confirmed for VIII:C
in heparin plasma. The starting VIII:C levels (0.9 ±
0.14 u/ml) were not significantly different from a group
of CPD donations with the same blood group distribution.
Striking losses of VIII:C were observed at low
temperatures in blood. Although a normal blood bank
refrigeration temperature of 4°C and not 0°C was used,
apparent cryoprecipitation of VIII:C was observed as was
seen for CPD blood. In this experiment warming at 37°C
was not performed. However, cryoprecipitation was
indicated as being the mechanism for VIII:C loss as
parallel losses were observed in VIIIR:Ag (Figure 3-3C)
at this temperature, with VIIIR:Ag being stable at room
temperature. Plasma samples in this series of
TABLE 3-2 IONISED CALCIUM IN PLASMA COLLECTED INTO DIFFERENT
ANTICOAGULANTS
Anticoagulant Calcium Ion-Specific Ionised Calcium
Electrode Reading
(mV) mM
Heparin (3 u/ml)+ - 90 0.56
CPD + Heparin (3 u/ml) - 50 < 0.01
+ Final heparin concentration in plasma
FIGURE 3-4
TITRATION OF CPD/HEPARIN PLASMA TO IONISED CALCIUM
LEVELS FOUND IN HEPARIN PLASMA


















































experiments were centrifuged prior to sampling for assay,
unlike corresponding samples in the CPD experiments.
Figures 3-3B and 3-3D show loss by cryoprecipitation of
VIII:C and VIIIR:Ag in heparin plasma at 4°C, with
stability of both activities at room temperature.
Measurement of fibronectin antigen levels in
both blood and plasma showed cryoprecipitation of this
protein in the cold (Figures 3-3E and 3-3F) with stability
being observed at room temperature.
(C) IONISED CALCIUM IN PLASMA WITH DIFFERENT
ANTICOAGULANTS
Two samples of blood were collected from the
same individual into equal volumes of CPD/heparin and
heparin anticoagulant (final plasma heparin (about)
3 u/ml). The ratio of blood to anticoagulant was the
same as used in normal blood donation i.e. (about) 7:1.
Plasma was separated from both these samples. The
ionised calcium levels in the paired samples measured
with an ion-specific electrode and shown in Table 3-2.
A stock solution of calcium chloride (55 mM)
was then used to bring the ionised calcium level of the
CPD/heparin plasma sample as recorded by the electrode,
to the level of the heparin sample. The resulting
titration curve is shown in Figure 3-4. About 0.7 ml
of stock solution were needed to bring the ionised
calcium level of a 4 ml CPD/heparin sample to that of the
heparin sample. It can be seen that calcium had to be
added back to a level of about 8 mM to overcome the
TABLE 3-3 EFFECT OF RECALCIFICATION OF CPD BLOOD AND PLASMA
ON VIII:C STABILITY
Sample Hours Post-Donation Factor VIII :C u/ml*
Blood 6 0.83 ± 0.17
Blood Calcium/heparin+ added
3 hrs, separated 5 hrs
1.03 + 0. 27t
Blood 18 0.73 + 0.17
Blood Calcium/heparin added
18 hrs, separated 20 hrs
0.65 + 0.14§
Plasma 6 0.84 + 0.25
Plasma Calcium/heparin added
3 hrs, frozen 5 hrs
1.1 + 0.4 t
Plasma 18 0.69 + 0.12
Plasma Calcium/heparin added
18 hrs, frozen 20 hrs
0.77 + 0. 25§
* Mean and standard deviation for 10 individual donations
+ In each case, the calcium/heparin was added in an
amount sufficient to result in a plasma concentration
of 10 mM calcium, 5 u/ml heparin
t Significantly higher than control, p < 0.01 for blood,
p < 0.05 for plasma
§ Difference from control not significant
FIGURE 3-5
EFFECT OF RECALCIFICATION OF CPD DONATIONS
Results show the effect of addition of a calcium/
heparin solution to give final concentrations of
(about) 10 mM and 5 u/ml in the plasma.
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effect of the CPD.
(D) RECALCIFICATION OF CPD DONATIONS
On the basis of the calcium level measurements
just outlined, a CaC^/sodium heparin solution was added
to samples of CPD blood and plasma, held at room temper¬
ature, 3 and 18 hours post donation. The amounts added
were such as to result in a final concentration of 10 mM
calcium and 5 u/ml heparin in the plasma. Plasma from
such samples was separated and frozen for assay 5 and 20
hours post donation respectively. Subsequent VIII:C assay
gave the results shown in Table 3-3. It can be seen that
calcium/heparin addition 3 hours post donation led to
recovery of VIII:C activity, such that blood which had been
thus treated had higher VIII:C levels 5 hours post donation
than blood which had not been recalcified. This difference
was significant (t = 3.48, p < 0.01 - paired t-test
comparing recalcified sample with 6 hour post donation
sample in CPD alone). Likewise, plasma recalcified after
3 hours showed higher VIII:C levels after 5 hours than
plasma in CPD alone (t = 3.04, p < 0.05, comparison as for
blood). Figure 3-5 demonstrates this effect.
Addition to blood or plasma of calcium/heparin
at 18 hours resulted in VIII:C levels at 20 hours that
did not differ significantly from those in samples held
for 18 hours in CPD alone (Table 3-3).
(E) EFFECT OF RECALCIFICATION WITH DIFFERENT AMOUNTS OF
CALCIUM ON VIII;C STABILITY
Plasma from 6 CPD donations were made to
TABLE3-4EFFECTOFRECALCI I A IONW THDIFFERENTMOUNTSOFCALCIUM ONVIII:CSTABILITYICPDPLASMA Calcium/(Heparin) AddedtoFinal Concentration mM(u/ml)VIII:CAfterOvernight Incubationa22°C u/ml*
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§Precipitateformedaf rovernightincubat on
TABLE3-5DEPENDENCEOFVIII:STABILITYIH PARINLASMAC TRATE CONCENTRATION CitrateAdded FinalConcentration mMVIII:CAfterOvernight Incubationat22°C u/ml*

























Alldonationstakei standardheparinntico gulant,withfi concentrationfabout8u/mlitheplasma *Meanandsta darddevi tionof6individualdon s +Significantlylowerthancont o ,p<0.02 tSignificantlyhigherthancont ol,p<0.05
different calcium concentrations 5 hours post donation
and left overnight at room temperature. Table 3-4 shows
the effect of such addition on VIII:C stability. CPD
plasma showed the usual pattern, with 63% of the starting
VIII:C being left after overnight incubation. This
instability was corrected to a considerable extent by
calcium/heparin addition to 10 mM total calcium.
Addition to higher calcium levels did not improve
stability over that observed with 10 mM calcium and at
higher calcium levels, an insignificant drop in stability
was observed. At 30 mM calcium, a precipitate was
observed after overnight incubation. It is possible
that this represented precipitation of calcium phosphate
formed by reaction with phosphate ions derived from the
CPD anticoagulant.
(F) DEPENDENCE OF VIII;C STABILITY ON CITRATE
CONCENTRATION
Plasma collected into heparin was held over¬
night, together with aliquots of the same plasma that
had been made to different concentrations of tri-sodium-
citrate. Table 3-5 shows the results. VIII:C levels
remained high in heparin plasma after overnight
incubation. This was maintained at citrate concen¬
trations of 5 and 10 mM. At 15 mM citrate, however, a
loss of VIII:C was observed, although this only became
significant at 20 mM citrate (t = 3.52, p < 0.02). The
difference between 15 and 20 mM citrate was also
significant (t = 2.95, p < 0.05). Adding calcium to
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0.74±23(0.41-1 12,7) 0.80±13(0.62-0 97,5) 0.84±18(0.7-1. ,4)
1.18±0 29(0.94-5,3) 0.83±14(0.63-98,5) 1.06±0 19(0.77-1 3 ,6)
0.87±31(0.4-1 5, 0) 0.82±13(0.62-0.98,10) 0.97±21(0.74-1 3 , 0)
*Resultsshowmean±standardd viation(ra ge,n mb rofdo s)
heparin plasma improved VIII:C stability (t = 2.66,
p < 0.05) over that of plasma to which additional calcium
had not been added.
(G) INFLUENCE OF MIXING PROCEDURE DURING DONATION ON
PLASMA QUALITY
Factor VIII:C and FpA assays were performed on
frozen plasma samples derived from the donations collected
using different mixing techniques. The results are
shown in Table 3-6. Although a wide range in individual
FpA levels was found, this was not related to mixing
techniques; indeed no mixing gave the lowest levels.
Factor VIII;C was also unaffected by mixing technique,
the slightly higher VIII:C in the fully mixed group levels
being accounted for by a higher incidence of blood groups
A, B and AB in this group (Table 3-7).
DISCUSSION
This study confirms the lability of VIII:C
during storage under blood bank conditions. Results for
blood drawn into standard CPD anticoagulant indicate that
temperature of storage is not as crucial a factor as has
been previously thought; indeed storage at low tempera¬
tures can be detrimental because of the cryoprecipitation
described in this study and in others (Vermeer et al 1976,
Rock and Tittley 1979). However, it must be noted that
the data in such studies have been obtained from experi¬
ments with small volumes of blood - a blood donation
stored in standard donation bags takes much longer to
cool down (Figure 3-2) especially if large numbers of
bags are packed together (Rock and Tittley 1979). Thus,
low temperature storage of blood under standard blood
bank conditions might not result in loss of factor VIII
by cryoprecipitation. Indeed, data for VIII:C levels in
donations stored at 18 hours at 4°C prior to plasma
separation indicates VIII:C levels of about 0.6 u/ml
(Prowse 1984) in contrast to the value of 0.4 u/ml found
in this study. However, the finding that low temperature
storage is not essential for VIII:C stability might
remove some of the logistical difficulties in procuring
plasma suitable for factor VIII fractionation. Other
studies have indicated that a prolonged room temperature
hold is not detrimental for other blood components (Avoy
et al 1978, Snyder et al 1983).
No difference was observed in the stability of
VIII:C between CPD blood and plasma. Thus, any VIII:C
loss observed is not the result of cellular contamination
of liquid plasma as has been claimed in some studies
(Mustard 1957, Nilsson et al 1983). It has been shown
that adding a wide range of proteolytic inhibitors has no
effect on the lability of VIII:C stored under blood bank
conditions (Stibbe et al 1972, Rock et al 1983b) although
one study claims that some stabilisation was obtained by
adding diisopropyl-flouro-phosphate (D.F.P.) (Rock et al
1983b). It is thus unlikely that VIII:C loss is through
degradation induced by cellular proteases.
This study confirms that the decay of VIII:C
over the period studied (18 hours) is biphasic, with about
4.4% of the initial VIII:C being lost each hour up to
6 hours post donation, and about 1.1% being lost each
hour for the next 12 hours. Thus, rapid separation and
freezing within 6 hours of donation can produce sub¬
stantial improvements in plasma VIII:C content which would
be lost if further delay occurs. This implies that
blood donations collected in mid and late afternoon would
require processing by staff working on an overtime or
shift basis, with resultant increased costs. Any factors
which would help stabilise VIII:C would thus allow blood
banks to extend the time period between donation and
separation. This would increase substantially the amount
of plasma suitable for factor VIII fractionation without
excessive additional costs.
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Given the above as the current situation,
improvements in plasma quality are suggested by the
findings in this study and others (Rock et al 1979,
Krachmalnicoff and Thomas 1983, Mikaelsson et al 1983a)
which demonstrate the stability of VIII:C in blood
collected in heparin. It has been known since the work
of Weiss (1965) that VIII:C is stabilised by ionised
calcium. Collection of blood in heparin - a non-
chelating anticoagulant - permits maintenance of ionised
calcium and stabilises VIII:C in both blood and plasma
(Figure 3-3) at room temperature. Losses of VIII:C,
VIIIR:Ag and fibronectin were observed in heparinised
blood and plasma stored at 4°C. These losses are
probably due to cryoprecipitation as was observed in CPD
blood and plasma at 0°C. Although the effect of warming
to 37°C was not assessed, parallel losses in antigen and
activity point to a physical removal of molecules. It
is possible that the heparin induced precipitation of
fibronectin and factor VIII in chilled plasma is also
contributing to the effect observed (Amrani et al 1982)
although in the present study VIII:C was also precipitated.
Amrani et al reported that VIII:C was not precipitated
from chilled heparinised plasma but they used different
amounts of heparin.
Several options are possible for exploiting the
improved stability of VIII:C in physiological calcium
levels. Collection of blood in heparin anticoagulant
would require that CPD be added back to the cells after
plasma separation, as otherwise the short shelf-life
(3 days) (Mollison et al 1942) of such red cell concen¬
trates would decrease their usefulness. This procedure
produces red cell concentrates with normal in vivo and
in vitro characteristics (de Jonge et al 1983); however,
in these studies separation and CPD replenishment was
effected shortly after donation. The effect, on red
cell concentrates, of prolonged storage of heparin blood
followed by CPD replenishment has not been assessed.
Plasma collection by plasmapheresis would avoid this
problem and allow collection of heparin plasma. However
plasmapheresis is expensive and cannot substitute for
whole blood collection to meet red cell concentrate needs
Addition of calcium/heparin mixtures to normal CPD blood
units after donation has been proposed (Rock 1982). The
present study shows that addition of calcium to a plasma
concentration of 10 mM 3 hours after donation gave
recovery of VIII:C in both blood and plasma (Figure 3-5).
Addition after 18 hours resulted in no significant effect
on VIII:C (Table 3-3). This data indicates that recal-
cification must be made shortly after donation. Other
studies (Rock 1982, Rock et al 1983b) indicate that
recalcification must be made within 4 hours of donation
for maximal recovery of VIII:C. This can be effected by
adding sufficient calcium and heparin to the standard
anticoagulant solution in the bag so as to result in
physiological levels of plasma ionised calcium. Such an
approach, however, would require that additional citrate
be added to the red cells after plasma separation. A
preferable option would be to add calcium/heparin to
plasma separated within 6 hours of donation and allow
recovery of VIII:C (2-4 hours) (Figure 3-5) (Krachmalnicoff
and Thomas 1983, Rock et al 1983b) prior to plasma
freezing.
The data in Table 3-5 suggests that citrate
concentrations of up to 10 mM in the plasma do not
affect VIII:C stability. It has been shown by Mishler
et al (1978) that using half-strength CPD anticoagulant
(final plasma citrate concentration about 14 mM) does not
affect the storage characteristics of banked blood.
Plasma collected by automated plasmapheresis with low
citrate anticoagulant has been shown to give greater
VIII:C concentrate yields than plasma collected manually
in normal anticoagulants (Robinson et al 1983). In
whole blood collection, however, use of low citrate
levels might result in coagulation of red cell concen¬
trates. The 10 mM plasma citrate concentration found in
this study to be compatible with VIII:C stability might
require supplementation with heparin to allow production
of stable red cell concentrates.
Measurement of ionised calcium in heparin
plasma supplemented with citrate (Table 3-5) gave values
lower than expected, considering the established normal
levels of plasma ionised calcium (about 1 mM) (Penny 1983).
It is known that the concentration of free ionised
calcium is markedly dependent on pH (Thode et al 1983)
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with levels dropping sharply with increasing pH. The
lack of a buffering anticoagulant in heparin and citrated
heparin plasma samples leads to marked increases in pH
as carbon dioxide is lost from the plasma (Krachmalnicoff
and Thomas 1983). This may explain the low calcium
levels which were measured.
Table 3-4 indicates that addition of 10 mM
calcium to CPD donations is sufficient to improve VIII:C
stability, further addition giving no additional benefit.
The residual ionised calcium levels measured by the
electrode were rather low compared to the amounts added.
This is probably the result of calcium ion sequestration
by other ions including phosphate in the CPD and by
binding to plasma protein. A precipitate was seen to
form after overnight incubation in the 30 mM calcium
sample and this might represent insoluble inorganic calcium
salts. Addition of further calcium to heparin plasma
did increase VIII:C stability (Table 3-5) a finding noted
in one other study (Mikaelsson et al 1983a). This suggests
that further calcium addition in CPD plasma is ineffect¬
ive in increasing VIII:C stability due to the sequestration
outlined above.
When all factors are considered, it is probable
that the best way to exploit the increased stability of
VIII:C in physiological calcium levels is to use this
effect to bring about recovery of VIII:C levels in plasma
separated up to 6 hours after donation. The data in this
and other studies indicates that recalcification during
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this period would lead to recovery of VIII:C activity
which would be preserved by subsequently freezing the
plasma. This procedure would require that calcium/
heparin be added to the plasma bag. Such an additive
system is at present not on the market but can doubtless
be manufactured if a demand for it exists. The extra
cost would be justifiable if a significant improvement
in plasma VIII:C content is achieved. However, use of
heparin as an anticoagulant has been observed to be
unsuitable for production of intermediate purity factor
VIII concentrate (Smith qu. Penny 1983) and other purifi¬
cation methods (Chapter V). Thus, the plasma VIII:C
content might not be the only factor to be considered.
The results of the study on different bag
mixing techniques indicate that the three methods of
mixing had no effect on FpA or VIII:C levels. The work
of Pflugshaupt and Kurt (1983) claims that inadequate
mixing results in thrombin formation and high FpA levels.
Further work in this laboratory (Prowse et al 1984a)
suggests that donation time and the stripping of the donor
lines are parameters that can affect plasma FpA. Plasma
quality may be further improved by pumping anticoagulant
into the donation line itself, rather than relying on
mixing in the bag. A device which ensures proportional
admixture of blood and anticoagulant in the donation line
has been reported to give plasma and platelets of better
quality than are obtained by routine methods (Unger et al
1983) .
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In summary, this Chapter concludes:
1 ) Mixing technique during donation using the current
plastic bag system is not a crucial parameter for
good quality plasma and the use of specially purchased
machines for this purpose is not justified. Adequate
stripping of donor lines and short venesection times
lead to plasma with a good VIII:C content and low FpA
levels, which is suitable for fractionation.
2) Plasma separation and freezing within 0 to 4 hours of
donation yields plasma with a high VIII:C content;
further delays lead to losses. However, plasma in
standard donations 18 hours after donation still had
about 0.65 u/ml in this study and is still acceptable
for fractionation. Storage temperature is not
crucial; as far as VIII:C goes, room temperature
(about 20°C) is satisfactory. Small scale experi¬
ments indicate that factor VIII may be lost by cryo-
precipitation in blood or plasma given prolonged
storage and sufficient cooling. However, in standard
donations stored at 18 hours at 4°C this effect is
not seen.
3) Use of anticoagulants which result in plasma ionised
calcium levels of 1 mM lead to enhanced VIII:C
stability and permit extension of the period between
donation and plasma separation/freezing. This would
require the use of special plastic bag systems and
would lead to the presence of heparin in the plasma,
which might affect fractionation.
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CHAPTER IV
EFFECT OF PLASMA FREEZING RATE




Although being gradually superseded by lyophi-
lised concentrates, blood bank cryoprecipitate (cryo)
still constitutes an important source of therapeutic
factor VIII in developed nations such as Britain (Rizza
and Spooner 1983) and the United States (Aledort 1982).
In underdeveloped countries, cryoprecipitate and fresh
frozen plasma, when available, often constitute the sole
form of replacement therapy, unless expensive foreign
concentrates are purchased.
Thus, any factors influencing the quality of
cryoprecipitate have an important bearing on the logistics
of haemophilia care. Many studies have investigated the
optimal conditions for cryoprecipitate preparation
(Kasper et al 1975, Slichter et al 1976, Vermeer et al
1976, Regional Transfusion Directors' Committee 1978).
An early report claimed that fast-thawing of the plasma
in an 8°C waterbath resulted in much better VIII:C yields
than the original overnight thaw in air (Brown et al 1967).
This was denied by one study (Bloom et al 1969) which
claimed that slow-thawing was better. Subsequent
investigations, however, tended to support the benefits
of 'fast' versus 'slow' thaw (Vermeer et al 1976, Prowse
and McGill 1979, Wensley and Snape 1980) although some
find no difference between the two types of thawing
(Kasper et al 1975, Rock and Tittley 1977). In 1978,
Mason introduced a modified method of fast plasma thawing,
in which the thawed supernatant was continuously siphoned
over leaving the frozen cryoprecipitate in the original
plastic pack; this was claimed to improve markedly the
factor VIII yield. Studies comparing different thawing
techniques confirmed these results (Prowse and McGill
1979, Kang 1980).
Although much data has been published regarding
thawing methods, indicating the superiority of fast
thawing, less certainty exists regarding the mode of
freezing plasma. Early studies (Pool and Robinson 1959,
Britten and Grove-Ramussen 1966) suggest an inevitable
loss of around 15% of the VIII:C when plasma is frozen.
Freezing of small volumes of plasma has been reported to
reduce this loss (Britten and Grove-Ramussen 1966, Kasper
et al 1975) suggesting that fast freezing is necessary,
but other reports find no difference between large and
small volumes (Preston 1967). Placement of fresh plasma
packs in a -30°C or -20°C freezer results in complete
freezing taking over 6 hours, with resultant losses in the
plasma VIII:C (Fiets and Feitsman 1982) and decreased
cryoprecipitate yields compared to faster freezing
(Slichter et al 1976, Rock and Tittley 1979). On the
question, "How fast is fast?", Kasper et al (1975) report
no difference in cryo VIII:C yields between plasma frozen
in 30 minutes in -70°C ethanol dry ice and plasma frozen
in one hour between dry ice sheets. Smith (1983a) reports
no difference between the VIII:C content of 5 litre pools
frozen in a Grant plate freezer (90-120 minutes) and
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single packs frozen in a liquid nitrogen controlled rate
freezer (10-20 minutes) suggesting that the volume of
plasma frozen is not critical per se, as long as freezing
to about -30°C is achieved in about one hour. Different
freezing rates have been reported to affect the protein
composition of cryoprecipitate while not influencing
factor VIII yields (Vermeer et al 1976); slower freezing
resulting in a higher amount of fibrinogen in the cryo¬
precipitate (Carlebjork and BlombSck 1983).
Installation of liquid nitrogen controlled rate
freezers or airblast freezers would involve greater
capital and maintenance costs than simple chest freezers
or use of cold ethanol. Considerations of product
quality and safety are also important, freezing in dry
ice/ethanol, for example, although comparatively cheap,
has been reported to result in passage of ethanol into
the plasma resulting in fibrinogen deposition in cryo¬
precipitate being much increased (Lane 1981).
Controversy also exists regarding optimal
conditions for storing frozen plasma. Some early studies
suggest that plasma VIII:C is rather labile at -20°C
(Penick and Brinkhous 1956, Pool and Robinson 1959) while
other studies report no loss at -20°C for periods of up
to 12 months (Preston 1967, Koerner and Stampe 1982).
Newman et al (1971) state that storage of frozen plasma
for periods longer than 3 to 6 months affects proteins
other than factor VIII and can result in processing
difficulties during concentrate production, due to high
fibrinogen content.
Measurements based on the theory of eutectics
(Mackenzie 1982 qu. Foster 1983a) show that phase change
occur in plasma at temperatures of -27°C and -40°C (and
possibly as low as -80°C). Storage at temperatures
below these points might be expected to have advantages
Practical considerations, however, play a role in what
kind of storage temperatures are used in practice, the
relative costs of refrigeration to -50°C, -40°C and -30
being 4.5, 1.6 and 1.2 fold that of -20°C storage (Watt
1982).
In this chapter, the effect of changing the
rate of freezing plasma on the quality of thaw-siphon
cryoprecipitate has been investigated. The effect of
storage of plasma at different temperatures for varying
periods of time has also been determined, in order to
find optimal conditions for frozen plasma storage. In
this regard, plasma was also deliberately subjected to
large temperature fluctuations during storage.
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METHODS
Plasma used in this study was CPD plasma prepared from
normal donations within 3 hours of blood donation. Plasma
pools of 6 donations were used in each experiment, thus
avoiding the variations in factor VIII content found in
different individuals. The plasma was pooled in a 2 litre
bag and aliquots of 200 ml were distributed into 300 ml
Fenwal R2011 transfer packs. The plasma was then frozen
and stored as follows:
'Slow Freezing': Packs of plasma were placed in thin
aluminium cassettes and placed in a -40°C cabinet freezer.
The cassettes were placed vertically and the packs had
the outlet ports down.
'Fast Freezing': Packs were placed in cassettes as in
slow freezing but were frozen in a -70°C ethanol bath
which had been cooled using liquid nitrogen.
Freezing Rates: For both these modes of freezing,
plasma temperature was monitored by a thermocouple
(Comark Instruments) placed in the middle of a pack which
was connected to a pen-recorder (Vitatron).
Storage Studies: Plasma pools prepared as above were
aliquoted into 6 separate packs and the plasma was frozen
in -70°C ethanol. Three packs from each pool were then
placed in a -20°C chest freezer, while the other 3 were
placed in a -40°C cabinet freezer. Six pools of plasma
were prepared and stored in this way. Daily checks
ensured that the freezer temperatures were keeping to the
reasonable limits (± 4°C) of the temperatures stated.
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Temperature Insult Studies: Six donation pools were
again prepared and plasma was aliquoted into three 300 ml
packs. These packs were all frozen in -70°C ethanol
and placed in -40°C storage. One pack was stored for
one week. The other 2 were removed after 2 days and
placed in a 4°C cold room for 4 hours. They were then
replaced in -4 0 °C storage. One of these packs was
subjected to the same procedure a second time. One week
after starting the experiment the packs were all processed
to cryoprecipitate. This process was done for 6 plasma
pools; a separate pack with a temperature probe monitored
the fluctuations in the packs subjected to temperature
insult. The remaining 3 packs from each pool were
frozen in a -40°C freezer and used for storage studies as
outlined above.
Cryoprecipitate Preparation: This was according to
Mason et al (1981) with some modifications. The plasma
packs were taken and 2 elastic bands, each 15 mm wide,
were placed one-third and two-thirds of the way down the
pack. Two metallic rods were placed through the slits
along each of the 2 lateral edges of the pack and clipped
together. The rods were joined to each other by a piece
of string, and together with the elastic bands provided
tension on the pack during thawing. The outlet tube of
the pack was joined to an empty 300 ml pack, and the
plasma pack was immersed in a 4°C water bath (Grant
Instruments) with the outlet ports at the bottom (i.e.
inverted thawing). The pack was weighed down with a
FIGURE 4-1
PLASTIC PACK WITH FROZEN PLASMA SET UP FOR THAWING
1. Frozen plasma block
2. Pack margins with slits
3. Hinged metal rods passed through pack margins
4. String joining metal rods
5. Elastic bands
6. Lead weights
7. Outlet port of pack




lead weight. Siphoning of the thawed supernatant was
initiated after about 10 minutes by raising the pack
momentarily out of the water bath. Thawing was continued
until the residual mass of cryoprecipitate was enmeshed
in a lump of lightly-pigmented ice, usually when 20-30 ml
were still left in the pack. The cryoprecipitate pack
was then sealed off and the cryo dissolved in a water
bath at 37°C for about 5 minutes. The cryoprecipitate
and cryosupernatant plasma volumes were then measured,
the 2 components were sampled and the samples were frozen
and stored in 2 ml aliquots for subsequent assay.
Figure 4-1 shows the details of the plasma pack set up
for the thawing process. No attempt was made to remove
residual factor VIII e.g. by saline washing.
Assays:
Factor VIII:C, Factor VIII:CAg, Factor VIIIR:Ag,
Fibrinogen and Total Protein were assayed as described
in Chapter II. Factor VIIIR:Ag was assayed by electro-
immunoassay, except for samples of cryosupernatant plasma,
the VIIIR:Ag in which gives indistinct precipitin lines
(Over et al 1978). For these samples an immunoradio-
metric assay (IRMA, Ch.II) was used. Fibrinogen was
assayed by electroimmunoassay.
FIGURE 4-2
TEMPERATURE PROFILES OF PLASMA FROZEN IN DIFFERENT
MEDIA
Results show temperature changes recorded by probe
placed in middle of pack. Probe was connected to
a pen-recorder which traced the changes in temperature
shown.
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(A) EFFECT OF PLASMA FREEZING RATE ON CRYOPRECIPITATE
QUALITY
Figure 4-2 shows the temperature profiles of
plasma packs frozen in a -70°C alcohol bath and a -40°C
deep freeze. Plasma frozen in -70°C alcohol took only
about 10 minutes to reach -30°C at the core of the pack,
while plasma frozen in the -40°C deep freeze took nearly
hours to reach this temperature. From these
recordings, it can be estimated that for fast freezing
(-30°C in 10 min), 23% of the time was needed for the
plasma temperature to reach 0°C, and 77% to drop further
to -30°C, while the corresponding figures for fast
freezing (-30°C in 2J hours) are 10% and 90%.
It was noticed that plasma that had been frozen
slowly had an even translucent appearance, while plasma
that had been frozen fast showed variations in pigment
density over the frozen surface. After overnight
storage at -40°C, plasma frozen under both these
conditions was processed to thaw-siphon cryo as described
in Methods. It was immediately noticed that plasma
frozen slowly produced a steady flux of particulate
material in the siphon lines during thawing. Plasma
frozen fast, however, produced a clear supernatant during
thawing, with no particles, unless thawing was actually
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FRACTIONS DERIVED FROM PLASMA FROZEN AT DIFFERENT RATES
Figure 4-3 shows the distribution of factor VIII
related activities in cryoprecipitate and cryosupernatant
prepared from the 2 types of plasma. Slow freezing
results in a lower amount of VIII:C being recovered
(expressed as the sum of the VIII:C recovered in cryo and
cryosupernatant) upon thawing the plasma; the difference
however is not significant (paired t-test, t = 1.16,
p > 0.1). Furthermore, the VIII:C in slowly frozen
plasma seems to be less cryoprecipitable, with only 47%
of the residual VIII:C being recovered in the cryopreci¬
pitate. These two effects lead to a comparatively poor
yield of VIII:C when plasma is frozen slowly. Fast-
frozen plasma, however, gave much better results -
425 u/kg of plasma was recovered in the cryo, compared
with 318 u/kg for slowly frozen plasma, a difference that
was significant (t = 3.19, p < 0.05). The poor cryo-
precipitability of factor VIII in slowly frozen plasma
was confirmed by assays of other factor VIII related
activities in cryoprecipitate and cryosupernatant -
Figure 4-3.
Fibrinogen was measured in cryoprecipitates
produced from both types of plasma. Plasma frozen by
fast-freezing gave higher yields of fibrinogen in cryo
than plasma produced by slow-freezing - 824 mg/kg
plasma compared with 522 mg/kg plasma (t = 4.6, p = 0.01).
In general, the flow of particulate material coming over
during thawing of slow-frozen plasma seems to represent
cryoprecipitate that for some reason is not retained

































TABLE 4-IB EFFECT OF STORAGE PERIOD ON PLASMA FROZEN IN -40°C DEEP
FREEZE. RESULTS SHOW MEAN ± S.D. FOR SIX DIFFERENT
EXPERIMENTS
Period Total VIII:C VIII:C Fibrinogen
of Recovered Cryo Yield Cryo Yield
Storage (Cryo + Super)
u/kg Plasma u/kg Plasma mg/kg Plasma
16 hours 610 ± 101 318 ± 111 522 ± 270
3 months 611 ± 183 306 ± 62 502 ± 79
during the siphoning process, leading to lower levels of
cryoprecipitated proteins in the cryo derived from such
plasma. The total protein yield in cryo was 4.3% and
5.9% for slow- and fast-frozen plasma respectively, a
difference which was not significant. In this regard it
must be noted that most of the cryo-protein comes from
the supernatant plasma left after siphoning is terminated.
The amount of this protein is thus expected to be
relatively unaffected by changes affecting the proteins
(such as factor VIII and fibrinogen) specifically
concentrated by cryoprecipitation.
(B) EFFECT OF PLASMA STORAGE CONDITIONS ON CRYOPRECIPITATE
QUALITY
The effect of different storage conditions on
plasma pools frozen in -70°C ethanol is shown in
Table 4-1A. Table 4-1B shows similar data for pools
frozen in a -40°C deep freeze.
Initial freezing rate can be seen to be a much
more important determinant for factor VIII yields than
storage conditions. As long as constant storage
temperature is maintained, there is no significant
difference in cryo factor VIII yields between plasma
stored at -20°C and -40°C. Cryo factor VIII yields did
not change during storage periods of up to 6 months for
plasma stored at both temperatures, the slight drop in
yield after 6 months storage being insignificant.
Fibrinogen content in cryoprecipitate likewise was unaf¬
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FIGURE 4-5 EFFECT OF TEMPERATURE INSUU (WARMING AND REFREEZING)
ON CRYOPRECIPITATE
(A) YIELD OF VIII C IN PLASMA FRACTIONS
(B) YELD OF FIBRINOGEN IN CRYOPRECIPITATE
(C) SPECIFIC ACTIVITY OF CRYOPRECIPITATE VIII: C ^ DBUUEI1 TWICE
□ CONTROL
■ INSULTED ONCE
storage. The same findings are apparent from the data
for slowly frozen pools of plasma.
(C) EFFECT OF TEMPERATURE FLUCTUATIONS DURING PLASMA
STORAGE ON CRYOPRECIPITATE QUALITY
Figure 4-4 shows the temperature fluctuations
recorded in the core of a plasma pack subjected to the
temperature insult described in Methods. The effect of
these fluctuations on cryoprecipitate production is shown
in Figure 4-5.
Although warming and refreezing frozen plasma
resulted in a 20% drop in the total amount of factor VIII:
recoverable from such plasma, this was not reflected by a
proportionate drop in cryoprecipitate factor VIII:C
yields. Rather, the amount of factor VIII:C in cryosuper
natant declined sharply upon temperature insult. The
fibrinogen content of cryoprecipitate was affected by
temperature changes, insulted plasma yielding twice as
much fibrinogen in cryoprecipitate (Figure 4-5B) a
difference that was highly significant (t = 4.31, p <
0.01). A second cycle of temperature insult produced no
further significant change. The specific activity of
cryoprecipitate factor VIII:C (expressed as u/mg of




In the thaw siphon technique, continuous
removal of thawed supernatant plasma maintains the cryo-
precipitate in the frozen state throughout the process,
thus ensuring that the temperature is kept close to 0°C.
This results in minimal loss of cryoprecipitate factor
VIII:C by dissolution and/or enzymatic degradation. On
the large scale production of bulk cryoprecipitate for
processing to factor VIII concentrate, a similar result
is achieved by plasma crushing and continuous thawing
with rigid temperature control (Foster et al 1982).
It was the intention of this study to investigate
the effects of two variables on cryoprecipitate quality,
(i) the rate of plasma freezing and (ii) the conditions
under which frozen plasma is stored. It was felt
important to use the high yielding thaw-siphon technique
as a thawing method, as a method involving high losses
during thawing might have masked any differences in yield
due to the other variables under investigation. At the
same time, it was the intention of the study to
investigate the effect of the two variables on the purity
of cryoprecipitate, so a modification of the original
technique ensuring a higher factor VIII specific activity
was used. Compared to the original technique, the
modified method produces a lower factor VIII:C yield -
about 500 u/kg plasma compared to about 600 u/kg plasma -
but gives a higher specific activity - 0.17 u/mg protein
versus 0.08 u/mg. The drop in yield was felt acceptable
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in order to obtain a higher purity. The specific
activity obtained in this study is lower than that
reported by Mason et al - 0.17 u/mg compared to 0.5 u/mg.
This is probably because of less efficient tensioning
during thawing with subsequent retention of excess plasma
protein with the cryoprecipitate. This is confirmed by
measuring the ratio of cryoprecipitate fibrinogen to total
protein using the present method - 0.16 compared to 0.7
in the method described by Mason et al.
Previous studies using the thaw-siphon technique
all used plasma frozen by fast-freezing methods. The
importance of fast-freezing is shown by the results of
this study. Following slow-freezing, a continuous flux
of particulate matter in the siphon lines is accompanied
by a marked decrease of all the factor VIII related
activities in the residual cryoprecipitate, with a
corresponding increase in the cryosupernatant
(Figure 4-3). The loss of cryoprecipitated material is
also reflected by lower levels of fibrinogen in the cryo¬
precipitate. Thus, although the total recoverable VIII:C
content was not different using the two freezing methods,
the loss of cryoprecipitate led to factor VIII recoveries
comparable or inferior to yields obtained by less optimal
thawing techniques (see Chapter V). Attempts to assay
the contents of the observed particles were unsuccessful,
as these dissolved by the end of the thawing period even
when the supernatant was collected in a flask placed in
melting ice.
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The different results obtained with slow and
fast-freezing suggest a different distribution of cryo-
precipitate in the plasma pack obtained by the two
methods. In fast-frozen plasma, cryoprecipitate appears
to be concentrated in the final 20 mis or so of siphoning
material. Slow-freezing seems to result in cryoprecipi¬
tate formation throughout the whole plasma block, as
evinced by the appearance of particles in the siphon lines
as soon as thawing commences, leading to loss of cryo-
precipitated proteins such as factor VIII and fibrinogen
in the supernatant. Mason et al (1981) have proposed
that fast-freezing involves a primary precipitation of
cryoglobulins (including fibrinogen and factor VIII)
followed by precipitation of other proteins as the
concentration of electrolyte in the liquid phase increases.
Upon thawing, the various proteins then elute in the
reverse order to that in which they separated during
freezing. It is possible that with slow-freezing
precipitation of cryoglobulins occurs throughout the
freezing process, leading to cryoprecipitate formation
through the whole plasma block. Elution of factor VIII
and other cryoglobulins would then occur throughout
siphoning, resulting in the losses observed.
The results of this study show that as long as
steady storage conditions are maintained, plasma can be
stored for long periods without affecting the quality of
cryoprecipitate. The work of Mackenzie cited above
suggests that complete freezing in plasma is achieved at
below -80°C. Although it has been suggested that storag
below the temperature of complete freezing is to be
preferred (Watt 1976), a temperature of -20°C was found
to be adequate. This finding has important implications
as the cost of -20°C refrigeration is considerably lower
that that of -40°C. Storage period also did not have a
crucial effect, the slight drop in VIII:C yield after 6
months being insignificant. There was no change in the
total fibrinogen and total protein in cryoprecipitate
after 6 months storage, and no difference between the two
temperatures studied.
Storage involving deliberate temperature insult
resulted in a marked drop in the total factor VIII:C
recoverable from plasma after processing to cryoprecipi¬
tate and cryosupernatant. This drop, however, was not
reflected in the amount of VIII:C recovered in cryo¬
precipitate, which remained relatively constant, but was
due to a sharp drop in VIII:C recovered in the cryo¬
supernatant. The increased lability of cryosupernatant
VIII:C compared to cryoprecipitate VIII:C has been
documented (Over et al 1978) and it seems that the
deleterious effects of temperature insult result in loss
of this form of VIII:C.
The marked increase in cryoprecipitate fibrin¬
ogen that results from temperature insult may be one of
the reasons for the variation in cryoprecipitate mass
that has been noted during bulk plasma fractionation
(Hershgold et al 1966, Newman et al 1971). Foster (1983
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has reported similar increases in cryo-fibrinogen in
plasma that has been stored at constant temperature for
increasing periods. The present results indicate that
temperature fluctuations are more likely to be the reason,
no increase in fibrinogen being apparent when a constant
storage temperature was maintained. Fluctuations may
occur during storage and/or transportation of bulk frozen
plasma, although warming of large plasma blocks is bound
to be less rapid than for the single donations used in
this study. It is uncertain why the cryoprecipitated
fibrinogen should increase after temperature insult.
Increased aggregation of fibrinogen molecules leading to
greater insolubility could be one explanation (Newman et
al 1971). Increased cryoprecipitate fibrinogen is
responsible for difficulties in extracting and further
processing factor VIII concentrates and results in poor
filterability and solubility. Maintenance of steady
temperatures during frozen plasma storage is therefore
important.
In summary, this study concludes :
1) Cryoprecipitation using the thaw-siphon technique
requires plasma that is frozen fast for good factor
VIII yields. The results of this and other studies
suggest that attainment of -30°C in the core of the
pack in about one hour should be sufficient.
Ethanol cooled to -70°C with dry ice can achieve this
very efficiently. Placing the packs in a plastic
bag should decrease any risk of ethanol leaking into
170
the pack, although this was never encountered in the
course of this work.
2) Storage of frozen plasma at -20°C until processing is
perfectly adequate in terms of product quality and is
much cheaper than refrigeration at lower temperatures.
3) Maintenance of refrigeration equipment is very
important to avoid temperature fluctuations leading
to the effects outlined in Results. This is
especially important if -20°C storage is used, as
minor breakdown of such equipment is more likely to
result in rapid temperature rises. Daily or
continuous monitoring of temperature is recommended.
CHAPTER V
APPROACHES TO PRODUCING A
FACTOR VIII CONCENTRATE FROM
HUMAN PLASMA IN BLOOD BANKS
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INTRODUCTION
At present, about 98% of the world's production
of factor VIII concentrates starts off with the production
of cryoprecipitate (De Vreker 1980). Cryoprecipitate
yield and quality depend on many variables (Chapter I)
and yields of 20 to 85% of the plasma VIII:C have been
reported (Masure 1969). By modifying the thawing
technique and using optimal freezing methods, yields of
about 500 u/kg of plasma can be obtained on a blood bank
scale (Chapter IV). Such thaw-siphon cryoprecipitate,
however, cannot substitute, in terms of convenience and
ease of storage and administration, for lyophilised
concentrate, which is produced at much lower yields.
Although cryoprecipitation is widely utilised,
the mechanism of the process is poorly understood.
Poison (1972) has proposed that the well known salting-
out of proteins is involved. In this theory, the
increasing salt concentration in the intercrystalline
spaces of frozen plasma causes precipitation of the most
insoluble proteins, including factor VIII and fibrinogen.
An alternative explanation proposed a steric exclusion
mechanism (Owen and Wagner 1972), in which exclusion of
high molecular weight proteins from volumes of solvent by
increasing concentrations of plasma protein leads to their
precipitation. A better understanding of the mechanism of
cryoprecipitation might allow improvements in product
quality and yield.
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The ease and simplicity of cryoprecipitation
have led to few investigations into alternatives for
concentrating factor VIII from plasma. The early
observations of Poison et al (1964) suggested that polymer
precipitation might provide a method of plasma protein
fractionation, but in the case of factor VIII, polymers
such as polyethylene glycol (Newman et al 1971) have
only been used in the later stages of purification. Use
of such polymers, which act through a steric exclusion
mechanism (Poison and Ruiz-Bravo 1972), might enable the
high molecular weight difference between factor VIII and
other plasma proteins to be exploited. So far, this
difference has mainly been used, in gel filtration, for
separations on an analytical scale (Chapter II, Ratnoff
et al 1969).
It is the purpose of this Chapter to develop
a simple and reliable process for the concentration of
factor VIII from plasma using methods applicable in
blood banks. The method sought after needed to give a
high yield of factor VIII with the product characteristics
of current lyophilised concentrates. In addition, the
method had to allow utilisation of other blood components
after concentration of factor VIII.
In this regard, some attempts were made to
improve cryoprecipitate yield by adding heparin (Rock et
al 1980b) or P.E.G. (Johnson et al 1979) to plasma which
was then thawed by different methods. Studies were
made on the mechanism of cryoprecipitation, in order to
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delineate conditions for better VIII:C yields. As an
alternative to cryoprecipitation, polymer precipitation
of unfrozen plasma was examined. Conditions derived
for factor VIII purification on the small scale were
then utilised on medium scale plasma volumes, thereby
modelling factor VIII concentrate production under blood
bank conditions.
METHODS
Cryoprecipitate production: Plasma for these experiments
consisted of pools prepared as in Chapter III or as
described in Results. All plasma was frozen by fast-
freezing as in Chapter IV.
Thawing: Two basic thawing methods were used:
1 . Fast-thawing. 200 ml packs of frozen plasma were
placed in a water bath at 4°C. The plasma was
allowed to thaw until visual inspection showed that
only a few ice crystals were left. This took about
100 minutes from the start of thawing. The cryo¬
precipitate was then sedimented either by (a)
centrifugation of the bags in a Mistral 6L centrifuge
for 36,000 g min. at 0°C. All but 20 ml of
supernatant plasma was then expressed out of the pack
using a Fenwal plasma expressor and 3 ml of 15 mM
citrate, 150 mM NaCl, pH 6.9 (citrate-saline) were
added to the cryoprecipitate (cryo) bag. The cryo
was then solubilised in a 37°C water bath, its
volume was measured and small aliquots (2 ml)
sampled, fast frozen and stored at -40°C until
assayed; or (b) transfer of the thawed plasma to
polycarbonate bottles and centrifugation in a Sorvall
RC-2B centrifuge for 80,000 g min. at 0°C. The
supernatant was then decanted and the cryoprecipitate
was dissolved in 10 ml of citrate-saline.
2. Thaw-siphoning and centrifugation. This was
performed according to Rang (1980). Packs of frozen
plasma were placed in a 4°C water bath. The outlet
tubing was attached to an empty 200 ml bag and
clamped. After about 10 minutes in the water bath,
the clamp was removed and 2 elastic bands were placed
around the pack as described in Chapter IV. The
pack was replaced in the water bath and siphoning was
initiated using a pair of Fenwal (R4415) tube-
strippers to force air out of the siphon line.
Siphoning was allowed to continue until about 60 ml
of frozen material remained in the bag. This point
was reached about 60 minutes from the start of
thawing. The siphon line was the clamped and the
residual material was allowed to thaw in the bag
until a few ice crystals remained. The thawed
plasma was then transferred to polycarbonate bottles
and centrifuged for 80,000 g min. in a Sorvall RC-2B
centrifuge. The supernatant was decanted completely
and combined with the supernatant obtained from
siphoning. The cryoprecipitate was dissolved in
10 ml of citrate-saline.
Small scale cryoprecipitation of plasmas of different
composition:
1. Preparation of plasma of different ionic strengths.
Low ionic strength; 10 ml plasma aliquots were
dialysed against 5 litres of distilled water for
4 hours at room temperature. Control samples were
held at room temperature for the same period, and
then adjusted to the same volume with isotonic saline.
177
High ionic strength: 10 ml plasma aliquots were
made to 2% NaCl by addition of solid crystals of NaCl
and stirring until dissolution was observed.
2. Preparation of plasma of low albumin content.
Albumin poor plasma was prepared by gel filtration
of 20 mis of plasma on a column (70 x 1.5 cms) of
Sepharose CL-4B (Pharmacia). The column was eluted
with citrate-saline pH 6.9. 6 ml fractions were
collected and assayed for VIII:C, VIIIR:Ag, fibrin¬
ogen and fibronectin as described in Chapter II.
Total protein was assayed by measuring the absorbance
of fractions at 280 nm. Fractions containing the
bulk of VIIIR:Ag, fibrinogen and fibronectin were
pooled and concentrated to 20 ml by ultrafiltration
on an Amicon PM-10 membrane. A control sample was
allowed to stand at room temperature for the length
of the procedure, which took about 22 hours from
when the plasma was collected.
3. Preparation of fibrinogen-depleted plasma. 10 ml
plasma aliquots were clotted with 0.5 mis of
Reptilase reagent (Pentapharm) at 37°C for 1 hour.
The resultant clots were removed with a thin wooden
stick, the clot being squeezed to express any
entrapped fluid. Controls were incubated for the
same period with 0.5 ml V of saline.
4. Preparation of fibronectin-depleted plasma. 10 ml
plasma aliquots were batch adsorbed with gelatin-
agarose (3 ml settled gel; prepared as in
Chapter II) for 3 hours at room temperature. Control
were adsorbed with 3 ml of Sepharose 4B. The
plasma was separated after centrifugation for 20,000
min.
The small aliquots of plasma prepared as
described above were frozen in a -40°C cabinet freezer.
Cryoprecipitate was prepared by thawing in a 4°C water
bath, centrifugation for 20,000 g min. at 4°C and
solution of the cryo in 1 ml of citrate-saline.
Salt precipitation of plasma (Poison and Ruiz Bravo 1972)
Aliquots of plasma were made 20% (w/w) NaCl by
addition of solid NaCl at room temperature with constant
stirring. After 15 minutes at room temperature, the
mixtures were centrifuged for 13,000 g min. and the
precipitate was dissolved in 0.1 of the plasma volume of
citrate-saline.
Polymer induced precipitation of plasma:
Polymer stock solutions were made by dissolving 40% w/w
of polymer in isotonic saline. The following polymers
were used: polyethylene glycol (PEG) Mn = 6000 (Union
Carbide); polyvinylpyrrolidone Mn = 10,000 and Mn =
40,000 (PVP 10, PVP 40) (Sigma); Dextran T 70, Dextran
T 150 and Ficoll 70 (Pharmacia Fine Chemicals); hydro-
xyethyl starch Mn = 40,000, Mn = 350,000 and Mn = 450,000
(HES 40, HES 350, HES 450) were generously supplied by
the Army Blood Supply Depot, Aldershot. A 40% stock
solution of human albumin was made by concentrating a
20% solution (Immuno) by ultrafiltration on an Amicon
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PM-10 membrane.
Polymer induced precipitation: Dilutions of stock
polymer solutions were added to plasma until the desired
final concentration was reached. The mixtures were
then held under the conditions described in Results,
after which the precipitates formed were sedimented by
centrifugation for 13,000 g min. Experiments were
performed on small scale (20 ml volumes of plasma) and
the conditions derived were used to process medium scale
volumes (200-1500 ml ).
Plasma concentration and cold precipitation: Plasma
was concentrated by ultrafiltration on an Amicon PM-10
membrane or by dialysis against 50% PEG 6000 in 20 mM
Tris, 150 mM NaCl, pH 7.2 as described by Owen and
Wagner (1972). The concentrated plasma was then held
at 0°C (melting ice bath) for 30 minutes, centrifuged
for 13,000 g min. at 4°C and the resultant precipitate
dissolved in 0.1 of the original volume of buffer as
specified in Results.
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RESULTS
(A) EFFECT OF HEPARIN ON CRYOPRECIPITATE FACTOR VIII
YIELDS
Table 5-1 shows that addition of heparin to
CPD plasma had no effect on the factor VIII yield in
fast-thaw cryoprecipitate. Increasing the amount of
heparin added did not improve yield and neither did
adding heparin to the anticoagulant in the blood bag
instead of addition to the plasma after separation.
Using the thaw-siphon/centrifugation technique
VIII:C yields were significantly increased compared to
yields using the fast-thaw method (p < 0.05) (Table 5-2)
Addition of heparin to the plasma did not affect yields.
Delaying addition of heparin until 3 hours after the
initial donation also did not affect yields.
Collection of blood in heparin anticoagulant
resulted in increased yields of cryo VIII:C compared to
collection in CPD (Table 5-3) but the difference was not
significant.
(B) EFFECT OF POLYETHYLENE GLYCOL (P.E.G.) ON CRYO¬
PRECIPITATE FACTOR VIII YIELDS
Table 5-4 shows the characteristics of cryo¬
precipitate prepared by the fast-thaw technique with
hard centrifugation and complete drainage of the super¬
natant. Addition of PEG 6000 to plasma to a final
concentration of 1% w/w did not increase VIII:C yields,
but the amount of fibrinogen in the cryoprecipitate was
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significantly increased (p < 0.01). The specific
activity of cryo VIII:C was also significantly lowered
(p < 0.01) when PEG was added to the plasma.
(C) PLASMA PRECIPITATION WITH NaCl
Table 5-5 summarises the characteristics of the
precipitate obtained by adding NaCl to a final plasma
concentration of 20% w/w. Although most of the VIIIR:Ag
precipitated, the VIII:C yield was comparatively poor.
Most of the plasma fibrinogen also precipitated, leading
to a low specific activity of VIII:C in the precipitate.
It was also noticed that the precipitates showed great
instability, with clotting occurring after one cycle of
freeze-thawing.
(D) CRYOPRECIPITATION OF PLASMAS OF DIFFERENT
COMPOSITION
Table 5-6 lists the characteristics of 'plasma'
of different composition prepared as described in
Methods. Table 5-7 shows the effect of these differences
on the characteristics of cryoprecipitate.
1. Plasma of different ionic strengths:
Decreasing the ionic strength of plasma by
dialysis increased the yield of VIII:C in cryo but
the difference compared to an untreated control was
not significant. Increasing the plasma ionic
strength by salt addition however resulted in signi¬
ficantly decreased yields of cryo VIII:C (p < 0.001)
and fibrinogen (p < 0.05). Cryo VIIIRrAg was also
FIGURE 5-1
GEL FILTRATION OF 20 mis POOLED CPD PLASMA ON
SEPHAROSE CL-4B COLUMN (70 x 1.5 cm)
Elution was with 15 mM citrate, 150 mM NaCl, pH 6.9
at 35 ml /hour. 6 ml fractions were collected.
The positions of elution of VIIIRrAg, fibrinogen and
fibronectin are shown. Fractions containing the
bulk of these proteins were pooled as shown and
concentrated as described in Methods.
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decreased, although not to the same extent as VIII:C,
while fibronectin yield was unaffected. It was
noted that some degree of clotting had occurred in
the cryo from high ionic strength plasma after
removal of the cryosupernatant.
Plasma of low protein content:
Gel filtration of plasma on Sepharose CL-4B
gave the elution pattern shown in Figure 5-1. The
relatively large sample:column volume ratio did not
permit sharp separation of the main proteins
according to their molecular weights. Nevertheless,
by pooling the fractions shown and concentrating them
to the initial volume, a low protein plasma with the
characteristics shown in Table 5-6 was obtained.
Although this material was somewhat depleted in
fibrinogen and fibronectin, substantial amounts of
these cryoprecipitable proteins were present, as was
VHIR:Ag. The production method led to loss of
most of the VIII:C however. Such protein-poor
plasma gave a very small cryoprecipitate, with low
levels of all the normally cryoprecipitable proteins.
Fibrinogen depleted plasma:
Clotting with Reptilase allowed fibrinogen
removal without affecting VIII:C (Funk et al 1971)
(Table 5-6). Cryoprecipitation gave low levels of
the other cryo-proteins, factor VIII and fibronectin
(Table 5-7) in the precipitate.
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FIGURE 5-2
SMALL SCALE PRECIPITATION OF CPD PLASMA WITH
HYDROPHILIC POLYMERS
20 ml aliquots of plasma were made to the appropriate
polymer concentration and held for 2 hours in
melting ice. The precipitates were then recovered
by centrifugation for 13,000 g min. at 4°C,
dissolved in 2 ml of 60 mM NaCl, 130 mM glycine,
70 mM dextrose, 20 mM citrate, pH 6.8 ('glycine-
dextrose' buffer) and stored at -40°C
0 0 VIII: C
• • VIIIR:Ag
1 A Fibrinogen
□ □ Total protein
HES CO HES 350 HES 150 OEXTRAN 150
FICOLL 70 PEG 6000
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4. Fibronectin depleted plasma:
Adsorbtion of plasma with gelatin-agarose
resulted in specific depletion of fibronectin
(Table 5-6). Subsequent cryoprecipitation led to
low yields of all the cryo-proteins in the precipi¬
tate (Table 5-7).
(E) POLYMER INDUCED COLD PRECIPITATION OF PLASMA
1. Small scale precipitation:
Preliminary observations indicated that
certain polymers formed precipitates when added to
plasma at low temperatures. Figure 5-2 shows dose
response results for the various polymers when
tested on 20 ml amounts of plasma under the conditions
described. All polymers tested produced selective
precipitation of VIII:C and VIIIR:Ag, but some
resulted in a better purification than others. In
particular, the various hydroxyethyl starches and
Ficoll 70 gave quantitative recoveries of VIII:C and
VIIIR:Ag at concentrations which produced minimal
precipitation of fibrinogen and total protein. At
higher concentrations, increased fibrinogen precipi¬
tation was observed and, in the case of HES 350 and
HES 450, the precipitates were somewhat insoluble.
At concentrations of between 2 and 4%, maximal
recovery and purification of factor VIII was obtained.
Other polymers were found to be less
selective. Except at the lowest concentrations
tested, PEG precipitated factor VIII and fibrinogen
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FIGURE 5-3
SMALL SCALE PRECIPITATION OF CPD PLASMA WITH HUMAN
ALBUMIN
Conditions for precipitation and recovery of
precipitates were as in Figure 5-2.
Recoveryinprecipitat s (°/0initialvalue)
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together and formed very insoluble precipitates.
Precipitates obtained by dextran addition were
sparingly soluble in the buffer used. Dextran
solutions tended to be very viscous and polymer was
retained in the precipitate. Since no attempt was
made to wash these precipitates, the insolubility
could be due to retention of dextran. Precipitates
obtained with PVP were unstable as some clotting was
observed upon freezing and thawing samples.
Precipitation of factor VIII from plasma
by albumin addition is shown in Figure 5-3. At
final concentrations of between 5 and 6% added
albumin, virtually complete precipitation of factor
VIII was obtained with little fibrinogen or other
proteins being precipitated.
Table 5-8 summarises the optimal
conditions for factor VIII precipitation on a small
scale (20 ml ) .
Medium scale precipitation:
The optimal conditions derived for small
scale precipitation were applied to plasma precipi¬
tation on a medium scale (between 400 and 1800 ml ).
The effect of an overnight incubation at 0°C as well
as the standard 2 hour one was also investigated.
The results are summarised in Table 5-9. Precipi¬
tations on a medium scale for 2 hours resulted in
concentrates containing the bulk of the factor VIII
with little contaminating proteins. Overnight
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incubation, however, resulted in decreased yields of
VIII:C and increased precipitation of other proteins.
3. Medium scale precipitation of plasma collected in
different anticoagulants:
• Six donations of CPD plasma were made 4%
with respect to Ficoll 70, and incubated for 2 hours
at 0°C. The resulting precipitates had the charac¬
teristics shown in Table 5-10. Six donations of
heparin plasma were similarly processed, but the
precipitates obtained were observed to be much
denser than those from CPD plasma. These precipi¬
tates proved very difficult to dissolve even at 37°C,
and reprecipitation occurred at room temperature.
Table 5-10 shows that in heparin plasma, considerably
more fibrinogen was precipitated than from CPD plasma.
(F) USE OF HES 40 TO PRODUCE A BLOOD BANK FACTOR VIII
CONCENTRATE
Table 5-11 shows the characteristics of a
concentrate prepared from a plasma pool of 1800 mis by
cold precipitation with 4% HES 40. The resulting
precipitate was processed according to the method of
Newman et al (1971) for bulk cryoprecipitate, i.e. by
extraction into 20 mM Tris-HCl pH 7 at 20°C, addition of
20 mM citrate, pH adjustment to pH 7 and freeze-drying.
Adsorbtion with alumina was not performed in this
experiment. Upon reconstituting the freeze-dried
concentrate, only 60% of the VIII:C that was aliquoted
into the vial was recovered.
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1) Dissolved precipitate 10.5 ± 3.8 6.9 ± 0.1
2) Dried precipitate dissolved in 10.3 ± 4.5 7.2 ± 0.06
dispensed volume
3) Dissolved precipitate adsorbed 9.8 ± 2.4 6.8 ± 0.08
with A1(0H)3
4) Dried adsorbed precipitate 10.2 ± 3.5 7.3 ± 0.14
dissolved in dispensed volume
5) (1) after 24 hours at 22°C 8.2 ± 4.0 6.9 ± 0.17
6) (2) after 24 hours at 22°C 5.7 ± 2.6 7.4 ± 0.12
7) (3) after 24 hours at 22°C 8.3 ± 1.9 7.0 ± 0.03
8) (4) after 24 hours at 22°C 5.9 ± 3.6 7.5 ± 0.19
Six donations of CPD plasma were each precipitated with
4% HES 40. The precipitates were each dissolved in 16 ml.
of glycine-dextrose buffer pH 6.8. One portion (7 ml ) of
each dissolved precipitate was freeze-dried, the other
(7 ml) portion was adsorbed with alumina, the pH was
adjusted to about 6.9 and it was then freeze-dried.
TABLE 5-13 CHARACTERISTICS OF FREEZE-DRIED HES 40 PRECIPITATE
OF PLASMA
Freeze-dried material from 12 individual donations was
















9.6 ± 2.7 u/ml
9.2 ±1.9 u/ml
6.5 ± 2.4 u/ml
594 u/kg




8.7 ± 3.2 mg/ml
3.2 ± 1.1 mg/ml
14.4 ± 1.5 mg/ml
6.8 ± 0.03
5 ±0.2 mMho
(Material from 4% HES 40 precipitation was dissolved in
0.06 M sodium chloride, 0.13 M glycine 0.07 M dextrose,
0.02 M citrate pH 6.5, and freeze-dried)
It was felt that the Tris buffer used for
extracting the HES precipitate might be unsuitable for
freeze-drying. The HES precipitate had a much higher
specific activity than the bulk cryoprecipitate which is
usually extracted into Tris buffer. A further experi¬
ment was performed in which 6 individual CPD plasma
donations were each precipitated with 4% HES 40 at 0°C.
The resulting precipitates were dissolved in a glycine-
dextrose buffer (Milligan et al 1981) at 37°C, and
freeze-dried. Table 5-12 shows the characteristics of
these precipitates. Stability over freeze-drying was
much improved using the glycine-dextrose buffer. However,
stability of the reconstituted material over 24 hours was
rather poor, with only 55% of the VIII:C immediately
after reconsititution remaining after 24 hours.
Adsorbtion of the initial dissolved precipitate with
alumina did not improve stability. The pH of the
reconstituted product was above 7 (Table 5-12) and rose .
further during incubation. It was felt that a lower
pH might improve VIII:C stability. In a further experi¬
ment, the pH of the dissolved precipitates was adjusted
to 6.6 prior to freeze-drying. This resulted in a pH
of about 6.8 upon reconstitution. Table 5-13 lists
the characteristics of concentrates from 12 individual
donations processed in this manner. As can be seen, pH
adjustment increased the 24 hour post-reconstitution
stability to 68%, a difference which was significant
(p < 0.05). Figure 5-4 shows the two-dimensional
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FIGURE 5-4
TWO-DIMENSIONAL IMMUNOELECTROPHORESIS OF VIIIR:Ag IN
FRACTIONS PRODUCED BY 4% HES-40 PRECIPITATION OF
PLASMA
Electrophoresis was at 200 V for 6 hours and 120 V for
18 hours in the first and second dimensions
respectively. The anode was to the right in the
first dimension and at the top in the second dimension.
Antiserum concentration in the second dimension was
0.2%.
The arc produced by the supernatant fraction was traced over wit
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immunoelectrophoretic pattern of the VIIIR:Ag in the 4%
HES supernatant and precipitate. It can be seen that
slower migrating forms of VIIIRrAg are concentrated in
the precipitate, with fast-migrating forms being left in
the supernatant.
(G) PLASMA CONCENTRATION AND COLD PRECIPITATION
Two methods were used to concentrate plasma
protein by water removal:dialysis against concentrated
PEG and ultrafiltration on a polycarbonate membrane.
The concentrated plasma was then incubated at 0°C and
the resultant precipitates were dissolved in glycine-
dextrose buffer. Table 5-14 shows the results. The
one experiment utilising dialysis gave a rather low
yield in VIII:C, although most of the VIIIR:Ag was
precipitated. Concentration using ultrafiltration gave
a very good purification of VIII:C at high yield, but
using the equipment available took over 6 hours to effect
a two-fold concentration of the plasma.
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DISCUSSION
Most studies reporting on the routine
production of cryoprecipitate agree that a yield of 40-
60% of the plasma VIII:C is the best that can be obtained
(Kasper et al 1975, Slichter et al 1976). Any factors
that increase VIII:C yields in cryoprecipitate without
affecting the production of other blood components are
bound to have a profound effect on the logistics of
haemophilia care. The recent association of develop¬
ment of the AIDS syndrome with use of commercial
concentrates has resulted in increased use of cryo¬
precipitate in the United States (Sandler and Katz 1984).
Thus, it is likely that efforts to improve cryoprecipitate
quality will continue.
This study does not support the claim that
addition of heparin to CPD plasma increases VIII:C cryo¬
precipitate yields (Rock et al1980b, Hanratty 1983).
Addition of heparin might be assumed to inhibit any
thrombin present in the plasma, and thus prevent the
long known degradation of VIII:C by thrombin (Rapaport
et al 1963). Indeed, the amount of heparin used
(1 u/ml) has been shown to inhibit totally the effect of
exogenously added thrombin on VIII:C in plasma (Sussman
and Weiss 1978). However, thrombin formation in fresh
plasma used in this study is minimal, as evinced by low
FpA levels (Chapter III) and heparin did not affect the
yield of VIII:C in cryoprecipitate. Collecting blood
directly into heparin/CPD anticoagulant also did not
affect VIII:C yields (Table 5-1), thus negating the
possibility that thrombin formation had occurred during
plasma production and heparin had been added too late to
prevent VIII:C degradation. It has also been observed
that antithrombin III is not concentrated in cryoprecipi-
tate (Cosgriff et al 1983) making it unlikely that heparin
can prevent VIII:C degradation even if thrombin generation
occurred during cryoprecipitate production. It is thus
difficult to explain the studies cited which claim
benefit in adding heparin. It has been suggested that
rather than working through a protective effect on VIII:C
from the action of thrombin, heparin acts by increasing
the physical cryoprecipitability of factor VIII and
other proteins (Rock 1983b). However, the results of
the present study show that provided cryo separation is
efficient, VIIIR:Ag yields approach 800 u/kg of plasma
without heparin addition (Table 5-4) suggesting that
VIII:C loss under these conditions is by inactivation.
Rock (1983b) claims that heparin increases the amount of
fibrinogen and total protein in the cryo, but the data
from the present study and others (Smit-Sibinga 1983) do
not confirm this. It should be noted that Rock reports
a yield of 9% in cryo-fibrinogen derived from CPD plasma,
a value that must be considered abnormally low. Yields
of 20 to 30% as found in the present study are the
normal range for cryo-fibrinogen. The study reported
by one of the groups (Hanratty 1982) uses the thaw-siphon/
centrifugation technique to produce cryoprecipitate. As
shown in this study, use of this technique leads to
increased VIII:C yields without heparin addition. It
has been claimed that addition of heparin to CPD plasma
must be made immediatley after donation if good results
are to be obtained. The data in this study, however,
find no effect of heparin addition upon donation, or one
hour and 3 hours after (Tables 5-1 and 5-2).
One factor resulting in low VIII:C yields is
loss by redissolving into the cryosupernatant. This is
shown by decreased yields in VIII:C and VIIIR:Ag using
fast-thawing compared to thaw-siphon/centrifugation
(Tables 5-1 and 5-2). Using the latter technique,
supernatant plasma is removed continuously throughout
most of the thawing period, thus minimising loss of
cryoprecipitate through redissolving. In the fast-
thawing method, cryoprecipitate remains suspended in
supernatant plasma throughout thawing, allowing re¬
dissolving. The conditions for the final separation of
cryoprecipitate are however also of importance. Thus,
when centrifuging bags of thawed plasma after fast-
thawing, it was observed that the cryoprecipitate often
failed to sediment fully, with fragments of precipitate
remaining floating in the supernatant. This is probably
due to an insufficiently hard centrifugation using the
Mistral machine, and to cryoprecipitate fragments being
trapped in creases in the plasma bag. Substantially
improved yields were obtained by transferring fast-
thawed plasma to polycarbonate bottles and using harder
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centrifugation. Using this latter technique, drainage
of the supernatant could be effected much more efficiently
than in bags, so that the cryo obtained had a much higher
specific activity (Tables 5-3 and 5-4).
Collection of blood in heparin led to increased
VIII:C yields in cryo, although compared to a group of
CPD donations the difference was not significant (Table
5-3). In this experiment, sedimentation was achieved
by spinning the bags of thawed plasma, with the problems
noted above. This might explain why the yields are
lower than reported by other studies (Rock et al 1979,
Smit-Sibinga et al 1981).
Transferring of thawed plasma from plastic
bags to bottles for centrifugation would involve
abandoning the closed plastic bag system. At the same
time, adoption of bottles for the whole process of plasma
processing to cryo cannot be recommended, as freezing
and thawing plasma in bottles would greatly prolong
freezing and thawing times, with possible resultant loss
in yield. Use of the plastic bag has the advantage
that the plasma is frozen and thawed as a flat slab, and
the thin bag ensures quick freezing and thawing. It
might be possible to adopt the approach described of
transferring thawed plasma to bottles but checks for
sterility would be essential. Hanratty (1982,1983) has
shown that use of such an open system can maintain
sterility, using a sterile room and laminar flow cabinets.
Addition of PEG to 1% did not result in
improved VIII:C yields, in contrast to the findings of
Johnson et al (1979). Fibrinogen in the cryoprecipitate,
however, was greatly increased and specific activity of
VIII:C was reduced. PEG addition led to the formation
of heavier cryoprecipitates, which might sediment better
during low speed centrifugation and lead to higher
yields. Using adequate centrifugation, however, no
benefit was obtained.
The findings shown in Table 5-7 do not support
the suggestion of Poison (1972) that cryoprecipitation
involves a form of salting-out of proteins. Decreasing
the salt content of plasma had no effect on cryoprecipi¬
tate composition, while increasing the ionic strength
depressed cryoprecipitation, possibly by dissolution of
cryo-proteins into plasma, after thawing at this salt
concentration (Smith et al 1979). Decreasing the
protein content of plasma greatly decreased cryoprecipi¬
tation. Owen and Wagner (1972) have suggested that a
steric exclusion of high molecular weight proteins by
increasing concentrations of low molecular proteins
during freezing is responsible for the precipitation of
cryo-proteins such as factor VIII, fibrinogen and fibro-
nectin. This is also supported by the precipitation of
factor VIII upon addition of albumin to plasma (Figure
5-3), and by precipitation of cryo-proteins upon
increasing the plasma protein concentration (Table 5—14) -
The findings in this study indicate that both of the
other major cryo-proteins (fibrinogen and fibronectin)
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are necessary for efficient factor VIII cryoprecipitation
to occur, a finding noted in one other report (Mazurier
et al 1983). The cold precipitation of plasma factor
VIII and fibronectin (Chapter III) also points to a cold
induced association of these proteins.
Alternatives to cryoprecipitation as a means
of concentrating plasma factor VIII were investigated.
Addition of NaCl to plasma, as described by Poison and
Ruiz-Bravo (1972) was not an effective method, as low
yields of VIII:C associated with unstable precipitates
were obtained. This method is also unsuitable because
it would preclude use of the supernatant plasma as a
volume expander or for further fractionation, due to the
high salt content.
Use of hydrophilic polymers led to more
promising results (Figure 5-2). Precipitation of
chilled citrated plasma with albumin, HES or Ficoll 70
was particularly effective and allowed a single-step
purification of factor VIII at a specific activity of
0.5 to 1.0 units/mg protein in greater than 80% yield,
in 2 hours. Casillas and Simonetti (1982) have reported
that the use of PVP also results in good factor VIII
purification. In the present study, however, precipi¬
tates obtained with PVP tended to clot, possibly due to
the presence of impurities in the polymer (Zuber and
Morgenthaler 1982). The other polymers tested, while
resulting in selective precipitation of factor VIII,
gave inferior results to those described above. Previous
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studies by Alexander et al (1975,1978) with low concen¬
trations of polymers added to chilled plasma indicated
that prolonged incubation (48 hours) resulted in
precipitation of fibrinogen and factor VIII with
dextran. Although no data was given, HES was stated to
be a less efficient precipitant, while albumin was found
to be ineffective. In the present study, both HES and
albumin were found to be effective agents for precipi¬
tating factor VIII selectively. The experimental
conditions used by Alexander et al differed from those
used in this study and this could explain these
discrepancies.
It seems likely that the mechanism of precipi¬
tation by the polymers described in this study is a
molecular exclusion process similar to that described
for dextran (Laurent 1963) and PEG (Juckes 1971). In
this regard, it may be significant that the discrimin¬
ation between factor VIII and fibrinogen/total protein
was worst with a linear flexible polymer - PEG - while
compact polymers such as Ficoll 70 and albumin gave much
better discrimination. HES has a branched structure
leading to a more compact shape, and this polymer was
also found to be a selective precipitant of factor VIII.
Another factor influencing discrimination between factor
VIII and fibrinogen is the incubation period at 0°C;
2 hours gives significantly better discrimination than
20 hours. It appears that factor VIII is rapidly and
completely precipitated within 2 hours, whereas fibrinogen
is slowly (and incompletely) precipitated over 20 hours.
Fibronectin is also precipitated by the polymers
(Table 5-13). As shown in this study (Chapter III)
incomplete precipitation of factor VIII and fibronectin
occurs in chilled plasma without polymer addition. It
appears that polymer addition results in equilibrium
between precipitate and supernatant phases being reached
sooner. Cold precipitation of fibrinogen without
polymer addition is very low, but 20 hour incubation in
the presence of polymer results in substantial precipi¬
tation of this protein. Figure 5-4 shows that precipi¬
tation with HES preferentially precipitates the slower-
migrating forms of VIIIR:Ag from plasma. Zimmerman et
al (1975b) have shown that these forms represent the
higher molecular weight multimers of VIIIRrAg. This
supports the hypothesis that polymer precipitation works
through a steric exclusion mechanism with higher
molecular weight proteins being precipitated first as
the polymer concentration is increased.
HES 40 was used to further develop polymer
induced cold precipitation of plasma factor VIII into a
method for producing a blood bank factor VIII concen¬
trate. This polymer is already used in haematological
practice for several purposes, including the preparation
of leucocyte-poor blood and the freezing of red cell
concentrates (Mishler 1982). Use of a glycine-dextran
buffer to dissolve the precipitates allowed lyophili-
sation with retention of the VIII:C activity (Table 5-12).
Loss of activity was observed with use of the Tris citrate
solution used to dry conventional intermediate purity
concentrate (which is of lower purity than the precipi¬
tates produced by HES precipitation). It is known that
higher-purity materials are less stable to freeze-drying
than materials of lower-purity (Bidwell 1955). The
reconstituted products showed rather poor VIII :C stability
over 24 hours, which was not improved by alumina
adsorbtion (Table 5-12). Stability was improved by
adjusting the pH of the solubilised precipitate to 6.6
prior to lyophilisation. As has been shown by Liu et al
(1980), carbon dioxide loss during drying results in a
higher pH in the reconstituted product, leading to
lowered VIII:C stability. In fact, adjustment of pH to
6.6 prior to drying resulted in a pH of 6.8 in the
reconstituted precipitate and the stability over 24 hours
was improved from 55% to 68%. Foster et al (1983b)
have shown that citrate addition, while being necessary
for adequate solubility and filterability, destabilises
VIII:C during processing; improvement of VIII:C
stability was attained by addition of ionised calcium
to levels existing prior to citration. The buffer used
to dry the starch precipitates contained 20 mM citrate
and further stabilisation may well be attained by calcium
addition. In this study, however, this was not
evaluated.
Table 5-13 shows that concentrates belonging
to the 'high-purity' grade (Smith and Bidwell 1979) can
be produced from CPD plasma donations at yields of about
600 u/kg. HES precipitation represents an attractive
alternative to cryoprecipitation as factor VIII is
obtained at a high yield and purity without the need for
freezing plasma. The concentrate can easily be obtained
using the multiple plastic bag system, as plasma can be
separated into a secondary or tertiary bag containing
enough concentrated HES to result in about 4% concen¬
tration in the plasma. Cold precipitation and centri-
fugation would allow harvesting of the precipitate. It
is suggested, however, that such single donation 'wet'
products suffer from several disadvantages as does
cryoprecipitate, notably lack of standardisation and the
need for frozen storage. High speed centrifugation
would also be necessary for harvesting the precipitates,
and the use of plastic bags might lead to the problems
described for cryo. A standardised dried product can
easily be produced, provided that special precautions
are taken to ensure sterility. Cold precipitates
produced from single donations could be stored frozen
until a sizable number have been collected. These
could then be solubilised and pooled in freeze-drying
buffer, ampouled and lyophilised to give standard units
of dried concentrate. Sterile filtration of the
solutions would be necessary but should not present a
problem in view of the low fibrinogen content. A
sterile freeze-dryer would also be necessary. However,
the fact that the final product can be subjected to
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standard pharmaceutical quality control and can be
labelled with the factor VIII content may justify the
capital expenditure involved in purchasing the required
equipment.
The presence of 4% HES in the supernatant
plasma might be seen as a disadvantage. However, such
plasma can be safely used as a blood volume expander as
HES itself has been used for this purpose (Mishler 1982).
Although it is probable that 4% HES will interfere with
the Cohn fractionation process to produce gamma-globulin
and albumin, this process is unlikely to be used by blood
banks with a small scale component programme. New ion-
exchange chromatographic techniques (Curling 1980,
Suomela 1980) are likely to be much more suitable for
production on a blood-bank scale. The presence of an
uncharged polymer like HES should still allow such
procedures.
An attractive alternative to additive-induced
cold precipitation is shown by the data in Table 5-14.
Concentration of plasma followed by cold precipitation
led to concentrates of high-purity and at good yields.
This study did not pursue this approach further, as the
equipment available did not allow fast concentration of
the plasma. Use of more efficient systems, e.g. hollow
fibres might be expected to effect concentration much
more quickly. It is possible that the high initial
capital costs might be justified if this method can be
adapted as a process to produce factor VIII concentrate.
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In summary, this Chapter concludes:
1) Cryoprecipitate yields by good technique are unaf¬
fected by addition of heparin or PEG to plasma, but
are improved if loss of factor VIII by dissolution
and/or inactivation are minimised. This can be
achieved by thaw-siphoning, but attention to the
final separation of cryo from supernatant plasma can
improve yields in fast-thawing.
2) Cryoprecipitation cannot be ascribed to a salting-
out mechanism, and salt-induced plasma precipitation
is an unsatisfactory method for factor VIII concen¬
tration. Cryoprecipitation appears to involve a
precipitation of the cryo-proteins - factor VIII,
fibrinogen and fibronectin - induced by low temper¬
atures and by high concentrations of other plasma
proteins produced during freezing.
3) Polymer induced precipitation of chilled unfrozen
plasma is an attractive alternative to cryoprecipi¬
tation and can be adapted to produce a standardised
dried factor VIII concentrate in a blood bank.
Simple concentration and cold precipitation of
plasma without any additives is also an attractive
possibility, but would require high initial capital
costs (Chapter VIII).
CHAPTER VI
PRODUCTION OF FACTOR VIII
CONCENTRATES OF HIGHER PURITY
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INTRODUCTION
More than 80% of infusions which haemophiliacs
receive are for the so-called 'spontaneous' bleeds not
associated with any obvious trauma, (Biggs 1978). The
level of VIII:C desired in a patient's blood to treat
such bleeds is 15 to 20% of normal. It is estimated
that a dosage of 10 u/kg body weight should have the
desired effect. This would imply infusion of about
700 units of VIII:C for a 70 kg man. Correspondingly,
less would be needed for boys, for whom, however, the
frequency of such bleeds is often higher (Rizza 1976a).
Factor VIII concentrates of intermediate purity can
usually be dissolved at about 15 to 20 units per ml.
This potency is enough to ensure that for the majority
of bleeds treatment can be administered by syringe
infusion, by the patient himself if on home therapy, in
volumes which have no appreciable effect on the blood
volume.
For dealing with major trauma and for surgery,
levels of 100 to 150% of normal are desirable (Rizza
1976b). The volumes of concentrate would be corre¬
spondingly larger if material of intermediate purity were
used, necessitating lengthy infusions by drip. This can
present problems if high levels are required immediately.
Massive doses are also sometimes used to overcome VIII:C
inhibitors (Rizza 1981). Thus, a minority of clinical
situations exist in which high-purity concentrates,
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which can be dissolved in concentrations of 30 to 50 units
per ml, are needed.
The tendency among commercial manufacturers
appears to be to produce concentrates of ever increasing
purity. Such products are often attractive to patients
due to their high solubility and conveniently small size,
allowing easy storage. Indeed inducements such as the
ability of a haemophiliac to carry 'his concentrate in
his pocket' are sometimes used in marketing these
products. However, present methods for the industrial
production of high-purity concentrates result in yields
which are far smaller than those obtained for intermediate
purity concentrates. Published data shows that yields
of less than 200 u/kg of plasma are obtained (Smith and
Bidwell 1979). High-purity concentrates are produced
by further purification of intermediate purity materials.
Quantitatively, the most important impurity is fibrinogen.
Most high-purity production methods consist of two steps -
the first to selectively remove fibrinogen and the
second to concentrate factor VIII (Chapter I). The
first step usually involves heavy losses of factor VIII,
which can be as high as 50%. Such losses in yield are
generally of lesser importance for commercial manufact¬
urers who obtain their starting plasma from paid donors
and can 'pass on' any additional costs in its procure¬
ment, in the interest of obtaining a purer, more
attractive product. For state owned concerns who rely
on a limited voluntary system of blood donation, losses
of this kind are unacceptable.
In addition to the reasons described above,
another reason exists for developing an efficient method
of fibrinogen removal. Sterilisation of factor VIII
concentrates by heat or chemical treatment has been
extensively investigated recently (Heimburger et al 1981
Prince et al 1983). Fibrinogen is rapidly denatured by
high temperatures and is precipitated by a variety of
chemical agents such as ether, which has been proposed
as a viral inactivating agent (Prince et al 1984). Thus
fibrinogen reduction is a necessary preliminary to
current methods designed to reduce the viral infectivity
of factor VIII concentrates.
In this Chapter, methods of further
purification of intermediate purity concentrates have
been investigated. The main scope has been the removal
of as much fibrinogen as possible, while retaining
factor VIII yields, in order to produce a solution that
might be sterilised by heating (Chapter VII).
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METHODS
Source materials for these studies consisted of cryo-
precipitates prepared as described below. In some
experiments, conditions derived for purifying cryo-
precipitate were used to process other materials as
outlined in Results.
Cryoprecipitate ('cryo'): Two types of cryo were
prepared:-
1. Small-scale cryo was prepared from 200 ml of fresh
plasma derived from 6 donation pools or single
donations. The cryo was prepared by thaw-siphoning
or fast-thawing, as described in Chapters IV and V,
and was dissolved for processing in its own super¬
natant plasma or in 15 mM citrate, 150 mM NaCl pH 6.9
(citrate saline) as specified in Results.
2. Tris extract of bulk cryo was prepared as described
by Newman et al (1971). 250 ml donations of fresh
plasma were frozen in dry ice/ethanol as described
in Chapter IV and stored at -40°C. For processing,
2 to 3 kilograms of this plasma were allowed to
soften in a 4°C cold room for 5 hours. The bags
of plasma were then placed in a 4°C water bath and
allowed to thaw. When thawing was complete, the
plastic bags were opened and the contents were
transferred to polycarbonate bottles and centrifuged
as described in Chapter V. After complete decant-
ation of the cryosupernatant plasma, the cryo was





































volume of extracting buffer was 30 ml for each
kilogram of starting plasma, and extraction was
performed by stirring the cryo-buffer mixture with
a magnetic stirrer for 10 minutes. The mixture was
then centrifuged for 40,000 g min. at 22°C and the
factor VHI-rich supernatant was decanted and stored
at -40°C. The residue from extraction was solubilised
at 37°C in citrate-saline and stored at -40°C.
Table 6-1 summarises the various stages of the
production of this material.
Purification Methods
Cold insoluble globulin precipitation: Small-scale
cryo was solubilised at 37°C in the residual supernatant
plasma or in buffer as described in Table 6-2 of Results.
The cryoprecipitate solution was then placed in 40 ml
polycarbonate tubes and held for 2 hours in a melting ice
bath. The pH of the solution was 7.1 ± 0.2 in all
instances. After 2 hours the tubes were centrifuged
for 60,000 g min. at 0°C in a Sorvall RC2B centrifuge.
The supernatant was removed and sampled. The precipitate
was dissolved at 37°C in 10 mis of citrate-saline.
The solubilised precipitate and samples from each step
of the process were stored at -40°C prior to assay.
Polymer induced precipitation: Stock solutions of
various polymers were prepared as described in Chapter V.
Precipitation of small-scale cryo and extracted cryo was
performed under various conditions as specified in
Results.
229
Glycine induced precipitation; This was performed
according to BlombSck and Thorell (1982). Small-scale
cryo prepared by fast-thawing and complete drainage of
the supernatant was used as starting material. The cryo
was dissolved in 20 ml of 55 mM citrate pH 6.8. 40 ml
of a buffer containing 3 M glycine, 125 mM NaCl and
25 mM imidazole pH 6.8 were then added to the cryo
solution. The addition was carried out in a 30°C water
bath with continuous mixing. The mixtures were allowed
to equilibrate for 15 minutes, after which the resultant
precipitate was harvested by centrifugation for 60,000 g
min. at 22°C, and dissolved in 20 ml of citrate-saline
at 37°C. The supernatant was then adjusted to pH 7.5
with 0.1 M NaOH and was cooled to 0°C in a melting ice
bath. Sufficient 40% w/w PEG 6000 was added to produce
a final concentration of 6.5% w/w PEG. The mixture was
left at 0°C for 30 minutes, after which it was centrifuged
for 60,000 g min. at 0°C. The supernatant was removed
and the precipitate was dissolved in 5 ml of glycine-
dextrose buffer (Chapter V). Samples of every stage of
the procedure were stored at -40°C for subsequent assay.
Extraction in the presence of glycine: Cryo was
extracted into buffer as described above for preparation
of Tris extract with the exception that instead of Tris,
glycine-imidazole pH 6.8 (2 M glycine, 83 mM NaCl, 17 mM
imidazole) was used. The extraction was performed at
30°C on a stirrer/hot plate with careful temperature
monitoring. The extraction was performed for 15 minutes
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and the mixtures were then centrifuged for 60,000 g min.
at 22°C. The extract was removed and the residue was
dissolved at 37°C in citrate-saline. Samples of all the
fractions were stored at -40°C for assay.
Zinc-induced precipitation: (Foster et al 1983a). Tris
extract of cryo was brought to 1 mM zinc by addition of
a 5 mM zinc acetate solution. The addition was made
slowly, with continuous stirring, at room temperature
(Foster et al 1983a). The mixture was allowed to
equilibrate for 15 minutes. The gelatinous precipitate
which formed was removed with a thin wooden stick; in
some cases small pieces of precipitate were removed by
centrifugation for 60,000 g min. at 22°C. The
precipitate proved to be poorly soluble. Some solubili-
sation was achieved by warming the precipitate to 40°C
in a volume of citrate-saline equal to 2 to 3 times the
volume of the initial extract. Insoluble material was
then removed by centrifugation. Samples of all the
fractions were stored at -40°C for subsequent assay.
Extraction in the presence of zinc: Cryo was extracted
into Tris buffer as described above, but 1 mM zinc
acetate was included in the extraction buffer.
Extraction was carried out for 15 minutes, after which
extract and residue were separated by centrifugation.
The residue was partly solubilised as described above.
Samples of extract and residue were stored at -40°C until
assayed.
FIGURE 6-1
DIAGRAMATIC REPRESENTATION OF A PRECIPITIN ARC IN A
TWO-DIMENSIONAL IMMUNOELECTROPHORESIS, TO ILLUSTRATE




Analysis of factor VIIIR:Ag in two dimensional Immuno¬
electrophoresis (2DIEP); Details of this technique are
found in Chapter II. 2DIEP was performed on samples of
various concentrates, the samples being analysed together
on one plate so that conditions were uniform for all the
samples. The precipitin arcs obtained were then
analysed as described by Ekert and Chavin (1977). The
arcs were divided into 3 electrophoretically different
regions, as shown in Figure 6-1. Tracings of the
individual arcs were made and migration distances were
measured and interpreted as follows:
1. Perpendicular and horizontal lines V and H were
drawn through the centre of the sample well.
2. A perpendicular line C was drawn between the centre
of the peak and line H, and the distance p was
recorded.
3. The length of the ascending and descending arms of
the precipitin arc were measured from the perpendicular
C to the end of the visible precipitin line. A
vertical line was drawn through the middle of the
ascending and descending arms to intersect with
line H; d^ and d2 were then measured and recorded
in mm.
An increase in distance d^ is interpreted to be the
result of a decrease in the amount of antigen with slower
electrophoretic mobility. An increase in d2 is the
result of a larger proportion of antigen with faster
mobility. An increase in p reflects an increase in the
mobility of the median fraction of antigen. Decreases
in these measurements are taken to be the result of the
opposite changes in the antigen population.
All other assays and analytical procedures are
described in Chapter II.
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FIGURE 6-2
POLYMER PRECIPITATION OF THAW-SIPHON CRYOPRECIPITATE
Incubations at 0°C and 10°C were carried out for
2 hours in melting ice and a thermostated water bath
respectively. Precipitates were dissolved at 37°C in
0.5 volumes of glycine-dextrose buffer (Chapter V)
• • VIII: C
V V VIII :CAg
O 0 VIIIR:Ag
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RESULTS
(A) COLD PRECIPITATION OF SOLUBILISED CRYOPRECIPITATE
Table 6-2 shows that a significant purification
of cryo solubilised in residual plasma can be achieved
by a second precipitation at 0°C. The cold insoluble
fraction that formed contained most of the factor VIII
and fibronectin of the initial cryoprecipitate.
Fibrinogen was also precipitated to a lesser extent. As
described in Chapter V, the 'fast-thaw' cryo gave lower
factor VIII yields than cryo produced by the thaw-siphon/
centrifugation method, which is also purer because of
complete drainage of the supernatant plasma. This type
of cryo was therefore subjected to cold precipitation,
in an attempt to improve the yield and purity of the
final fraction. However, using this method, precipi¬
tation of cryo proteins was significantly decreased
(p < 0.02) compared to fast-thaw solubilised in super¬
natant plasma.
Incorporation of heparin into the system,
either by processing heparin plasma or adding heparin to
CPD plasma, did not affect factor VIII yields. Heparin
addition, however, resulted in a significant increase in
the amount of fibronectin precipitated when cryo dissolved
in buffer was held at 0°C (p < 0.05).
(B) POLYMER INDUCED PRECIPITATION OF CRYOPRECIPITATE
Figure 6-2 shows the results of polymer assisted
precipitation of cryoprecipitate at low temperatures. It
FIGURE 6-3
PRECIPITATION OF CRYO EXTRACT AT DIFFERENT IONIC
STRENGTH
Cryo extract was prepared from FFP and precipitated
at 0°C with albumin. Ionic strength was increased by
making the 20 mM Tris extract 0.2 M with respect to
NaCl
• • VIII :C
0 O VIIIR: Ag
A A Fibrinogen
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FIGURE 6-4
PRECIPITATION OF CRYOEXTRACT AT DIFFERENT pH VALUES
Cryo extract was prepared from FFP and precipitated
0°C with Ficoll-70. pH was varied by addition of
0.1 N NaOH




can be seen that, in contrast to plasma (Chapter V)
cryoprecipitate fibrinogen tended to precipitate with
factor VIII. Precipitation of reconstituted lyophilised
concentrate (Protein Fractionation Centre, Edinburgh)
produced similar results.
Attempts were made to suppress fibrinogen
precipitation at low temperatures. Increasing ionic
strength has been shown to increase fibrinogen solubility
at pH values between 6 and 7 (Leavis and Rothstein 1974,
Smith et al 1979). However, increasing the salt content
of extracted cryo by 0.2 M (Smith et al 1979) did not
improve discrimination between factor VIII and fibrinogen
in albumin-induced precipitation (Figure 6-3).
Increasing the pH of the mixture in order to work as far
from the isoelectric point of fibrinogen as possible did
not improve the separation of factor VIII from fibrinogen
in Ficoll-induced precipitation (Figure 6-4).
Fractional precipitation with PEG at room
temperature according to the method of Newman et al (1971)
(Chapter I) led to high losses of factor VIII in the
first precipitate (4.5% w/w PEG) designed to remove
fibrinogen, although a two-fold purification of VIII:C
in the second precipitate (11% w/w PEG) was achieved.
(C) PURIFICATION USING GLYCINE
Table 6-3 shows that addition of glycine to a
concentration of 2 M at 30°C precipitates most of the
fibrinogen in cryoprecipitate while leaving most of the
factor VIII in the supernatant. Addition of PEG to the
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plasma prior to freezing was unnecessary (Chapter V) for
optimal factor VIII yields, and so this part of the
original technique (Blomb&ck and Thorell 1982) was
omitted. In order to concentrate the factor VIII and
remove glycine, the 2 M glycine supernatant was cooled
to 0°C, as this procedure has been used to precipitate
factor VIII in glycine-rich solutions (Shanbrom and
Fekete 1971). However, no precipitate formed under
these conditions. Concentration and further purification
of factor VIII was achieved by precipitation of the
glycine supernatant with 6.5% PEG at 0°C (Table 6-4).
It was estimated that the average VIII:C yield using
this procedure was about 83% from cryoprecipitate, with
an average 2.1 fold purification over cryoprecipitate
being achieved.
Direct extraction into glycine-containing
buffer was attempted as an alternative to cryo solubili-
sation/reprecipitation. Using this approach however,
lower VIII:C yields were obtained as considerable amounts
of VIII:C were retained in the insoluble fibrinogen-rich
residue.
(D) PURIFICATION USING ZINC
Preliminary experiments on zinc precipitation
showed that addition of zinc acetate crystals to give
1 mM final concentration of zinc resulted in precipitation
of most of the fibrinogen in cryo extract; however up to
40% of the VIII:C was also precipitated. Addition of
the salt as a 5 mM solution led to near quantitative
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PROTEIN COMPOSITION OF FACTOR VIII CONCENTRATES
5% SDS-PAGE was done as described in Chapter II. The
gels were dried and analysed by densitomery
A. Cryoprecipitate dissolved in buffer
B. 2 M glycine supernatant of cryoprecipitate
C. 4% HES 40 precipitate of plasma
D. 1 mM zinc acetate supernatant of 4% HES precipitate
E. Clinical intermediate-purity concentrate
F. 1 mM zinc acetate supernatant of intermediate-
purity concentrate
G. Cryoprecipitate solubilised in supernatant plasma
H. Cold insoluble fraction of cryoprecipitate
I FIBRONECTIN
II ALBUMIN AND a-CHAIN OF FIBRINOGEN
III B-CHAIN OF FIBRINOGEN
IV y-CHAIN OF FIBRINOGEN
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recovery of VIII:C and VIIIR:Ag in the supernatant,
with over 70% of the fibrinogen being precipitated
(Table 6-5A). Experiments using HES 40 precipitates
(Chapter V) instead of cryo extracts produced similar
results (Table 6-5B).
Direct extraction of cryo into 1 mM zinc
acetate-20 mM Tris buffer did not give recoveries that
were as good as the above precipitation technique.
Assay of the partially dissolved residue indicated that
factor VIII as well as fibrinogen was retained in the
precipitate, resulting in lower yields in the extract.
(E) EFFECT OF PURIFICATION PROCEDURE ON CONCENTRATE
PROTEIN COMPOSITION
Figure 6-5 shows the protein components of the
various concentrates described in this Chapter determined
by SDS-PAGE and densitometric scanning of the bands
produced. It is apparent that glycine- and zinc-
precipitation lead to a great reduction in fibrinogen,
with the other main components - fibronectin and
albumin - being relatively unaffected (Figure 6-5A and B,
C and D, E and F). Figure 6-5G shows the pattern for
cryoprecipitate solubilised in its own plasma. The
protein composition is similar to that of normal plasma
except that the fibrinogen and fibronectin bands are
stronger, showing the concentration of these proteins in
cryoprecipitate. Cold precipitation led to a further
concentration of fibronectin and fibrinogen, with
reduction of other proteins including albumin (Figure 6-5H).
FIGURE 6-6
TWO-DIMENSIONAL IMMUNOELECTROPHORESIS OF VIIIR:Ag IN
FRACTIONS OF DIFFERENT PURITY
Electrophoresis was carried out at 200 V for 6 hours
and 120 V for 18 hours for the first and second
dimensions respectively. The anode was to the right
in the first dimension and on top in the second dimension.
Antiserum concentration in the second dimension was 0.3%.
The precipitin arc produced by solubilised cryo was
partly traced over with a marker pen to improve visual
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TABLE 6-6 ANALYSES OF VIIIR:Ag BY TWO-DIMENSIONAL IMMUNO-
ELECTROPHORESIS
Sample dl P d2
Solubilised Cryo 6 12 19
Cold Precipitate of Cryo 6 12 16
Glycine-Purified Cryo 7 12.5 17.5
Extracted Cryo 10 12 18
Zinc-Purified Extracted Cryo 9.5 12 16
4.5% PEG Fraction of Extracted Cryo 6 10.5 18
11% PEG Fraction of Extracted Cryo 11.5 17 19.5
Samples were analysed by 2DIEP as described in Methods,
d^, p and d2 denotes the respective nigration distances
in mm.
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Thus, purification with this method involves mainly
removal of albumin, while with the other techniques
fibrinogen is the main component removed.
(F) FACTOR VIIIRsAg IN PURIFIED FRACTIONS
Figure 6-6 shows the immunoprecipitin arcs of
the various concentrates subjected to two-dimensional
Immunoelectrophoresis with antiserum to VIIIR:Ag.
Table 6-6 summarises the electrophoretic data obtained,
as described in Methods, from these arcs. The electro¬
phoretic pattern of solubilised cryo is similar to that
of plasma (see Figure 5-4) with slow-moving VIIIRrAg
forms that are conserved upon glycine - or cold - precipi¬
tation. Cold precipitation results in a decrease in
the amount of fast moving VIIIR:Ag (as witnessed by a
drop in d2>. Compared to solubilised cryo, extracted
cryo shows a decrease in the slowest moving VIIIRrAg
forms (as seen by an increase in d^), with no further
decrease in slow moving VIIIRrAg occurring as a result
of zinc-precipitation. Fractional PEG precipitation
leads to a loss of VIIIRrAg of slow and medium mobility
(as seen by increases in d^ and p) in the final (11% PEG)
precipitate, compared to the initial cryo extract. The
first precipitation with this technique - 4.5% PEG,
designed to remove fibrinogen - leads to loss of VIIIRrAg
in the fraction. The electrophoretic analysis indicates
that this precipitate (usually a waste fraction in large-
scale fractionation) is rich in slow and medium moving
forms of VIIIRrAg.
TABLE6-7SUMMARYOFCHARACTERISTICSHIGHER-PURITYF CTORVCON N ATES ProductSpecificAct vity VIII:Cu/mg Protein
Fibrinogen %ofTotal Protein
YieldofVIII:C
Purification Over Intermediate Material*
%of Intermediate Material
U/kg Starting Plasma






























*Definedasspecificct vityofinalco centrate/specifica ivityf intermediateaterial.
Table 6-7 summarises the characteristics of
the various concentrates produced by the methods
described in this Chapter.
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DISCUSSION
The growing realisation that despite intensive
donor screening the majority of haemophiliacs develop
liver abnormalities (Mannucci et al 1982) has made the
inactivation of the probable viral contaminants in
coagulation factor concentrates a priority. However,
present methods of sterilisation require fibrinogen
removal for the reasons outlined above. Since fibrinogen
is also the major contaminant of extracted cryoprecipitate,
its removal also results in a significant purification
and allows higher solubility and potency.
Two recent studies (Rock et al 1980b, Smit-
Sibinga et al 1981) have made use of a two-step method
to produce a higher-purity factor VIII concentrate on a
blood bank scale. These groups have claimed that
collection of blood in heparin or heparin addition to
CPD plasma allows factor VIII yields in cryoprecipitate
to be significantly increased, and also permits the
utilisation of a second precipitation at 0°C which
precipitates and concentrates the factor VIII. They
postulate that this second cold precipitation is possible
because heparin induces precipitation at 0°C of fibro-
nectin, which is often associated with factor VIII during
fractionation (Chapter V). The results of the present
study, however, do not support this hypothesis. As can
be seen (Table 6-2) cooling of solubilised cryoprecipitate
results in precipitation of fibronectin and factor VIII,
together with some fibrinogen, irrespective of the
presence of heparin. These results indicate that what
is necessary for cold precipitation to occur is not the
presence of heparin, but a high protein concentration in
the cryoprecipitate. This is shown by the relatively
small precipitate and low factor VIII yields obtained
from cryo totally drained of supernatant and dissolved
in buffer, compared to cryo dissolved in its own super¬
natant plasma. These results are not surprising in
view of the findings discussed in Chapters III and V
regarding the spontaneous and polymer induced cold
precipitation of plasma factor VIII fibrinogen and
fibronectin. As I have shown, increasing the plasma
protein concentration by albumin addition or simple
concentration allows near quantitative precipitation of
factor VIII and fibronectin in the cold. It is
suggested that the cold insoluble precipitation reported
by previous workers (summarised in Lane et al 1983) is a
result of this phenomenon. The initial cryoprecipitation
concentrates factor VIII and fibronectin to a level which
results in a further albumin-induced precipitation when
the cryo is dissolved in supernatant plasma and chilled.
It is noteworthy that the other groups using cold preci¬
pitation (Lane et al 1983) all reported a protein concen¬
tration of about 60 mg/ml in the initial cryoprecipitate,
suggesting that considerable plasma protein was left with
the cryoprecipitate. The starch gel electrophoresis
reported by one group (Welbergen 1981) also demonstrates
a high albumin content in the initial cryo. This high
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content of residual supernatant plasma protein is almost
unavoidable using the plastic bag system (Chapter V).
Using centrifugation and drainage (Chapter V) results in
a cryo which when dissolved in buffer has a protein
concentration of 20 to 30 mg/ml, compared to 60 to 70 mglml
when dissolved in a similar volume of supernatant plasma.
Heparin addition to this material increased the amount of
fibronectin precipitated but did not affect factor VIII
yield.
The use of hydrophilic polymers to effect
further purification of cryoprecipitate did not give
results as promising as those obtained with plasma
(Chapter V). In general, it was found that factor VIII
and fibrinogen precipitated together during polymer
induced precipitation (Figure 6-1). Varying pH
temperature or ionic strength did not improve separation.
It is possible that aggregation of fibrinogen molecules
during processing (Newman et al 1971) is responsible for
the poor separation observed. Fractional precipitation
with PEG at higher temperatures, although removing much
of the fibrinogen, gave low VIII:C yields. Thus, it
seems that with the classical PEG fractionation scheme
that is used by a number of manufacturers, substantial
fibrinogen removal is only possible at a considerable
sacrifice in yield (Bidwell et al 1976).
The use of the recently described warm glycine
precipitation technique (BlombSck and Thorell 1982) gave
very promising results (Table 6-3). The precipitation
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of fibrinogen with glycine was first noted by Edsall and
Lever in 1951. Wagner et al (1964) showed that precipi¬
tation of plasma at 0°C with 2.3 M glycine gave factor VIII
rich fractions. Subsequently this principle was utilised
in Hyland's Method IV to purify cryoprecipitate (Shanbrom
and Fekete 1971). In these early methods, precipitation
was carried out at low temperatures resulting in co-
precipitation of factor VIII and fibrinogen. It seems
that utilisation of higher temperatures results in
selective fibrinogen precipitation. Concentration of
the supernatant factor VIII is necessary to remove
glycine and produce a more potent solution. This can
be readily achieved by subsequent PEG precipitation in
the cold (Table 6-3). It is of interest that simple
cooling to 0°C of the factor VIII rich glycine super¬
natant failed to precipitate factor VIII, thus high¬
lighting the role of fibrinogen as a 'carrier' in such
precipitations.
Foster et al (1983a) have utilised zinc ion
precipitation of extracted bulk cryoprecipitate to
remove fibrinogen from intermediate purity concentrate.
Zinc ion fractionation of plasma proteins was described
by Cohn et al (1950) and Maeda et al (1983) have
investigated the mechanism of zinc-induced fibrinogen
precipitation. The interaction between zinc and
fibrinogen has also been studied by metal-chelate
chromatography (Scully and Kakkar 1982). The results of
the present study confirm that 1 mM zinc precipitates
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fibrinogen selectively. Careful reagent addition as a
dilute stock solution was found to be crucial for good
results, as addition of the salt as crystals resulted in
precipitation of VIII:C along with fibrinogen. It is
probable that this is a result of local over-concentration
of the reagent, as Foster et al (1983a) have shown that
addition of amounts exceeding 1 mM also precipitate
factor VIII. One minor disadvantage of this method is
the insolubility of the fibrinogen-rich precipitate
obtained, making it difficult to retrieve fibrinogen as
a by-product.
An attempt was made to incorporate glycine and
zinc directly into the buffer used in the 'Newman'
procedure for extraction of factor VIII from cryo. It
was hoped that this would result in retention of fibrin¬
ogen in the insoluble residue with factor VIII being
recovered in the extract. This would eliminate the
need for a second step to precipitate the fibrinogen.
However, use of extracting buffers incorporating reagents
at a concentration known to selectively precipitate
fibrinogen led to much VIII:C being retained as well.
Analysis of VIIIR:Ag by two-dimensional Immuno¬
electrophoresis (Figure 6-6 and Table 6-6) revealed that
solubilised cryo had a population of VIIIRrAg rich in
slow moving forms. Slow moving forms of VIIIR:Ag are
known to represent the higher molecular weight multimers
of the protein (Zimmerman et al 1975b) and are associated
with high VIIIR:RCF activity (Over et al 1978). It has
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been suggested that the presence of these forms of
VIIIRrAg is necessary for the ability of concentrates to
correct the bleeding time defect in von Willebrand's
disease (Weinstein and Deykin 1979). Cryoprecipitate
has this ability, whereas higher purity materials
lacking higher molecular weight forms of VIIIR:Ag do not
(Nilsson and Hedner 1977). It can be seen from my
results that glycine precipitation of solubilised cryo
preserved the latter's higher molecular weight forms of
VIIIR:Ag and this product has been reported to correct
the bleeding time defect of von Willebrand's disease
(Thorell et al 1983). Extracted cryo can be seen to
show some depletion of higher molecular weight VIIIRrAg;
this might be due to the use of low ionic strength
extraction buffers, as VIIIRrAg is known to be more
susceptible to proteolysis under these conditions
(Hellings 1981). Fractional PEG precipitation of
extracted cryo, which is one of the commonest techniques
in industrial factor VIII fractionation, removes sub¬
stantial amounts of higher molecular weight VIIIRrAg in
the discarded 4.5% PEG precipitate. The VIIIRrAg in the
final 11% PEG fraction showed a marked anodal mobility.
Thus it can be postulated that loss of higher molecular
weight multimers having high VIIIRrRCF activity during
fibrinogen removal is the cause for the inability of PEG-
fractionated concentrates to correct the bleeding time in
von Willebrand's disease. As has been pointed out,
however, (Chapter I and references therein) correction of
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the bleeding time is known to be more dependent on some
other less well characterised activity than on VIIIR:RCF.
Table 6-7 summarises the options for further
purification investigated in this Chapter. It is
suggested that zinc precipitation under the described
optimal conditions is the best alternative available.
Cold insoluble globulin precipitation works through albumin
removal and leaves considerable amounts of fibrinogen
in the product (Table 6-7 and Figure 6-5). The final
product is thus unsuitable for heat treatment.
Fractional PEG precipitation although efficient for
fibrinogen removal, gives low factor VIII yields. Both
glycine and zinc precipitation result in fibrinogen
removal with high VIII:C yields. The glycine technique
however requires high concentrations of glycine and
temperatures of 30°C are necessary. Zinc salts are
cheaper than glycine and the addition can be carried out
at room temperature. Furthermore, the residual zinc
in the supernatant increases viral inactivation during
subsequent heat treatment (Foster 1984: personal
communication).
In summary this Chapter concludes:
1. Of the options investigated for removal of fibrinogen
from cryoprecipitate, glycine or zinc precipitation
under the conditions described results in adequate
purification with high factor VIII yields.
2. Combination of the HES precipitation method
(Chapter V) with subsequent zinc precipitation appears
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to be the method of choice for producing a high-
purity factor VIII concentrate.
CHAPTER VII
ADDITIONAL APPROACHES TO
OPTIMAL USE OF DONATED FACTOR VIII
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(A) PASTEURISATION OF FACTOR VIII CONCENTRATES
INTRODUCTION
As has been outlined (Chapter I) viral infection
is the major hazard of factor VIII replacement therapy.
Several studies have demonstrated asymptomatic liver
damage in haemophiliacs treated with factor VIII concen¬
trates (summarised by Mannucci 1981). The increased
likelihood of viral contamination in large plasma-pool
concentrates has led to some clinicians advocating the
use of single-donor or small-pool materials such as
cryoprecipitate (Gabra et al 1982). The use of
accredited donors is an additional method of reducing
such risks. However, single-donor materials cannot be
standardised for their factor VIII content and precise
dosage is thus impossible. Small-pool materials such
as lyophilised cryoprecipitate necessitate a large
proportion of the product being sacrificed for quality
control if complete pharmaceutical testing is to be
carried out. Moreover, some doubt exists as to whether
such products reduce the risk of hepatitis viral infection
as evinced by liver dysfunction (Levine et al 1977).
Studies employing classical plasma fractionation
schemes show that contaminating hepatitis virus is
concentrated in the albumin fraction, with other fractions
including coagulation factor products being relatively
less contaminated (Hoofnagle et al 1976). However,
albumin solutions have an excellent record of non-
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infectivity, while coagulation factor concentrates are
high-risk products. This is undoubtedly due to the
ability to subject albumin solutions to heat in the
presence of stabilisers, thus inactivating contaminating
viruses. The lability of coagulation factors has
resulted in approaches other than heat treatment being
attempted to remove or decrease potential viral contamin¬
ants. Thus, Einarrson et al (1981) have successfully
decreased hepatitis virus contamination of prothrombin
complex concentrates by hydrophobic affinity chromato¬
graphy on alkylated agarose. These adsorbents
selectively removed the virus while showing minimal
affinity for coagulation factors II, VII, IX and X.
Such an approach, however, is not applicable to factor
VIII as Morgenthaler (1982) has shown that these
adsorbents bind factor VIII irreversibly as well as the
virus. Johnson et al (1976) have used PEG precipitation
to remove hepatitis virus from albumin and prothrombin
complex solutions. Precipitation with 20% PEG allowed
removal of virus in the precipitate, thus utilising the
large molecular weight difference between the proteins
and the viral particles. The high molecular weight of
factor VIII however would result in co-precipitation with
the virus under these conditions.
Recently, Brummelhuis et al (1983) have shown
that addition of specific human immunoglobulin to
hepatitis B to blood products (including factor VIII
concentrate) produced from deliberately contaminated
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plasma neutralised the infectivity of these preparations.
This approach, however, is specific to infectivity with
hepatitis B virus. Similarly, Prince et al (1983,1984)
have shown that lipid extraction techniques, such as
detergent or ether treatment, result in a decrease in
infectivity, an approach which is restricted to lipid-
coated viruses.
As far as hepatitis B goes, the application of
sensitive radioimmuno techniques in screening donations
and final products can cut down considerably on the
infectivity risk. However, given that the sensitivity
of present day techniques is 3 or 4 orders of magnitude
greater than the minimal infective dose, a similar
reduction in viral titre is required to eliminate
infectivity. This consideration determines the extent
of viral inactivation/removal that a particular process
has to effect.
The possibility that the agent responsible for
the AIDS syndrome is a virus emphasises the need to
develop general methods of viral inactivation. In this
regard, the well tried heat treatment is an attractive
option. Heat treatment has been used by one manufacturer
to produce a factor VIII concentrate with reduced
hepatitis infectivity, the factor VIII being stabilised
during heating in a sucrose-glycine solution (Heimburger
et al 1981). Although no stage yields were given,
factor VIII losses of about 80% over the starting material
(cryoprecipitate) occurred. Prior to heating, the
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concentration of contaminating virus and other proteins,
including fibrinogen, was decreased by glycine and salt
precipitations. Losses of factor VIII in these steps
are likely to have contributed to the low yields. The
final concentrate had factor VIII antigen/activity ratios
similar to the starting material, suggesting that
physical loss of factor VIII molecules was occurring over
the process. If such losses could be prevented, yields
would be improved. This can be done by using a higher
yielding method of removing fibrinogen (Chapter VI).
Heat treatment would also require the use of stabilisers
to effect selective preservation of factor VIII while
allowing inactivation of contaminating viruses.
In this section, a new method of viral inacti-
vation-heat treatment in the presence of sorbitol-
glycine (Macleod et al 1 983)-has been applied to produce -
a factor VIII concentrate with decreased risk of viral
infectivity. The characteristics of the product have
been examined, both as regards its in vitro properties




Materials for heat treatment were cryoprecipitate
extracts and HES 40 plasma precipitates prepared as
described in Chapters V and VI. Fibrinogen content was
reduced by zinc precipitation (Chapter VI).
Heat treatment was performed as follows: (Macleod et
al 1983). The solution for heat treatment was placed
in a plastic beaker on a magnetic stirrer/heater. With
constant stirring, solid glycine was added to a final
concentration of 50 g/litre of solution. The pH of the
solution was monitored and kept above 7 by addition of
1 M NaOH as necessary. The final pH was adjusted to
7.5. Solid sorbitol was then added slowly to the
solution, addition being made by scattering sorbitol
lightly over the surface with constant stirring. As the
sorbitol went into solution, the temperature of the
mixture dropped. The temperature was kept above 30°C
by heating with careful monitoring using a thermocouple.
Care was taken to ensure that the temperature did not
exceed 40°C. Sorbitol was added to a final concentration
of 1850 g/litre of original solution. When the sorbital
addition was complete, the mixture was transferred to a
glass bottle and stoppered. The bottle was then placed
in a water bath and heated under the conditions stated in
Results. After heating, the mixture was treated (see
Results) to remove the heat-stabilising additives.
Samples from the various stages of the procedure were
frozen at -40°C for subsequent assay.
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Clinical evaluation of heat-treated factor VIII concen¬
trate : A heat-treated factor VIII concentrate was
produced at the Protein Fractionation Centre, Edinburgh,
by the method of Newman et al (1971) (Chapter I) with
fibrinogen reduction by zinc precipitation of the cryo-
precipitate extract (Chapter VI). This material had the
characteristics shown in Table 7-2 and passed all the
quality control criteria for a clinical product. The
concentrate was infused into a haemophilic patient in the
Haematology Department of the Royal Infirmary of
Edinburgh. Blood samples were taken before and at
sequential time intervals after the infusion.
Recovery of infused factor VIII:C was calculated using
the formula:
amount of VIII:C recovered in plasma
recovery (%) =
amount of VIII:C infused
To calculate the amount of VIII:C recovered in the patient's
plasma, the VIII:C content 20 minutes after infusion was
multiplied by the plasma volume, assuming 41 ml of
plasma per kg body weight.
Half-life of infused VIII:C was calculated froma semi-
logarithmic plot of plasma activity versus time, as
shown in Figure 7-3.
All other assays and analytical methods were
as described in Chapter II.
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FIGURE 7-1
TWO-DIMENSIONAL IMMUNOELECTROPHORESIS OF FACTOR VIII
CONCENTRATE PRE AND POST HEAT TREATMENT
Electrophoresis was carried out at 200 V for 6 hours
and at 150 V for 18 hours in the first and second
dimensions respectively. Antisera to VIIIR:Ag,
fibrinogen and fibronectin were incorporated into




SDS-PAGE OF FACTOR VIII CONCENTRATE PRE AND POST
HEAT TREATMENT
Gels were 5% polyacrylamide. Electrophoresis was
at 30 V for 18 hours.
2- 7 5
TABLE 7-2 ANALYTICAL PROFILE OF CLINICAL HEAT-TREATED FACTOR VIII
CONCENTRATE
Factor VIII:C Content 145 i.u/vial










Cellulose Acetate Electrophoresis Normal







Isoagglutinin (Indirect Coombs Test) Aj A2 B 0
1/8 1/4 1/8 Negative
Data for vials reconstituted in 25 ml of distilled
water.
Data supplied by Quality Control Department of the
Protein Fractionation Centre, Edinburgh.
RESULTS
A. PASTEURISED FACTOR VIII CONCENTRATE: In vitro
Characteristics.
Table 7-1 confirms the findings of Macleod et
al (1983) regarding the stability of factor VIII heated
in the presence of sorbitol-glycine. The use of 50%
sucrose and 2 M glycine as stabilisers (Heimburger et al
1981) was also examined but the procedure resulted in low
VIII:C yields and was not persued further. An attempt
to stabilise factor VIII with citrate, as has been
proposed for antithrombin III (Wickerhauser et al 1979)
was unsuccessful as addition of citrate to 0.5 M caused
immediate precipitation of the majority of the protein in
the concentrate.
Figure 7-1 shows that heat-treatment did not
affect the properties of the main proteins in the concen¬
trate, as determined by two-dimensional Immunoelectro¬
phoresis. The primary structure of the proteins was
also unaffected, as seen on SDS polyacrylamide gels
(Figure 7-2).
B. PASTEURISED FACTOR VIII CONCENTRATE: In vivo
Characteristics.
Table 7-2 lists the characteristics of the
heat-treated factor VIII concentrate that was infused
into a haemophilic patient. Table 7-3 summarises the
in vivo results of this infusion, together with data
for similar infusions using other factor VIII products.
TABLE 7-3 IN VIVO STUDIES WITH VARIOUS FACTOR VIII PRODUCTS
Preparation Infused Recovery Half-Life
(%) (hours)
A) Frozen Cryoprecipitate* 100 8
B) Intermediate Purity Concentrate* 122 10.5
C) Heat-Treated Concentrate+ 92 12.3
Data shows results of infusions to one patient (K.M.)
given at different times.
Recovery data for A & B were calculated using a
concentrate standard, a method which gives higher
recoveries than when using a plasma standard, as in C.
Data for similar infusions of A & B to other patients
were similar.
* Data taken from Toolis et al (1980)
+ Data from the present study
FIGURE 7-3






Half life was estimated by measuring the time it took




In vivo recovery and half-life of the heat-treated
material compared well with those obtained with materials
that had not been heat-treated. Figure 7-3 shows the
in vivo behaviour of various factor VIII related activities
after infusion. VIIIRrAg measured by Laurell assay
tended to give higher values than when measured by IRMA,
possibly due to antigenic breakdown with subsequent
increased electrophoretic mobility, as has been noted for
other, non-heated concentrates (Chapter I) (Prowse et al
1981). Figure 7-1 indicates that the heating step had
no effect on the mobility of VIIIR:Ag.
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DISCUSSION
The present study confirms that heat-treatment
is a practical option to effect sterilisation of a
factor VIII concentrate. Use of the sorbitol-glycine
stabilisers allows heating to be carried out with
retention of VIII:C activity. The protection from
thermal denaturation of proteins by sugars has been
extensively studied (Lee and Timasheff 1981 and
references within). Thermodynamic measurements have
suggested the hypothesis that stabilisation is due to
the increase in solvent surface tension by sugar
addition, making protein unfolding with subsequent
increased surface area thermodynamically unfavourable.
The stabilisers also protect model viruses added to the
system (Table 7-4) and the modified heating conditions
(70°C for 30 minutes following the standard 60°C for 10
hours) are necessary to effect selective viral inacti-
vation. The same workers have found that heating at
70°C for 30 minutes results in a viral kill equivalent
to that obtained when this procedure is followed up by
60°C for 10 hours (Foster 1984, personal communication).
In vitro analyses of the product showed that
no changes were induced in the proteins in factor VIII
concentrate by heat-treatment. Whereas heat-treatment
has been shown to result in changes in two-dimensional
Immunoelectrophoresis in antithrombin III concentrate
(Wickerhauser et al 1979) no such changes were apparent
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in the factor VIII concentrate. Other studies by Dawes
et al (1983) also confirm the antigenic identity of the
proteins pre- and post-heating, suggesting that formation
of neo-antigens did not occur. Studies of in vivo
behaviour are more important in demonstrating the suita¬
bility of the heat-treated material. In vivo recovery
and half-life of VIII:C were similar to those obtained
with other products not subjected to heat-treatment.
Since heating appears to have no deleterious effects on
the characteristics of the product, it can readily be
used clinically, prior to confirmation of its decreased
infectivity. As far as hepatitis B is concerned, a
decrease in infectivity can be tested by challenging the
concentrate with virus prior to the inactivation
procedure, followed by infusion into chimpanzees
(Brummelhuis et al 1983, Prince et al 1983). Since the
heated product carries no greater risk of infectivity and
is hopefully much safer than the current material, such
studies are not mandatory prior to its issue for clinical
use.
(B) ASSOCIATION OF FACTOR VIII WITH BLOOD GROUP
INTRODUCTION
It has long been known that persons of blood
groups A and B have higher factor VIII levels than
persons of group 0 (Preston and Barr 1964, Wahlberg et al
1980). This higher activity results in higher amounts
of factor VIII being recovered in single donation cryo-
precipitate from group A compared to group 0 donors
(Regional Transfusion Directors' Committee 1978). One
study has reported higher relative yields in thaw-siphon
cryoprecipitate prepared from group A as compared to
group 0 plasma (Prowse et al 1982). Oligosaccharide
structures characteristic of blood group A, B/O have
been shown to be associated with the factor VIII molecule
although the question of whether they are covalently
linked is uncertain (Sodetz et al 1979, Samor et al 1982)
In this study, the association of factor VIII
with blood group activity has been investigated using
purified factor VIII concentrates prepared from group
specific plasma. The aim was to define more closely
the nature of the association.
METHODS
Factor VIII concentrates: Non-group specific inter¬
mediate purity concentrate was obtained from the Protein
Fractionation Centre, Edinburgh. Group A- and group 0-
specific high purity concentrates were obtained from
Kabi Vitrum, Sweden.
Solid phased antibodies: Rabbit anti-A substance, immuno
globulin (affinity purified on Synsorb A) and non-immune
immunoglobulin were supplied by the Reagents Laboratory,
Edinburgh Blood Transfusion Service, and were coupled to
cyanogen bromide activated Sepharose 4B (Chapter II).
Factor VIIIR:Ag and factor VIII:CAg were isolated from
the group specific concentrates by the method of
Tuddenham et al (1979) using immunoadsorbent chromato¬
graphy. Briefly, sheep anti-VIIIR:Ag immunoglobulin
was coupled to Sephacryl S-1000 (Pharmacia) and the gel
was mixed with group specific concentrate for 18 hours at
room temperature. The gel was then packed into a column
was washed sequentially with 300 ml of 15 mM citrate,
150 mM NaCl pH 7.2 and 300 ml of 50 mM imidazole/HCl
pH 7.2, 0.01% Tween 80. VIII:CAg was then dissociated
from the bound VIIIRrAg by elution with 300 mM CaCl2,
50 mM imidazole/HCl pH 7.2, 0.01% Tween 80, 0.1% turkey
serum. VIIIR:Ag bound to the antibody was eluted 3 M
KSCN in imidazole buffer. The peak protein-containing
fractions were then dialysed against two changes of
5 litres of 50 mM Tris, 150 mM NaCl pH 7.2, 0.01% Tween
80. Pools of VIII:CAg- and VIIIR:Ag-containing fractions
FIGURE 7-4
PRINCIPLE OF IMMUNOADSORBTION OF BLOOD GROUP
ASSOCIATED FACTOR VIII
Immobilised anti-A antibody was incubated with
factor VIII solutions. Group A substance present
binds to the antibody, along with any associated
factor VIII. The antibody beads are then removed
and the supernatants assayed for residual factor VIII.
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were stored frozen for subsequent experiments.
Reaction of factor VIII with immobilised antibodies:
The principle used is shown in Figure 7-4. Solutions
of factor VIII were incubated with solid phased anti¬
bodies or buffer (50 mM Tris, 150 mM NaCl, pH 7.2).
Incubations were performed at room temperature with
continuous mixing. After one and four days of
incubation, the beads were removed by centrifugation and
the supernatants were collected and frozen for subsequent
assay.
FIGURE 7-5
ADSORBTION OF FACTOR VIII BY IMMOBILISED ANTIBODIES
Results show the mean and standard deviations of 3
experiments. The percentage adsorbtion compared to
the initial values was estimated by subtracting the
residual activities from the starting activities.
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Figure 7-5 summarises the results obtained.
A. GROUP A CONCENTRATE;
Anti-group A antibody adsorbed 75.2% of the
VIIIR:Ag and 79.6% of the VIII:CAg from the group A
concentrate, while non-immune rabbit IgG adsorbed 16.7%
of the VIIIR:Ag and 25.9% of the VIII:CAg. The
difference between incubations carried out with anti-A
and non-immune IgG was significant, (p < 0.001) using an
unpaired t-test, for both VIIIR:Ag and VIII:CAg.
B. GROUP 0 CONCENTRATE:
Anti-group A and non-immune IgG both adsorbed
small amounts of VIIIR:Ag and VIII:CAg; the difference
between the two antibodies were not significant.
C. NON-GROUP SPECIFIC CONCENTRATE:
Four day incubations resulted in clotting of
the samples and thus no assays could be performed. Small
amounts of VIIIR:Ag and VIII:CAg were adsorbed by both
types of antibody after one day incubations; the
difference between the two antibodies was not significant.
D. FACTOR VIIIR:Ag POOLS:
These were prepared from both types of group
specific concentrates:
1. Group A pool.
One day incubations produced adsorbtion of 17.2% by
immobilised anti-A and 15% by the non-immune IgG
compared to starting values; the difference was not
significant. Four day incubations led to
adsorbtion of 54% by the anti-A and 22% by the non¬
immune IgG, a difference which was significant
p < 0.005.
2. Group 0 pool.
For both incubation periods, the two antibodies
adsorbed small amounts of VIIIR:Ag; the difference
was not significant.
E. FACTOR VIII:CAg POOLS:
The VIII:CAg activity isolated proved very
labile to freeze-thawing and no activity was measurable
when the samples were assayed.
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DISCUSSION
Previous studies on the association of blood
group activity with factor VIII have relied on haem-
agglutination inhibition techniques to demonstrate the
association (Sodetz et al 1979, Samor et al 1982). Such
an approach,, however, will not distinguish between blood
group substance associated with factor VIII or present
as a contaminant in the factor VIII preparation. The
use of immobilised specific antibody avoids this
possibility, as any factor VIII removal must be through
a close association with the blood group substance
recognised by the antibody. It is acknowledged that
this approach will not determine whether the association
is covalent (Sodetz et al 1979) or is the result of
adsorbtion of blood group substance to the factor VIII
molecule during purification (Samor et al 1982).
However, this study confirms that blood group A substance
remains associated with the factor VIII molecule during
the production of a high purity concentrate from group A
plasma. Such plasma is known to have higher levels of
factor VIII related activities than group 0 plasma. The
reason for this is unknown at present, but could be
related to a possible increased in vivo half-life for
factor VIII due to incorporation of group A substance in
the molecule. Confirmation of this hypothesis would
require in vivo survival studies of factor VIII derived
from group specific plasma into haemophilic patients.
Association of group A substance with
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factor VIII might have been expected to result in some
specific depletion from non-specific concentrate, which
is made from plasma pools presumably containing a
considerable number of group A donations. It is possible
that this was not observed due to the lower purity of
the non-specific concentrate, leading to blockage of the
anti-A antibody with free group A substance in the
preparation. The higher purification of the group
specific concentrate would lead to removal of such un-
associated blood group substance, allowing reaction of
the antibody with blood group substance linked to
factor VIII.
It has been suggested that group A plasma
donations be preferentially used to derive cryoprecipitate,
in order to increase the potency of this material
(Tomasulo et al 1980). Such a practice, however, would
be too restrictive. A more practical option would be to
increase plasma levels of factor VIII using external
stimuli, an aspect that is studied in Section C of this
Chapter.
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(C) RESPONSE OF FACTOR VIII TO DDAVP INFUSION, VENOUS
OCCLUSION AND EXERCISE
INTRODUCTION
Factor VIII levels in blood are known to be
increased by a number of external stimuli, including
venous occlusion, physical exercise and infusion of
hormonal agents such as vasopressin and its synthetic
analogue 1-desaminocysteine (8-D-arginine) vasopressin
(DDAVP) (Bloom 1977). DDAVP has been used clinically
to treat patients with mild factor VIII deficiency,
whose low factor VIII levels may be raised to levels that
can support haemostasis by DDAVP infusion (Mannucci et al
1977). However, some concern has been expressed due to
the anti-diuretic action of the analogue (Lowe et al 1977).
DDAVP has also been used to raise VIII:C levels in blood
donors prior to donation, the resulting high levels being
recoverable in a concentrate and subsequently in vivo
(Nilsson et al 1979). This approach has also been
attempted in exploiting the increase in plasma VIII:C
following exercise; cryoprecipitate produced from
exercised donors however did not result in higher in vivo
VIII:C levels when infused into haemophiliacs (Gastel et
al 1973).
In this study, different factor VIII related
activities were measured following DDAVP infusion, venous
occlusion and exercise of male volunteers, with the aim
of defining the factor VIII response in normal
individuals following these stimuli. The relative
benefits of the 3 stimuli in raising factor VIII levels
in blood donors can then be assessed.
METHODS
Studies were performed on 6 male volunteers,
who were subjected to the 3 different stimuli as
described by Prowse et al (1984b) (Appendix of this
thesis). All assays were performed on frozen citrated
plasma samples and were as described in Chapter II.
The Laurell technique was used for measuring VIIIR:Ag.
FIGURE 7-6
CHANGES IN FACTOR VIII FOLLOWING DDAVP INFUSION
0.3 ug/kg was infused. Results are shown as mean
standard deviation.
























INDIVIDUAL AND MEAN (± standard deviation) INCREASES
IN THE VARIOUS FACTOR VIII ACTIVITIES 30 MINUTES AFTER
DDAVP INFUSION AND IMMEDIATELY AFTER VENOUS OCCLUSION
AND EXERCISE
Average basal levels of the activities were
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RESULTS
Figure 7-6 shows that during DDAVP infusion
VIII:C rises significantly before VIIIRrAg, although such
differences were marginal. The rise of VIIIR:RCF
following DDAVP infusion paralleled the increased in
VIII:C more closely than that of VIIIR:Ag. Maximum
levels of these activities did not occur until 30 minutes
or more after infusion. All subjects showed at least
a 2.3 fold increase in VIII:C 45 minutes after infusion
(mean 2.63 fold; p < 0.01) and at least a 1.6 fold
increase in VIIIRrAg 75 minutes after DDAVP infusion
(mean 2.49 fold; p < 0.01).
In contrast venous occlusion produced a lower
response in both VIII:C (1.4 fold, p < 0.05) and VIIIRrAg
(1.48 fold; p < 0.05) and one subject gave no response at
all. Similar results were obtained following exercise,
although in this case the increase in VIIIRrAg of 1.24
fold (p < 0.05) was less than that of VlllrC (1.47 fold;
p < 0.05) and a different subject was a non-responder.
Figure 7-7 summarises the response of the
different factor VIII related activities to all 3 stimuli
tested. In each case, assay of VIII:CAg confirmed the
results obtained by VIII:C measurement and in each case
the rise in VIIIRrRCF was significant (p < 0.05).
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DISCUSSION
The principle of administering an external
agent to blood donors with the aim of increasing the
procurement of a particular component is already
established in blood transfusion practice. Thus, donors
are injected with glucosteroids prior to leucapheresis
in order to increase the blood level of granulocytes
(French 1980). The immunisation of rhesus-negative
volunteers with rhesus-positive cells to product anti-D
immunoglobulin is also well known (O'Riordan 1973). The
present study confirms that a similar principle can be
used to increase the concentration of factor VIII in
donor plasma. It was felt important to measure changes
in all the different factor VIII related activities, in
order to ensure that the VIII:C rises observed represented
an actual increase in factor VIII, rather than a spurious
increase through e.g. activation. It has been claimed
that the VIII:C rise following exercise is a result of
activation, possibly by thrombin (Kopitsky et al 1983)
but the present study shows that following this and the
other stimuli, VIII:CAg also increases, confirming an
increase in the mass of this protein.
Of the 3 stimuli studied, DDAVP infusion
produced the highest increase in plasma factor VIII
related activities. It has been shown that the high
factor VIII levels in plasma following DDAVP infusion can
be recovered in low purity (Nilsson et al 1979) and high
purity (Mikaelsson et al 1 983b) factor VIII concentrates.
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This high in vitro yield is reflected in the in vivo
recovery of these products. In contrast, cryoprecipitate
from exercised donors, while containing higher levels of
factor VIII than normal cryoprecipitate, does not show
the higher in vivo recoveries expected from the in vitro
yield (Gastel et al 1973). It has been shown that
intra-nasal administration of DDAVP can also increase
factor VIII levels that are recoverable in concentrates
(Mikaelsson et al 1982). Although the dosage required
is an order of magnitude greater than the intra-venous
dose, this might be a more practical way of increasing
the factor VIII levels of plasma intended for concentrate
production. Donors would have to inhale the analogue
and then be bled 1-2 hours after, in order to allow a
maximal rise in factor VIII levels. Good donor
organisation would thus be required. Recently, another
vasopressin analogue has been described which is claimed
to increase factor VIII levels without the anti-diuretic
effect of DDAVP (Cort et al 1981). If this effect can
be confirmed in blood donors, it might be more acceptable
in transfusion practice to use this agent as a means of
increasing the factor VIII content of blood donations.
It is suggested that administration of such substances,
if found acceptable to donors, is a valuable way of
improving factor VIII procurement.
CHAPTER VIII
GENERAL DISCUSSION AND CONCLUSIONS
(A) INTRODUCTION
It is expected that the near future will see
factor VIII concentrate overtaking albumin products as
the driving force for plasma procurement in industrialised
nations (Curling 1982). This ever increasing demand for
factor VIII has resulted in local production in blood
banks remaining a crucial factor in the overall supply.
This is because such materials, mainly in the form of 'wet'
cryoprecipitate, produce a much higher yield of factor
VIII than concentrates from fractionation centres. This
situation is even more accentuated in countries which
depend totally on this form of production due to lack of
fractionation facilities. Great efforts are continuously
being made to increase the supply of plasma delivered to
fractionation centres in a form that is suitable for
factor VIII production (i.e. fresh frozen plasma) in
order to phase out such local, non-standardised products.
The recent introduction of a dedicated plastic pack for
this specific purpose is a case in mind (Lane 1981).
However, so long as yields by present day fractionation
techniques remain below 300 u/kg of starting plasma, a
voluntary blood donor system which produces 'recovered'
plasma is unlikely to supply all the material needed.
The question thus arises whether plasma needs to be
treated in a special way for factor VIII production and
whether small-scale, local and regional production of
high yielding products can substitute for the low yielding
large scale production of conventional fractionation.
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The question of yield relating to plasma supply
and quality, while ever predominant in state-backed
voluntary blood programmes, is less relevant for commercial
manufacturers of plasma fractions. In these concerns,
"Source Plasma" from paid plasmapheresis donors is the
raw material, in contrast to the "Recovered Plasma" which
forms the bulk of the supply for national blood services.
Product presentation and attractiveness to patients and
clinicians are more important than yield, as the plasma
source can be increased by buying more material and
passing on the price to the consumer. Recently, it has
also been shown that such high-potency concentrates may
also be pasteurised, thus having the added attraction of
a potentially reduced active virus content. It is not
the purpose of this study to enter into a discussion of
the ethics involved in the commercialisation of blood
donation. However, the ever increasing price of these
materials alone may be sufficient grounds to justify a
programme of self-sufficiency. The limitation of the
plasma supply to a pool of dedicated voluntary blood
donors, with a fully documented and satisfactory medical
history, also increases the safety of the product,
compared to materials derived from large numbers of a
continuously changing paid donor panel.
It has been the aim of this study to explore
ways in which local or regional blood banks can generate
enough factor VIII for self-sufficiency while retaining
the product characteristics currently only obtained in
3 1 0
large-scale production. The results achieved in this
study will be discussed in relation to work done by others
in this area.
(B) IMPROVEMENT OF THE SUPPLY AND QUALITY OF PLASMA AS
A RAW MATERIAL
Increasing the number of blood donors will
obviously increase the potential supply of plasma available
for factor VIII production. It has been estimated that
an annual rate of 50,000 donations per million population
is required to cover the needs for blood transfusion in
an industrialised nation (Hassig and Lundsgaard-Hansen
1978). The same study reveals that proper management of
a blood component programme should result in the generation
of sufficient plasma to satisfy factor VIII needs in the
form of intermediate-purity concentrate. In developing
countries with a less sophisticated health service, the
level of blood donation/requirement is much less, but can
be expected to rise as general health care is improved.
Achievement of the level of donation described above,
coupled with the use of an 80% component programme,
should lead to a balanced level of self-sufficiency with
regards to factor VIII and red cells. However, recent
developments, particularly progress in sterilising
factor VIII concentrates, lead to decreased process
yields and make it more difficult to achieve the necessary
plasma input through a standard blood donation service.
In this regard, rather than increasing the number of
blood donors (and thus wasting red cells) several options
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are possible:
1. Plasmapheresis of donors with the specific aim of
increasing the amount of factor VIII produced by blood
banks has been described (Andronescu et al 1983).
This approach has also been used to procure plasma
destined for large-scale fractionation - currently,
such plasma costs about £46 per kg to produce
(Robinson et al 1983). Although expensive, this
option allows measures which cannot be achieved
easily in whole blood collection e.g. use of different
anticoagulants to improve VIII:C stability (Chapter
III). However, it must be emphasised that procuring
sufficient quantities of whole blood should be the
first priority for a developing blood transfusion
service.
2. Use of red cell concentrates instead of whole blood
releases considerable amounts of plasma suitable for
factor VIII production. The Swiss experience
(H&ssig and Lundsgaard-Hansen 1978) has shown that it
is possible to issue up to 80% of blood requests in
the form of red cell concentrates. An essential
feature of this programme is the acceptance of the
policy by clinicians and a judicious use of plasma
substitutes as volume expanders (Mellstrand 1983).
The preparation of such substitutes should thus be
included in any programme aiming for self-sufficiency
in plasma fractions.
3. Increasing the volume of plasma per blood donation.
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Use of the red cell additive SAGM (saline, adenine,
glucose, mannitol) has allowed the volume of plasma
obtainable from a 450 ml blood donation to be increased
from 220 mis to 280 mis (Httgmann et al 1983). The
optimal additive system has now been incorporated into
the standard multiple plastic bag systems for whole
blood collection. The increase in cost relative to
the old single or double bags is partially offset by
the increased volume of plasma that can be harvested.
4. Increasing the VIII:C content of plasma destined for
factor VIII production. It has been suggested that
the long known association of blood group A with
increased factor VIII levels (Chapter VIIB) be used
in selecting plasma donations for cryoprecipitate
production (Tomasulo et al 1980). This practice,
however, must be considered unnecessarily restrictive.
Treatment of donors to increase factor VIII levels,
such as administration of the vasopressin analogue
DDAVP (Chapter VIIC) is a more promising option and
has been used successfully (Nilsson et al 1979,
Mikaelsson et al 1982). Combining this option with
a plasmapheresis programme on a relatively small
number of dedicated donors could well reduce the
necessary donor panel for factor VIII procurement to
a few hundred donors. The benefits of this are
numerous, particularly in the patient-safety aspect
mentioned above.
5. Improving plasma VIII:C stability. The lability of
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FIGURE 8 - I : PLASTIC BAG SYSTEMS FOR OPTIMAL PRESERVATION











































VIII:C in blood donations has resulted in many studies
designed to improve VIII:C stability so that more
plasma can be processed to factor VIII concentrate.
On a blood bank scale recent attention has focused on
the stability of VIII:C at physiological ionised
calcium levels, achieved either by collection of
blood in heparin or by recalcifying standard donations.
The results of this study and others published
recently indicate that a significant stabilisation of
VIII:C in the crucial first few hours after donation
is attainable by modification of the standard anti¬
coagulants so as to result in higher ionised calcium
levels (Chapter III, Krachmalnicoff and Thomas 1983,
Mikaelsson et al 1983a, Rock et al 1983b). The
present day anticoagulant formulations have been
based mainly on considerations of red cell viability
and safety upon transfusion. Given the growing
demand for factor VIII, an anticoagulant composition
which is more compatible with VIII:C stability and
which does not interfere with other components would
be attractive. Two possible options, based on the
results of the present study, for exploiting the
calcium-induced stability of VIII:C by modifications
of present day anticoagulants/multiple bag systems
are shown in Figure 8-1 .
a) Collection into anticoagulants of lower citrate
concentration: In this approach, the standard CPD
formulation would be altered so as to result in a
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final plasma citrate of 10 mM, rather than the 25 mM
attained by the usual anticoagulant. This citrate
concentration would allow VIII:C stability to be
preserved (Chapter III) . In order to maintain anti¬
coagulation, this 'low-citrate CPD' could if necessary
be supplemented with heparin, and if required
additional citrate could be added to the red cells
after plasma separation. A possible plastic bag
system for this option is shown in Figure 8-1A.
Although provision is made for citrate supplementation
of red cells following plasma removal, further
research is needed to determine whether 10 mM citrate
is adequate to preserve red cell viability. Mishler
et al (1978) have previously shown that a concen¬
tration of 14 mM citrate is sufficient for this
purpose.
b) Recovery of plasma VIII:C by recalcification:
Recalcification to 10 mM calcium within 4 to 6 hours
following donation results in recovery of plasma
VIII:C, which is stable for up to 18 hours (Chapter
III). Separation of plasma can thus be delayed
until transportation to the regional centre. Plasma
can then be separated and expressed into a calcium/
heparin solution. After allowing VIII:C to recover
to higher levels (2 hours - Chapter III), plasma can
be processed to concentrate the factor VIII. This
option can also be carried out within an enclosed
plastic bag system - Figure 8-1B. In this system,
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additional citrate is not necessary for the red cells
as collection is effected in standard CPD anti¬
coagulant. A tertiary pack with citrate is included
for receiving residual plasma after factor VIII
extraction, to allow continued anticoagulation after
the heparin has degraded.
Both these approaches might result in
heparin being present in the plasma being processed.
The fractionation of plasma derived from heparin
donations (about 12 u/ml of heparin in the plasma)
has been shown in this study to result in processing
difficulties. Smith (qu. Penny 1983; personal
communication) has shown similar difficulties in
processing such plasma to intermediate-purity concen¬
trate. Further studies are necessary to determine
whether the lower amounts of heparin resulting from
the above options would result in similar difficulties.
It is suggested that the necessity for
preserving VIII:C until plasma separation/processing
can take place justifies the use of potential new
collection systems as outlined in Figure 8-1. A
similar system has already been commissioned by a
Dutch blood bank for producing cryoprecipitate from
heparin donations (Smit-Sibinga et al 1983). Further
bag modifications would allow for subsequent extraction
of the factor VIII (Figure 8-2). Stabilisation of
VIII:C until regionally-collected donations can be
processed at the main centre will have marked effects
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on the amount of therapeutic material that can be
derived. It can be estimated that an extra 300 units/
kg of plasma may be obtained in plasma processed
18 hours after donation, an increase over present
procedures of 50%.
(C) PROCESSING OF PLASMA TO BLOOD BANK FACTOR VIII
CONCENTRATES
Cryoprecipitate:
The characteristics of blood bank cryo have
been discussed (Chapters I, IV and V). Despite its
inconvenience from the point of view of storage and
administration, the material still enjoys widespread use,
primarily because of the ease of preparation and the
relatively high factor VIII yield which is obtained.
Efforts to improve its quality have therefore continued
and include the following:
1. Lyophilisation of small (5 to 20) pools of single-
donation cryos by pooling aseptically into a stabil¬
ising buffer and then freeze-drying (Milligan et al
1981). The product thus prepared can be stored at
4°C instead of having to be deep-frozen. Because of
the low purity, however, the potency is only about
5 u/ml when reconstituted, and syringe infusion is
thus not possible.
2. Plasma additives have been proposed as a way of
increasing yield. The present study does not support
claims that PEG (Johnson et al 1979) or heparin
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(Rock et al 1 980b) increase factor VIII cryoprecipi-
tability (Chapter V). It has been shown that the
physical separation of cryoprecipitate is more
important in this regard, fast centrifugation being
necessary (Chapter V, Foster 1983b). Practical
difficulties in centrifuging bags of frozen plasma
might make transfer into bottles for centrifugation
a better option, but this would involve loss of
sterility.
3. Thaw-siphoning as introduced by Mason (1978)
undoubtedly improves markedly the yield of the
preparation, and if combined with a terminal centri¬
fugation step can also greatly enhance the purity
(Kang 1980, Chapter V). As has been found in this
study, however, plasma freezing has to be rapid to
effect maximum yield, a feature that does not seem as
crucial when using standard thawing techniques (Rock
and Tittley 1979). Care is required in storage of
frozen plasma prior to processing, as temperature
fluctuations result in increased fibrinogen deposition
in the cryo, making subsequent processing difficult
(Chapter IV).
4. Double precipitation of heparin cryoprecipitate has
aroused much interest as a means of increasing the
purity of blood bank cryo at high yield (Lane et al
1983). A variant of the technique employing a closed
system throughout has been successfully tested in vivo
(Smit-Sibinga et al 1984). Heparin collection has
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been claimed to a) increase factor VIII cryo yields
and b) permit utilisation of a second cold precipi¬
tation with a resultant increase in purity. The
present study has examined in detail the behaviour of
factor VIII in the cold in various components (plasma
and cryoprecipitate, both in heparin and CPD anti¬
coagulants) and can find no evidence of a specific
heparin effect (Chapters III and VI). The increase
in specific activity which is obtained upon chilling
blood bank cryoprecipitate (irrespective of plasma
anticoagulant) might be of some advantage, but this
study shows that the final preparation has a fibrin¬
ogen content that precludes sterilisation by heat-
treatment .
Alternatives to cryoprecipitate:
A large number of variables can influence the
freezing and thawing of plasma, and thus the final cryo
yield. Strict attention to every stage of the process
is thus essential, requiring a high level of technical
skill that might not be possible in a developing blood
transfusion service. The processing of unfrozen plasma
would avoid some of the variables affecting cryo yields.
Rapid processing or VIII:C stabilisation would allow the
use of liquid plasma as a raw material. This study has
therefore investigated alternatives to cryoprecipitation
as a means of concentrating factor VIII (Chapter V). Two
options are suggested from the results:
1. Polymer induced cold precipitation. Chilling plasma
FIGURE 8 - 2 : PLASTIC BAG SYSTEMS FOR OPTIMAL HARVESTING
OF BLOOD COMPONENTS
A .
Scheme I - Triple bap- system
Blood Is collected Into A, platelet-poor plasma Is expressed
into B, (red cell additives are expressed from C to A), the
plasma is chilled and the factor VIII rich precipitate is
harvested and the factor VHI-poor plasma is expressed from
B to C .
Products: red cell concentrate (p.naemia)
factor VHI-poor plasma (plasma expansion eg: shock)




Scheme II - Quadruple bap system
Blood is collected into A, platelet-rich plasma is expressed int<
D, (red cell additives are expressed from C into A), platelet
concentrate is harvested in B, platelet-poor plasma is
expressed into B, the plasma is chilled to produce the
factor VIII rich precipitate and the factor VHI-poor plasma
is expressed into C.
Products: red cell concentrate (anaemia)
factor VHI-poor plasma (shock)
factor VIII HES-precipitete (further processing)
platelet concentrate (thrombocytopenia)
Use of the additional bag allows harvesting of platelet-
concentrate, but the volume of plasma available for Factor VIII
production is lesB than for Scheme I as (1) production of
platelet rich plasma does not allow hard centrifugation in
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order to remove the maximum volume of plasma in the SAG
procedure, (11) a volume of about AOmls of plasma has to be
left with the platelet concentrate.
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in the presence of hydrophilic polymers results in
precipitation of factor VIII and other proteins
(Chapter V, Casillas and Simonetti 1982). By
selecting the appropriate conditions, a selective
concentration of factor VIII is achieved. Yield and
purity of the resultant fraction are better than
normal cryoprecipitate. The precipitate obtained
by HES 40 precipitation has been further treated to
obtain a freeze-dried concentrate (Chapter V). It
is suggested that this simple technique can provide a
superior alternative to cryoprecipitation as a means
of concentrating factor VIII. Processing of in-house
donations immediately after collection allows precipi¬
tation of the plasma to give a factor VIII rich
fraction in less than 3 hours. A similar concentrate
using PVP as a plasma precipitant has been shown to
give good in vivo results upon infusion to haemophilic
patients (Casillas et al 1983). This study suggests
that HES is a preferable reagent in this regard, both
in terms of the results obtained in plasma precipi¬
tation and the clinical acceptability. Figure 8-2
proposes a scheme for component production in a blood
bank, incorporating polymer-precipitation of factor
VIII and allowing other blood components to be
harvested. The plastic bag system shown is based on
the circular multiple bag configuration described by
Lovric (1982) which is already available. Included
are potential anticoagulant combinations in order to
preserve VIII:C as well as red cell additives such as
SAGM, to increase the volume of plasma that can be
harvested.
Plasma concentration and cold precipitation. Amongst
other polymers, albumin is an effective selective
precipitant of factor VIII (Chapter V). The same
result can be achieved by concentrating the total
plasma protein by water removal and chilling the
concentrated plasma obtained. This process can
easily be done in a blood bank using equipment which
can rapidly concentrate litre volumes of plasma. A
hollow fibre system capable of this task can be
expected to cost about £10,000. The procedure would
obviously involve abandoning the closed plastic bag
system and thus any final products derived would have
to be rendered sterile by filtration at the end of
processing. The concentrated residual plasma would
require treatment to allow its use as a volume
expander. It is possible that adequate sterility
precautions would allow production of uncontaminated
products, although this method presents greater
practical difficulties than polymer-induced precipi¬
tation. It is suggested that the method might be
more applicable as a preliminary step in full-scale
plasma fractionation, rather than in a programme for
component production, as the final products derived
can then all be subjected to sterile filtration as
part of the fractionation procedure.
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(D) FURTHER PROCESSING OF BLOOD BANK CONCENTRATES
1. Scale of operation. Single donation products such
as 'wet' cryoprecipitate, suffer from the inherent
disadvantage of lack of standardisation. The
requirement of full-scale pharmaceutical quality
control gives freeze-dried concentrates an advantage
in this respect. Concentrates may be dispensed in
multiple vial lots from a single resevoir of pooled
material. If care is taken to ensure batch homo¬
geneity, single vials from each pool can be assumed
to be representative, and the characteristics of a
batch can be defined by tests on individual vials.
A proportion of each batch would thus be used for
quality assurance. This factor argues against
products such as small-pool lyophilised cryoprecipitate,
as a large proportion of the product would have to be
sacrificed for quality control. Although it has been
argued that a restriction of pool size decreases the
risk of viral exposure (Gabra et al 1982) this is
likely to be true only for patients who are treated
very infrequently. While pooling in industrial
fractionation is done at the stage of preliminary
extraction of factor VIII from plasma, blood bank
procedures can effect pooling at the later stage when
the preliminary concentrate is processed to the final
solution. The high yield of the HES 40 precipitation
technique developed in this study means that pooling
on a 100-200 donation scale would produce an adequate
TABLE 8-1 MEASURES TO ENSURE STERILITY IN BLOOD BANK
CONCENTRATE
Process in sterile room (filtered air, 4°C) with laminar flow
cabinets (Hanratty 1983).
Sterilise all vessels and buffers used in processing
(Gabra 1980).
Filter final solution through appropriate filters (0.22 |im)
(Margolis and Rhoades 1981).
Lyophilise using sterile dryer (MyllylS 1983).
Quality assurance on final product - tests for sterility, toxicity
and pyrogenicity (WHO, 1978).
batch size and enable the necessary tests to be done
on representative samples. As described above,
production to the preliminary concentrate stage can
be done within a closed system. Further processing
requires the use of an open system and additional
measures are necessary to ensure sterility. Table 8-1
summarises these. Although these precautions were
not taken during the present study, as the products
were not destined for patient use, the HES 40
concentrate described in Chapter V could easily be
produced using these precautions. In particular,
sterile filtration should be possible due to the low
fibrinogen content. In this regard, it is worth
noting that the double cold precipitate obtained from
heparinised plasma cannot be sterile-filtered
(Hanratty 1982, personal communication) presumably due
to its high level of fibrinogen (Chapter VI).
Additional costs are obviously accrued by taking these
measures. These would be proportional to the scale
of the operation - MyllylS. (1983) reports a cost of
£80,000 per sterile dryer in the Finnish Red Cross
Blood Transfusion Service plant, but these machines
had to dry a whole range of fractions in addition to
factor VIII concentrate. Precise prior costing for
a blood bank starting a concentrate-producing programme
is difficult, particularly when the equipment has to be
imported. Against these costs has to be taken into
account the consequence of a reliance on imported
material.
Further purification. The main reason for further
purification is fibrinogen depletion with the aim of
sterilising the material (Chapters VI and VIIA).
Further purification on a blood bank scale has seldom
been attempted, probably due to the low yields obtained
using classical precipitation techniques. A chroma¬
tographic approach has been used successfully in blood
banks in Australia and New Zealand, in which cryo-
precipitate was produced from single donations, pooled
and purified by passage through a column of controlled
pore glass (CPG) (Margolis and Rhoades 1981, Woodfield
et al 1983). The resulting fibrinogen-depleted
material was obtained at a yield of 90% of the VIII:C
relative to cryoprecipitate. From the results of the
present study (Chapter VI) it is clear that separation
methods based on molecular exclusion and cold precipi¬
tation, while very successful on plasma, are much less
promising when further purifying concentrates.
Selective removal of fibrinogen however can be rapidly
achieved by glycine or zinc ion precipitation
(Chapter VI, BlombSck and Thorell 1982, Foster et al
1983a). Of these options, zinc ion precipitation is
to be preferred as glycine precipitation would require
dilution of the factor VHI-rich fraction prior to
heat treatment. Zinc ions in the factor VHI-rich
fraction can be removed by PEG precipitation (Foster
1983, personal communication), but this is not
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FIGURE 8-3 PRODUCTION OF A BLOOD BANK FACTOR VIII CONCENTRATE
WHOLE BLOOD DONATION
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necessary as subsequent heat-treatment would remove
zinc in the reagent-removal operation (Chapter VII).
Figure 8-3 describes the various stages for production
of a factor VIII concentrate as described in this
Thesis (Chapters V, VI and VII).
Product safety - sterilisation. No fractionation
process can totally eliminate the risk of viral
infection associated with products derived from human
plasma. Heat-treatment (Chapter VII) appears to be
the best option at present available, being a general
viral inactivation method rather than a specific
approach such as immuno-adsorption or lipid extraction.
The data reproduced in Chapter VII (Foster et al
1983c) indicates that a range of viruses are inacti¬
vated using this technique. A heat-sterilised
concentrate can therefore be expected to decrease
significantly the risk of infection. Further
measures in this regard include the restriction and
characterisation of the donor pool as discussed above,
the introduction of sensitive screening assays for
viral markers and the holding of frozen plasma in
quarantine to allow follow-up of donors (Lane 1981,
Smith 1983a). This last option cannot be applied
for processes, such as those described in this Thesis,
relying on liquid plasma, and also assumes a level of
organisation that is difficult to achieve in a
developing blood transfusion service. Further
research in viral screening/inactivation is necessary
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as long as human plasma remains the raw material for
factor VIII products.
(E) BLOOD TRANSFUSION AND FACTOR VIII IN DEVELOPING
COUNTRIES
The main theme of this study has been the
procurement of factor VIII in countries without access to
modern technology. A recent forum recommended the
following order of priorities for transfusion services in
such countries:
(a) Provision of whole blood
(b) Provision of components
(c) Plasma fractionation (UNIDO 1982)
The adequate provision of whole blood for
general hospital use is obviously the first priority of a
transfusion service. The estimation of 50,000 donations
annually per million inhabitants mentioned above is based
on the level of hospital care in a major industrial nation
and includes services such as cardiovascular surgery,
transplants etc., which are not provided in developing
countries. It can be expected that the development of
the health service will include provision of some of these
services, although not to the extent found in industrial
nations. As an adequate blood donation rate is achieved,
plasma will become available, through judicious use of red
cell concentrates, for producing factor VIII. Staging
the development of a blood transfusion service as
recommended above would involve, using present day methods,
the production of single donation frozen cryoprecipitate.
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The unsuitability of this product as far as administration
and storage are concerned, however, precludes its use as
a substitute for imported concentrates. Cryoprecipitate
production is a satisfactory first step in a situation
where treatment was non-existent or was limited to whole
blood or plasma transfusion. The product, however, would
be unacceptable to a haemophiliac population used to
adequate home-therapy with imported concentrates provided
by the state health service. In this situation, which
exists for example in the author's country, development
of the transfusion service as far as factor VIII production
goes must be geared to the production of concentrates
with the same basic characteristics as the imported
materials.
Use of the appropriate technology, as described
in this study, should allow the provision of factor VIII
concentrate in the required amounts. It has been
estimated that the amount of factor VIII needed for
haemophilia care in a population is 1-2 international
units per capita per annum (Smit-Sibinga 1983). Assuming
that a total blood intake of 30,000 donations per million
population is achieved to cover red cell needs, then an
80% component programme will produce about 5,000 litres
of plasma, although a proportion of this would be required
for clinical use as fresh frozen plasma and platelet
concentrate.
Rapid processing or VIII:C stabilisation will
allow liquid plasma to be processed for factor VIII
production. Processing of 4,500 litres of fresh plasma
by the HES 40 precipitation technique can be expected to
yield about 2} million units of factor VIII concentrate,
which are adequate to cover needs. Processing by thaw-
siphon cryoprecipitation can be expected to produce the
same amounts, with the disadvantages associated with this
non-standardised product. This, albeit simplistic,
estimation does not take into account certain factors,
e.g. loss of yield by sterilisation, inability to achieve
the required level of red cell usage, which would decrease
the amount of factor VIII produced. However, the
additional options discussed, such as increasing the
volume of plasma available per donation through the use
of SAGM, pharmacological stimulation of donors etc., can
all contribute towards offsetting these losses.
The technical problems of producing on a blood
bank scale as opposed to the laboratory scale experiments
conducted in this study are considerable. However, it is
believed that the advantages of blood bank production of
factor VIII concentrate can allow developing countries to
attain self-sufficiency in this product within a compre¬
hensive programme for the development of the blood
transfusion service. The necessary capital expenditure
is not excessive, considering the present cost of imported
concentrates, and can be partly offset by aid programmes
for this purpose (UNIDO 1982).
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(F) CONCLUSIONS
This study has focused on optimising the
procurement of factor VIII from donated blood. Other
plasma fractions, at present available commercially
through industrial fractionation, can also be derived in
blood banks using the appropriate technology. The use
of chromatographic techniques has already enabled the two
main plasma fractions - albumin and immunoglobulin - to
be prepared in regional or local blood banks (Curling
1983). Although the clinical safety of such products
requires further verification, particularly as regards
transmission of viral hepatitis, it is possible that the
Cohn (alcohol precipitation) fractionation system,
predominant in industrialised countries, will be substi¬
tuted by such techniques in developing nations. The
preliminary extraction of factor VIII from plasma, using
the methods described in this study, should not interfere
with the fractionation of other proteins using these
alternative techniques. The possibility thus exists that
small-scale processing on a local or regional level will
allow developing nations to become self-sufficient in all
blood products once the supply of raw material is assured.
Much interest has been generated recently on
the use of genetic engineering for the production of
plasma proteins, including factor VIII (Newswatch 1982,
Maddox 1983). It is obvious that the commercial companies
are acquiring a monopoly on the expertise and the
technology involved. Although vast problems must be
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surmounted before factor VIII can be successfully produced
with this technology, the commercial stimulus will
doubtless produce a clinical product in a few years time.
This will alleviate greatly many problems presently
hampering the procurement of factor VIII, particularly
the risk of viral contamination of the product. However,
the need for purifying, concentrating and sterilising the
product will still exist, and techniques to perform these
operations will still be needed. It is suggested that
the use of processing methods similar to those described
in this Thesis for small-scale processing of plasma will
be more relevant in this regard than the Cohn system for
fractionating bulk plasma. Transfusion services also
need to examine the possibilities for such non-plasma
derived production methods. Thus it seems that studies
in the field of factor VIII fractionation are going to be
of relevance to the future as much as they are today.
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Fig.1Changei plasminogenactivatorfollowingDDAVPinfusi n. 0.3ugDDAVP/Kgwasinfusedto6subjectsfr mt15minndPA levelsd terminedbyeuglobulinlysisli eas ay(OO)andt-PA immunoassay(□□).Resultarehownmea(±SD)and significant(p<0.05)increasesarshownbyfilledsymbols. Resultsareexp essedm anndsta dardd via ions,thsignifi¬ canceofdifferenc sbetwe ngroupb i gassessedyhStud ntpair t-testandcorrelationsbetweenthin rem tPAandF c orVIII determinedusingthP arsonco relationcoeff cie t.
prepostrepostc ntrolpreost
Fig.2Plasminogenactivatorlevelsfoll wingdiff r tstimuli.Basald maximumlevelsofPAdeter inedbyeug obulinlysisti ea aynd radioimmunoassay.In vidu la dean(±SD)re u tsareshownf r DDAVPinfusion,venousocclusionandxerci e.F rthimm noassay meanserumlev lsarelsoshownbytshadedp rtionfthistogram. Resultsfortheunoccludedarmf ll wingvenousclusionareshown (control).P st-DDAVPinfusionresultsrepresentamixturefres l s from15and30minstheax mumlev lschievedw retaken.T ythereforedifferslightlyfromsultsshownnFig.1.Ap st-stimulation levelsweresignificantlyreater(p<0.05)thcorr spondingbasal values.
Results PlasminogenAct valor-Ativity PA,determinedbyclotlysisassay,increa ed4.5foli p a ma euglobulinfollow ginf siofDDAVPat0.3ug/Kg.Therise wasmaximalim edi telyfterinfus on(Figs.1nd2)n l subjectsshowedale st3foldriinPAactivity.Fo lowingVO therisinPAactivityaveraged3.4fold(Fig.2)althoughtwo volunteers,classifi dlowresponders,gavle sthan2f l increases.Asmall,butsignificant(average18%)r siPA activitywaslsono edithunoccludedarm.Tm anrii PAactivityfollowingexercisewa2.3fold(Fig.)andagain subjectsgavelessth n2foldris ,o lynfth ebei gl w respondertVO.Forallhretimulithakresponsef activitywassignif can(p<0.01).Correspondingsul s( o shown)wereobtain dusingtfi riplatea say. PlasminogenActival r-Antig Byradioimmunoassayb sallevelsft-PAantigen7ng/ml werefound.Thisros1.95fol(p<0.01)f llowingDDAVP infusion,4.20fold(p<0. 5)afterVOnd1.33f l(<0.05) afterexercise(Figs.1and2).Ths ayl oco firmedth significantriseiPAthunoccludedarmfoll wingVO(1.31 fold,p<0.05).Fig.2alsoshowst eproportionft-PAantige whichcanbindfibri ,ansthusotfoundserum,d ff rsfo eachstimulus. FactorVIII Fig.3showst atduringDDAVPinfus onVIII:Cr sesignifi¬ cantlybeforeVIIIR:Ag,althoughsuchdifferencesma ginal. TherisinVIIIR:RCFafterDDAVPinfusionparallelledth increasenVIII:Cmorecl selythant tofIIR:Ag.Max¬
imumlevelsofth seactivitiesdidnotoccuruntil30inro e afterinfusion.Allsubjectsh wedaleast2.3foincr a ei VIII:C45minafterinfusion( ea2.63fold,p<0.01)dt least1.6foldincreasenVIIIR:Ag75minf rDDAVP infusion(mea2.49fold,p<0.01). IncontrastVOproducedaloweresponseib thVIII:C(1.4 fold,p<0.05)andVIIIR:Ag(1.48fol ,<0.05)ando e subjectgavenoresp nsell.Similarresultsw reobt in d followingexercise,althoughinthcast ein reaseiVIIIR:A of1.24f ld(p<0.05)waslesth nthatofVIII:C(1 47ld; p<0.05),anddifferentsubjecwasnon-responder(Fig.4) ForallthreestimulissayfVIIIC:Agconfirmedheresults obtainedbyVIII:Cmeasurementi achc sehrii VIIIR:RCFwassignificant(p<0.05,Fig.4)ComparisonofPA activityndVIII:Crevealedsignificantcorrel ion(p<0.05)betweenthincrem tsnt setwoproteinsfoll wingVOa d exercise,butnotDDAVPinf sion. OtherAssays Plasmaconcentrationsffibri ogen,antithr mbinIII,- thromboglobulin,plateletfac r4,thrombospondinnt tal proteindidnotchangeafterDDAVPi fus onex rcise.VO resultedinsomeincreasb tthecouldaccountedf rin termsofhaemoconcentrationashowby19%in r seitotal proteinc nte tfplasmabta edfrthoccludedrm.Ith twovolunteershogavethhi h stfac rVIII:Cresponset DDAVPnochangeifact rXIIwasfou df ll wingnyfth threestimuli. Directradioimmunoassayfplasmprostacyclinme b lites showedab sallev f22±6pg/ml.Thisro e,butnot significantly,a terDDAVPinfusion(17±45%,=3)VO(40 ±53%,n=4)andexercise(936 ,=5).
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Fig.3ChangesifactorVIIIollowingDDAVP infusion.Fact rVIII( /dl)determinedas:C, VIIIC.Ag,IR:R Fand1I :Afterinfu¬ sionof0.3ugDDAVP/K .SeeFig.1f rdetails. Fig.4actorVIIIincrementsfollowingdifferent stimuli.Individ alandmean(±SD)i creasesu/ dl)inthevariousfact rVIIIactivities30m nfter DDAVPinfusion,andmmediatelyfterv n us occlusionandexercise.Averagb sallevelsfthe activitieswerVIII:C101,III:Ag83 VIIIR:RCF97andAg8u/dl.Seet xtfor significanceoftheseresults.
However,ininevolunt ers,hoallflus ednfused
higher(0.4ug/Kg)dosfDDAVP,t66±54%increase plasmaprostacyclinmetabolitesw ssignificant(<0.01).Atth samedose24%riwasnot dip tienti hsev rv Willebrand'sdiseasewhohadnormalbasallevelsoft-PAntigen (5.5ng/ml)andctivity4ELTu ts)bexhibitedofactor- VIIIorPAresponsetDDAVP. Preliminarystud esin3ubjecthow dt anfusioof 0.4ug/KgDDAVPhadnoeffectonthP rfact rVIII responsetVOde ermined2hrlater.Inofth srii plasmarostacyclinmetabolitesfoll wi gVOw sdemon trated thepreviousday,butswaabolishedDDAVPinfusion priortoVO. Discussion Thet r estimulius dint istu ywerchosenprod ca maximalresponsewithinsh rtperiod,althoughtofheix subjectswerenoexhaust dbythstandarercise.Ve o s occlusionf rlongerthan20miproducesofurthincre factorVIII(25).UsingthesetimulieincreaplasmaPA andfactorVIIIdiffereinachseiscrep n i swer notedbetwe nthc angeiactivityndantigel v lsforeach protein.ThusDDAVPandVOproducedr piisinP activitywhileexerciseh dlesffe t.Incont a tt-PAantigen wasincreasedmostbyVO.Fore chstimulusthproportionof t-PAantigenfou di serumlsodiffere .Th sma rial apparentlyt-PA-inhibitorcom lex swh ch,unlikhfre enzyme(26),isinactivandu abltobifibrin( 227).Ihe
presentstudy,thproportionofantigeb undfibridu g clottingvariedfrom8%und rbasalcon i io s,t45%fol wi VO.Theformationoft-PA-inhibitorc mpl xesex la s discrepanciesbetweenactivitydntigessaysinhstimuli usedhereavnoff ctonintrinsicrurokinase-likePA(28, 29). FactorVIIIwasrele sedmores wlyth nPAfollowing DDAVPinfusion,b tdesp teth s,produc dagreat r increasenplasmafactorVIIIth nOorexercis .I h , exceptVO,ane ssoffactorIII:Cv rIRAgwa observedafterstimulation.Thish lsbe nreportf submaximalVO(30).Therap dinc easefactorIIIR:RCF, relativetoVIIIR:Ag,afterDDAVPinfusionmaybxplain d bythereleaseofhigh rmultime sVIIIR:Ag,whichav beenassociatedwithVIIIR:RCFc ivity(31). SincePAandfactorVIIIR: grproducedbyendoth lial cells(32,33)DDAVP,VOandexercisemightlsobexpected toaffectotherpotentialendoth liamarkers.Ifact,ocha gei plasmalevelsoffibr n ctin(34),thrombospondin5anti- thrombinIII(36)rplateletfactor47w sobse v dafterny ofthesestimuli,al houghhighd sesfDDAVPproduc d significantriseiplasmarosta yclinmetabolites.Th sunre¬ latedtochangesinPAorf torVIIIsi cpatientw thv e vonWillebrand'sd se sewhogavnoPAorfact rVIIIresponse followingDDAVPinfusionreta neds mepr tacyclinmet bo¬ literesponse.Fur hermore,prioDDAVPinfu nhadnffect onthePArfactorVIIIresp nseOinormalsubj ctsb abolishedthpreviouslyo servpro tacyclinme bo te¬ sponse.
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Previousstudiesoncha gesinpl sma6-ketoprosta landinFj during,orfollowingDDAVPinfusionhaveproducedc ntrasting results(14,1538940).Somefthesediscrepanci sayari e fromdifferencesnthspecificityvariousantib diesus di theradioimmunoassays(41).Tas ayu edherewperf rmed onunextractedplasmasampl sandhsensitivityf5g/ml, detecting95±percentofadded6-k oprostaglandinF,. Equivalentresultsareobtai edfollowingadditiofhydrol sed prostacyclintheassaysy t m.Tasdete tso - dependentincreaseiplasmaantig nduri gnf sioofpro ta¬ cyclintopatie ts,ndnundet ctablelev fn igenith plasmaofatientst kingnon-steroidalnt -in lammatorydrug (Belch-inpreparation).Theassayt usd tectsm t bolitesof prostacyclin.Althoughiwasrigi allydescribedasf r 6-ketoprostaglandinF,,inviewfthefacttly40p rc tf prostacyclini me bolisedthiproduct(42)anda sspec¬ trometryrevealsnochangei6-k toprostaglandinFjaf DDAVP(40),thesomewhatcu b rsometer ,prostacyclin metabolite,hasbeenusedinpreference. Insummary,DDAVPinf sion,venousocclusioa dexerci e produceaspecificinc aseplasmaPAndfactorVIII,butth extentofreleaseandthen igen:ctivityra of rachprotein differsfoeachstimulus.Dif rentsubjectsalsog vel w responsestachstimulu .Sucdiff re cesm stbexplainedy anyhypothesisadvancedtexpla ntmech n mfr l eb differentstimuli.Despitenu eroustudichmechanisms remainunclear,althoughih sb esugge tedth tDDAVPs viaacerebralreceptor(5,43)andth tef ctoVIII,bun t PA,releasefollowingex rciseisnhibitedbybeta-ad en rgic blockingagents,whereassuchdrugsh vnoeff ctot responsetov n usocclusion(44,45).Suchresultsimplythat,f factorVIIIandPAreleaseoccu sfr mcommontisst , differentstimuliacthroughdi f r tpathwaysndhismi t accountforsomeftheres ltspre ent dher . Acknowledgements TheassistanceofMr.GcK y,1.Abbottndr .Briffini performingfact rVIII:RCF,anti hrombin111ndlILCAssays respectivelyi gratefulacknowledged.D .Coll n(Departm nt MedicalR search,CatholiUnive sityofL uvenBelgium)kindl suppliedpecificantiserumnmelanomaactivatorsi s t ngpth radioimmunoassayfort-PA.A.FarrugiawassupportedbyB itish Councilommo wealthSch lars ip(MLT/1/81). References 1CashJD,G derAMao ta.ThRele sefPlasminog n ActivatorandF ctVIIIbyLVP,,DDAVP,T IIanOTi Man.BrJHaematol1974;27:363-364. 2MannucciP,AbergNilssonIRobertsonB.echanismof PlasminogenActivatora dFactVIIIIncreasefteso ctive Drugs.BrJHaematol1975;30:81-93. 3NilssonIM,VilhardtHolmbergLAstedtB,As ociationbetwee FactorVIIIRelatedAntig nanPl smi ogenctivato .aMe Scand1982;211:105-11 . 4ProwseCV,SaGaderAMortJHshD.pecificityin theFactorVIIIResponseaso res inInfusi niMa .BrJ Haematol1979;41:437-447. 5CashJD,G derAMul rLortH.Str cture-Activity RelationsoftheFibrin lyticResponseVas res niMa .CliSci Moled1978;54:403-409 6BrozovicM.Physiol gicalechanismsiCoagulationndFibrin ly¬ sis.BrMedull1977;33:231-238. 7MannucciP,RuggeriZaretFI,C pitanioA.DDAVP: NewPharmacologicalAppr achttheM nagementofH em philia andvonWillebrand'sD sease.Lancet1977;:68 -872
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StudiesonhProcurementfC agulationF ct rVIII: SelectivePrecipi ationofFact rVIIIw thHydrophilic Polymers
A.Farrugia*,B.G iffin*D.Pepper**a dC.Prowse* FromtheEdinburgh&S-Ec tlandBlooi BloodTransfusionServiceH adquart r:
ransfusionService*,RoyalInfirmary,andScottishN ti al .UnitLaborato'^IEdinburgh,Scotland
Jo
Keywords FactorVIII-FibrinogenPolym r-Pr tei -precipitation Summary Earlyworkonthepurificationff ctorVIIIs gpoly thy¬ leneglycol(PEG)indicatedthatotherpolyme smightlsob usedtoprecipitatefactorVIIIleavingfib inog ns lutio . Recentlypolyvinylpyrrolidone(PVP)haslsbeedvocat df r thispurpose. Inthisstudy,differentconcentrationsa dmol cularw ightsf hydroxyethylstarch,de t an,PEGVPFicoll,Percond albuminwereexaminedfoth rab lityoprecipitatethf ctor VIIIcomplexfrcool d(n tf z n)eshCPDplasma.A optimalconcentrationsrqua titativer cov ryfVIIIR:Ag andVHfCTiAgwasachievedi2hrithm nimalprecipitationof fibrinogenrtotalprot i .Thestseparationsw reb e ved withhydroxyet ylstarch,albuminrFicoll.PVPandEGgave inferiorpurifications.R sultfocryoprecipitateandint medi¬ ate-purityfactorVIIIconcent atew reinf riorth sobtain d withplasma.Simplepre-concentrationfplasmariorthillingisanttractivealter ativeforla gsc lcontinuousproduction. Introduction Sinceitsntroduction,byP olandSh nnon1965(1) cryoprecipitationhasbecomethemajorth df rp oductionf factorVIIIoncentratesfr mplasmaiblooda ks.Bulk cryoprecipitation(2)isalsthetandardiniti ls ageproduc¬ tionofintermediateandh ghpurityfactorVIIIoncen rates clinicaluse(3). Improvementsinthyieldanpurifica ionffactorVIIIfrom plasmabycryoprecipitationm yachievedmod f c tionf thehawingtechnique(4,5)orbyoll ct onfl odihepari (6).TheearlyobservationsfP isoal.7)suggestedth t polymerrecipitationmightprovideaet dfplasmapro ein fractionation,buinthecaseffa torVIIIpolym rssuchs polyethyleneglycol(3,8)havn ybeeus dinthl rs epsf purification.Recently,polyvinylpyrrolidonehasbepro sed asselectiveprecipitantforactorVIIIfromplasmaand cryoprecipitate(9). Despitethelargdifferenc sinmole ularwe ghtb tw n factorVIIIomplex( a.10x06)andfibrin g n0.346)o high-yieldinglargsca esep rationasbe nasothisf c . Smallsc eep ration(bygelfiltrati n)v rysuccessfulb t cannotbeappliedolargscal .Wheno el oksts cific requirementsofapurifi dfactorVIIIoncentrate,iscl arthat Correspondencet :Dr..Prows ,S-Ec tla dBl oT ansfu ion ^Service,RoyalInfirm ry,EdinburghScotland
removaloffib inogensthajorunsolvedprob em.If bri ¬ gencablargelyeliminatedfromthproductt n( )smal er reconstitutionv lumeipossible,(b)amorerapidresolutionti ispossible,(c)thereconstitut dmaterialil slik ytoclot clogfilterstc.,and(d)hemat rialisoreeasilysterili dbyfiltration,adiatioorhe t.Iwasthepurposeoft iw rk produceasimple,eliablproc ssf rthconcentrationff ctor VIIIcomplexwithretentionfbiologicalact vitie(s)hi hyi ld andwiththeeliminationofasuchfibrinogenpossible. Theprecipitationofplasmarotei sbyv rietyfhyd ph lic polymerswaexaminedtodeter ineifh ywoulllowpurif ca¬ tionffactorVIIIwithahigyieldapurification.Ther sults indicateth tisc nbeachievedwithhydroxy t yls arch,Ficol oralbumin,rsimplyconcentrationfplasma,withoutthene d forreezing. Materialsandetho s Humanplasmaw sobtainedfronor alb okdon tionsken intoCPDanticoagulant. Cryoprecipitatewaspre aredbyththaw-siphont chnique(10)f om singledonations.Isomeexperiments,cry p ecipitatewasreparedf atwolitreplasmao landextractedn o0.03plasmavolu esft is buffer(3). IntermediatepurityfactorVIIIconcent atew sobt inedfr mth ProteinFractionationCe tre(Edi burgh)andwasfreeze-d iedprepara¬ tion,preparedbythemethofNewmantal.(3)Forth sestu i s,t is materialwasdissolvedinonehalf^0therecommendedv lum .Or" CUratesaline(C-S)buffer0.015Mcitrate,.NaClpH7.2.' Glycine-citrate-glucose(GCG)buffer0.06MN Cl,19sodium citrate,0.007Mglucose,0.013GlycinpH6.5. Polymerstockolutionsweremadebydi solving40%w/wfp l mer inisotonicsaline.Thf ll wingpolymerswereus d:polyethyleneglycol (PEG)*Mr=6,000(UnionCarbide);polyvinylpyrrolidone(PVP1 , PVP40)Mr=10, 00andr40,0 0(Sigma);dextranT7 ,xt n T150,PercollandFic l7(PharmaciaFi eC e icals);hyd oxy thyl starchM=40,000(HES),r350, 0( ES5 )ndMr= 450,000(HES5 )weregenerouslysuppli dbythArmBlooS p Depot,Aldersho .40%st ckolutionfhumaa buminw sdeby concentratinga20%solution(Immu o)byultrafiltratioA ico PM-10Membrane. Assays FactorVIII:Cwasass yedbone-stagetechniqubasnt activatedpartialthrombopl stinti e,usi gnut matedclo n t ctor (Coag-a-pet),ndreagentssuppliedbyGeneralDi osticsInc.Fa or Vll|!jf|\gwasassayedbone-sitef uidphasimmuor diom tricsay;(11),factorVIIIR:Ag,fibrinogenandfibronectinw eassayed electroimmunoassay(12)usi gcom erciallbtainedantiser(Behring- werke). Totalproteinw sass yedbthBiur ttechnique(13).D xtranw s foundtocausein erferencethisssay.D xtran-containingolutions were,therefore,assay dbab orbanct280nmfoll winguitable dilution.
!Polymer-InducedPrecipitation Dilutionsofst ckp lymers utionswereaddedthpr t in mixturesund rinvestigationuntilthdesiredfi aconcentrationwasI reached.Thmixtureswt nheldun ercon itionsdescribedi Results,afterwhichthprecipitatesformedwsepar tedbyen rifuga- jtionfor13,000gminatthetemperatureus df rpr cipitation.Prec i- ;tatesw redissolvedinG-C-Gbuff r,thexperimentswithlasma,o !inC-Sbufferithexperimentswithcryoprecipitateandconc rates, iTheprecipitatesw rdissolvedn0.1-0.03fthriginalvolumef r iplasma,0.5volu ef rcryoprecipitatend1v lumf rc centrate. Plasmare-Concentr tiona dC lPre ipit tion Plasmawasconcentr tedbyultrafiltrationnAmicoPM-10 Membraneorbydialysisag inst50%w/wPEG6 00ntris-buffered| salinepH7.2(14).Thconcentratedplasmawast nheld0°Cf rj30min,spun,andtheresultantprecipitatedissolved0.1fthriginalj volumefG-C-Gbuffer. Results PolymerPrecipitationfChill dasma Preliminarystud esindicat dthatlowtemperaturesw r necessarytoeff ctprecipitationwi hc rt ifthepolymers.All experimentswerether forepe fo m dbyaddingp lymers lu¬ tionheappropriatec nce tr tiona dhilli gt emix ur sf 2hronmeltingic . Fig.1showst edose-responser ultsfort evariouspolym rs whentest don20mlamountsfplasma.Alpoly erstested producedselectiveprecipitationffactorVIII:CanVI 1R:Ag,butsomeresul edinabetterpurificationthanth s. Thereisomeevidencethatpolym rsat iigh stc ncent¬ rationsdemonstratedinhibitionfthfact rVIII:Cbioassay. Thiswasindic tedbytdiscrepancybetw eio sand factorVIIIR:Agimmun assay,aneffectth twparti ularly noticeablewithHES450,dextr nT1andPVP,althought lowpolymerconcentrationsth rsconcorda cebet eenth yieldsoffactorVIII:Candt rVIIIR:Ag.Ainhibitionf factorVIII:CbioassayyPVPhbeendemon tratedZuber andMorge thaler(15).Suchninhibitionmightxplainthdr pinfactorVIII:C,butn tfactorVIIIR-.Agahighp lymer concentrations.Specificina tiva onff rVIII:Ctthe e concentrationsa n tbdis oun edwoticeableth t
PVPproducedclott dprecipitatesw hl wfa orIII:Cyields








Fig.IPrecipitatingeffectofvariouspolymernhumanp asma0°CP l erst cksol tio sw reddedt20lliquotstilhindi atedl concentrations(weight/weight)w rachiev d.Tmixtureswheli ltingif2,c n ifugeda dctiv ti shpr c pitatesdeterm ned. (-•-FVIII:C;O-II1R:Ag;-fibrinogen;totalpr tein).Meaerc tprecipitationshowf r36experime tsf chlymer. Fig.2Precipitationeffectofhumaalbuminl sma0°Conditi swereiF g.1. 2052







































































































































(Amiconembrane) Resultspresentedasercen ageyi dsofstartlfp asma.Pl smavol sr ngfr400-1800mi n.d.=otdetermined. secondpipri rtoprecipitationino deminimisec llular contamination.Thisw sfoundtbenece sarye sure precipitateswoulddiss lvadeq ately. PlasmaConcentrationdolPre ipi ati SincealbumindditionresultedifactorVIIIpr cipi ation, simpleconcentrationfplasmawasal otr dme ns precipitatingfactorVIII(14).Inoneexp rimentus gdialysis against50%PEGfor2hr,precipitationfVIIIR:Agwi h minimalprecipitationofroteinswasaccompl shed,bu lyh l oftheVIII:Cwasrecov redinprecipitate(Tabl2). Ultrafiltrationgavebet erresults,ule twithourequip¬ ment,tookapproximately8hwhprocessing400isplasma. PolymerPrecipitationflas aF act ons A.Crycprecipiiate.Thetwotypesofcryoprec pi ateus d differedintheircomposition:ryopr cip tatepr areby modifiedthaw-siphontechn quehav nglowerpr tei ,factor VIIIandfibrinogencontentthabulkryoprecipitateextra t d j0nto"5i2^risbuffer. Fig.3showst eresultobtainedf rthaw- iphoncryoprec pi¬ tatewithHES450ndalbumin.Precipita ionoffac orVIII fibrinogenoccurredconcur tly,althoughs mdisc minatio fromt talproteinw sbserved.Separ texperim ntsi h
Finalpolymerconcentration(g"/•)
Fig.3PolymerprecipitationoLthaw-siphoncryoprec i ate.C ndit o s wereasinFig.1foincubatiorenO0C;in ubationt0° rc r i d outinawaterbath.(-V-FVIljyjAg).
Fig.4Polymerprecipitationofinter ediatepurityFVIIIconce trate.ConditionswereasiFig .1nd3HES4500°C 123 Finalpolymerconcentration(g7«)Albumin0°C precipitationcarriedout10° n2 °dn timpr vethe discriminationbetweefact rVIIIandf brinogen.Results obtainedw thtr sextractofbulkcryopr cipitatewersim l r (resultsnothown). B.Intermediatepurityconcentrate.Alb mina dHES450 wereagainusedspr cip tationag ts.Aab einF g4, nousefuldiscriminationbetweefactorVIII,fibr genandtotal proteinwasobservedund rthconditionstud ed. Discussion Thisstudydemonstratesth tprecipita ionfplasmawi h hydrophilicpolymersal owselectiveh rv stingff ctorVIII. Precipitationofchilleditratedplasmawithbumin,hyd oxy- ethylstarchesorFico l70waparticularlyeffectivendllow d singleteppurificationoffactorVIIIatsp cificctivityo0.5 1.0units/mgpro eini greaterth80%yi ld,i2hr.Ilarg r scaleexperiments,thyieldoffactorVIII:Cr ducedtbout 70%.Precipitationwi hVPinourhands,d tpro uce goodresultsastho edescrib dbyCa l asanSimonetti(9),b
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Itmaybesignificanth tedi crimina ionb tweefa r
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